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Influenza virus continues to be a major worldwide human health problem 
because it rapidly evolves antigenic changes and resistance to antiviral drugs. This 
rapid evolution is a consequence of the virus’ high mutation rate, which generates high 
genetic diversity and promotes adaptation. Most of these genetic variants, though, have 
a decreased ability to infect and replicate. Therefore, high mutation rates are a double-
edged sword, providing abundant raw genetic changes for selection to act upon while 
burdening the viral population with low fitness members. My dissertation focuses on 
precisely characterizing influenza’s mutation rate, investigating the viral consequences 
of increasing the mutation rate, and describing mechanisms that allow influenza to 
tolerate increased mutation rates.  
I developed a novel assay that has permitted the first ever complete 
characterization of influenza’s mutational spectrum. Using this assay, I determined that 
overall mutation rates are similar between evolutionarily divergent viruses but that the 
rates of individual mutation classes can differ. I also found that the range of 
temperatures that influenza encounters within the human respiratory tract does not 
affect the mutation rate of a mammalian-adapted influenza strain in an MDCK cell 
culture system. To test the effect of an increased mutation rate, I treated influenza with 
the mutagenic nucleoside analogs, ribavirin, 5-azacytidine, and 5-fluorouracil. I found 
that each increases the mutation rate in a characteristic way. Influenza virus is intolerant 
of these changes, due to an increased production of genomes carrying detrimental 
mutations. Evolving influenza in low concentrations of nucleoside analogs failed to 
select for population-wide resistance but did select for two low frequency polymerase 
mutants (PB1 T123A and PA T97I) that were resistant to 5-fluorouracil. Both 
polymerase mutants mediate resistance the through maintenance of high genome 
synthesis upon 5-fluorouracil treatment. Additionally, I found that PB1 T123A has a 
fidelity phenotype that prevents the characteristic increase in C to U mutations by 5-
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fluorouracil. My work has led to the first full description of influenza’s mutation rate. It 
has also provided valuable new insights into how influenza is affected by and tolerates 











 Influenza virus is a respiratory pathogen causing millions of human infections 
worldwide during annual seasonal epidemics (1). Despite the availability of vaccines 
and antiviral drugs, hundreds of thousands of deaths are associated with the virus each 
year. Novel strains of the virus circulate within the human population each year, limiting 
the effectiveness of vaccination and pre-existing immunity (2–4). Additionally, antiviral 
resistance has emerged among circulating influenza strains, making control of the virus 
difficult (5, 6). These challenges in influenza control are due in large part to the rapid 
rate of virus evolution. Rapid evolution is a key property of influenza virus that results 
from the biological characteristics it possesses as an RNA virus.  
 Influenza virus has a genome composed of single-stranded RNA. Its genome is 
in the (-) sense, meaning that it is the reverse complement of the RNA that gets 
translated into proteins. All influenza A viruses have genomes divided into eight 
segments that encode for at least 10 proteins (7, 8). These include protein basic 2 
(PB2), protein basic 1 (PB1), protein acidic (PA), hemagglutinin (HA), nucleoprotein 
(NP), neuraminidase (NA), matrix protein 1 (M1), matrix protein 2 (M2), nonstructural 
protein 1 (NS1), and nuclear export protein (NEP). Each of these proteins is essential 
for efficient viral replication. Infectious viral particles consist of the 8 (-) sense genome 
segments and a protein core containing M1 and M2 proteins enclosed within a plasma 
membrane envelope studded with HA and NA proteins (9). Each genome segment is 
found as part of a complex called the viral ribonucleoprotein (vRNP) that contains 
several NP molecules and one molecule of PB1, PB2, and PA (10).  
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Viral infection initiates when HA binds to sialic acid on the surface of a host cell 
(8, 11). The virus then enters the cell by receptor-mediated endocytosis. The 
acidification of the endosome initiates fusion of the viral envelope with the membrane 
and release of the 8 vRNPs into the cytoplasm. The vRNPs traffic to the nucleus where 
replication begins with the viral replicase (PB1, PB2, PA) synthesizing (+) sense mRNA. 
PB2 and PA function to steal the 5’ methylated caps from cellular RNA molecules that 
PB1 (the RNA-dependent RNA polymerase (RdRp)) uses to prime viral mRNA 
synthesis. The viral replicase also catalyzes the synthesis of both full length (+) sense 
complementary RNA and full length (-) sense genomic RNA. Newly synthesized 
genomic RNAs and viral proteins form vRNP complexes and exit the nucleus under the 
direction of NEP. At the cell surface the vRNPs organize into new viral particles with 
M1, M2, NA, and HA. Particles bud from the cellular membrane and are released 
through the cleavage of bound sialic acid by NA.  
Each infected cell produces hundreds or thousands of new viral particles, but 
only a fraction of these are infectious (12). The specific infectivity of a virus is the 
proportion of viral particles or genomes that are capable of fully completing a viral 
replication cycle. Each new particle is thought to include one copy of each genome 
segment. This genome packaging fidelity is reliant on unique complementary 
sequences at the 5’ and 3’ ends of each genome segment (13, 14). If a cell is co-
infected with two or more genetically distinct viruses reassortment can occur during 
packaging and lead to novel virus genotypes containing genome segments derived from 
multiple infecting viruses (15). These reassortment events have generated many of the 
pandemic strains that have significantly affected human health, including the 1918 
Spanish flu and the 2009 H1N1 swine flu (16, 17). While reassortment of influenza 
genome segments can lead to dramatic changes within the viruses that infect humans, 
the smaller changes caused by mutations are key to influenza being a major health 
problem year after year.        
 






Figure 1.1. The replication cycle of influenza virus 
Influenza virus initiates infection when HA binds sialic acid on the host cell surface. The virus 
enters the cell through receptor mediated endocytosis. Acidification of the endosome causes 
membrane fusion and the release of the 8 vRNP complexes containing the viral genome into the 
cell cytoplasm. These vRNPs traffic to the cell nucleus where the synthesis of mRNA begins. 
Viral mRNA is translated in the cytoplasm and the resulting proteins allow for genome 
replication in the nucleus and the assembly/release of new virions at the plasma membrane of 
the cell.    
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Viral Mutation Rates   
 
 Influenza, like most RNA viruses has a high mutation rate. The mutation rates of 
RNA viruses have been estimated between 10-6 and 10-4 mutations per nucleotide per 
replication cycle (18). These mutation rates are several orders of magnitude higher than 
those of organisms with DNA genomes (19). The reason for this high mutation rate is 
that all known RNA viruses, except for coronaviruses, lack mechanisms for proofreading 
or correcting errors made by the RdRp during genome replication (20, 21). Mutations 
are the raw material upon which selection acts. High mutation rates, combined with 
large population sizes, provide RNA viruses with the ability to evolve rapidly. Often, 
mutation rates are roughly equal to the inverse of the genome length, meaning that one 
new mutation is made in every genome that is replicated (22). Given that tens of 
millions or even billions of viruses can be produced daily within an infected person, 
viruses are able to quickly produce vast swarms of genetically diverse variants (23). 
This rich genetic diversity is thought to allow a virus to adapt to environmental changes 
or strict selective pressures. Influenza’s high mutation rate is a key factor in allowing for 
the changes that permit the virus to rapidly evade existing humoral immunity or become 
resistant to antiviral drugs. The major problems this rapid evolution poses for human 
health are evident in the necessity for yearly vaccine reformulations and the widespread 
resistance to both neuraminidase inhibitors and adamantanes (5, 6).  
 Mutations made by viruses can be measured in two ways, mutation frequencies 
or mutation rates (18, 24). Mutation frequencies are a measure of how many mutations 
are present within a viral population at the time of sampling. The mutations measured in 
this way are highly sensitive to both the presence of pre-existing mutations and 
selection acting upon newly generated mutations. These factors may complicate 
comparison of mutation frequencies across multiple conditions or virus strains. On the 
other hand, mutation rates measure how many new mutations are generated per a 
discrete unit of time, such as per virus replication cycle or per RNA strand replicated. 
Mutation rates are superior to frequencies because they represent the generation of 




When making comparisons between rates, the units need to be taken into 
account. Rates per replication cycle represent a theoretical maximum while per RNA 
strand replicated is the minimum (18). This is due to a virus’ mode of replication, which 
can be either linear or binary (25–27). For single stranded RNA viruses with linear or 
stamping machine replication, each new genome has only 2 synthesis events involved 
in its creation. The first produces the complementary replication intermediate while the 
second synthesizes the new genomic RNA strand. This will cause the mutation rate per 
replication cycle to be two times higher than the mutation rate per RNA strand 
replicated. For a virus with binary replication, there are several rounds of synthesizing 
both (+) sense and (-) sense intermediates before the final new genome is synthesized. 
Since mutations rates are measured in the final genomic product, the ratio of the 
mutation rate per replication cycle to the mutation rate per RNA strand replicated 
approximates how many replication intermediates each new genome progresses 
through and informs about a virus’ mode of replication. Influenza is thought to have a 
replication mode that is near linear (18).           
Viral mutation rates (including influenza’s) have often been measured using 
sequencing based methods (28–32). Since rates are per unit time, when the mutations 
were generated needs to be known in order to use sequencing for mutation rate 
measurements. This can be achieved by either starting with a single viral genotype, or 
measuring only mutations that prevent the virus from replicating and, therefore, 
occurred in the previous replication cycle. Single viral clones can be isolated from a viral 
population by either plaque purification or limiting dilutions. Once a genotype is fixed, 
the virus is allowed to replicate prior to sequencing individual clones from the expanded 
population. The number of replication cycles or strand replication steps that occurred 
between genotype fixation and sequencing is used to convert the measured mutation 
frequencies into rates (18). Since the mode of replication is poorly defined for most 
viruses, these measurements are usually in the units of mutations per nucleotide per 
replication cycle. This method has the advantage of being able to measure all 12 
substitution mutation classes as well as insertions and deletions. This method has 
traditionally been used with Sanger sequencing, which presents the drawbacks of being 
very low throughput and providing low power to accurately measure rare mutations. 
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Efforts to improve the throughput and power by using next-generation sequencing 
methodologies have met with problems due to the need to control for mutations 
introduced by reverse transcriptase during sample preparation (see Chapter 2) (33, 34). 
An additional drawback of using sequencing to measure mutation rates is the sampling 
bias associated with selecting clones to sequence. Clones selected for sequencing by 
plaque purification or limiting dilutions will have high replication fitness and will bias 
measurements towards mutations present only in fit genotypes (35, 36).  
A second method that has been used for measuring mutation rates is a 
fluctuation test. This is a classical genetic assay developed by Luria and Delbrück in the 
1940s (37–40). This test relies on being able to unambiguously differentiate between 
genotypes possessing mutations that present a specific phenotype and those that do 
not. For viruses, this scorable phenotypes is most commonly resistance to antibody 
neutralization (41–45). Fluctuation tests are performed by infecting large numbers of 
parallel cultures of cells with low numbers of infectious virions. While the virus is in the 
exponential phase of growth, each culture is assayed for the number of viruses 
possessing a mutation leading to the scorable phenotype. The number of mutations in 
each culture depends upon the mode of replication and selection. Mutation rates can be 
calculated using the amount of viral replication and the number of phenotype-producing 
mutations present in each culture. Alternatively, by using the null class model, the 
proportion of cultures with no viruses presenting the scorable phenotype (P0) can be 
used to measure the mutation rate independently of both replication mode and selection 
(18). The generation of mutations follows a Poisson distribution, which states that P0 = 
e-m(Nf – Ni), where m is rate of mutation to the scorable phenotype per RNA strand copied, 
Nf is the final viral titer, and Ni is the initial viral titer (18, 39, 40). To convert m to a 
meaningful mutation rate, the number of mutations that can produce the scorable 
phenotype needs to be known. This means that the mutation rates measured in this way 
are an average rate of all the mutation classes that can cause the scorable phenotype. 
While the rates measured using fluctuation tests are usually very precise, they often 
lack in the spectrum of mutations that can be assayed. The rates are often based on 
only a few of the 12 possible mutation classes.            
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Influenza A virus mutation rates are been reported using both of the described 
methods. Using sequencing based techniques influenza’s mutation rate has been 
estimated to be between 7.1 x 10-6 and 4.5 x 10-5 mutations per nucleotide per 
replication cycle (18, 28–30). These values are based upon very low numbers of 
mutations, only 5 to 24, within hundreds of sequenced clones. Using fluctuation tests 
with resistance to monoclonal antibody neutralization as a scorable phenotype, 
influenza A virus’ mutation rate was estimated to be 2.7 x 10-6 to 3.0 x 10-5 depending 
on the antibody used (18, 41, 42). The mutations that caused resistance to antibody 
neutralization were biased towards G to A mutations. These estimates only provide an 
average rate for the mutation classes that they can detect and fail to represent the full 
range of mutation classes that can be generated. Generally, across a range of 
polymerases, transition mutations, which exchange purines for purines or pyrimidines 
for pyrimidines, are thought to occur more frequently than transversions which 
exchange between the nitrogenous base structures (32, 46, 47). The precise biases 
among mutation classes can differ substantially depending on the system being studied. 
For instance, poliovirus has been shown to generate C to U and G to A mutations at the 
highest rate, while frequency measurements in influenza suggest that A to G and U to C 
are most common (48, 49). In order to truly understand influenza’s mutation rate and its 
effect on viral evolution, a more thorough understanding of the biases among all of the 
mutation classes is greatly needed.   
 
Altered viral mutation rates 
 Most RNA viruses encounter a variety of replication environments. Whether 
these environments are different cell types, host organisms, or temperatures, it is 
possible that they may cause changes to the virus’ mutation rate. Several viruses, 
including human immunodeficiency virus 1 (HIV-1), cucumber mosaic virus, and 
vesicular stomatitis virus (VSV) have been shown to have mutation rates dependent on 
the host cell type (45, 50, 51). Influenza virus replicates throughout the respiratory tract 
of humans. This environment includes a variety of cell types and a temperature gradient 
ranging from 32°C in the nose to 37°C in the lung alveoli (52, 53). Additionally, in febrile 
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influenza, temperature can increase to 39°C or higher (54).  Influenza viruses also 
replicates in birds. In addition to the cell type differences between mammals and birds, 
the core body temperature of birds is around 41°C (55, 56). Work with purified influenza 
replicase complexes suggests that its mutation rate is temperature dependent (57).  
 Mutator and antimutator viruses possessing higher or lower mutation rates than 
the wild type virus have been identified for several viruses including poliovirus, foot and 
mouth disease virus (FMDV), HIV-1, chikungunya virus, coxsackievirus, and influenza 
virus (41, 58–65). Some of these viruses with variant polymerase have mutation rates 
that differ 2- to 3-fold from wild type. These findings suggest that mutation rates are not 
fixed and that they may be a phenotype that is under selective pressure.     
 The ability of environmental factors and polymerase mutants to modulate viral 
mutation rates raises the question of what effect mutation rate changes have on the 
virus. This can be answered directly using mutant viruses with altered polymerase 
fidelity. In many cases, both increased and decreased mutation rates are detrimental to 
the fitness of the virus. Higher mutation rates are thought to be detrimental due to the 
fitness effects of mutations. It has been well reported that the majority of single point 
mutations have detrimental fitness effects with a large proportion being lethal and 
completely preventing replication (66–68). In influenza virus, the lethal fraction of single 
point mutants is estimated to be 30% (69).  
A virus with a higher mutation rate will synthesize more genomes containing a 
lethal mutation, decreasing the fitness of the viral population. Alternatively, there are two 
leading hypotheses as to why lower mutation rates are bad for viral fitness. The first 
suggests that in order to increase polymerase fidelity there must be slowed replication 
kinetics (44, 70, 71). Slower replication will allow a virus to be outcompeted by a faster 
virus with a higher mutation rate. The second hypothesizes that a viral population with a 
lower mutation rate has less genetic diversity present (59, 62). Lower diversity may 
attenuate a virus’ ability to adapt and present it with a fitness disadvantage. Regardless 
of the reason, these results suggest that viral mutation rates have evolved to be at or 
near a fitness optimum. There is one reported case, however, that may contradict this 
model. The polymerase mutant R84H in FMDV exhibits a modest 1.4-fold decrease in 
mutation frequency and retains fitness both in vitro and in vivo (72). Since frequency 
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measurements were used, it is unclear if this mutation generates a true difference in the 
virus’ mutation rate. Other putative FMDV fidelity variants, however, do show a fitness 
decrease consistent with the results from other viral systems.  
 The finding that most mutations are detrimental to viruses led to the proposal of 
using mutation rate as an antiviral target. Lethal mutagenesis is the process of using 
mutagenic drugs, typically nucleoside analogs, to increase a virus’ mutation rate (73–
75). It was hypothesized that if the mutation rate could be increased above an error 
threshold that the viral population would quickly collapse due to an inability to maintain 
the production of viable viral genotypes. Producing more mutations in each genome will 
lower the likelihood of any genome being infectious (Figure 1.2).  
Lethal mutagenesis was first demonstrated in HIV-1 (76). Later work has shown 
that several mutagenic agents can induce lethal mutagenesis in a wide variety of RNA 
viruses (77–83). These mutagenic agents include the antiviral drug ribavirin, which has 
been clinically prescribed for several RNA virus infections for decades without a clearly 
defined mode of action. Others include the nucleoside analogs 5-azacytidine and 5-
fluorouracil. Each of these compounds are thought to be misincorporated during the 
synthesis of viral genomes, causing mutations (84). The structure of the nucleoside 
analog determines the classes of mutations that it is able to generate. In addition to viral 
mutagenesis, nucleoside analogs have broad effects on cellular metabolism which also 
contributes to their antiviral properties. The study of lethal mutagenesis has provided 
important contributions to the study of RNA viruses besides its strong potential as a 
broadly applicable antiviral strategy. These studies have also provided useful tools for 




                             
Figure 1.2. Lethal mutagenesis of RNA viruses 
Viral populations that make more mutations will make fewer infectious virions. Three viral 
populations that make an average of 1 (solid), 1.5 (dotted), or 2 (dashed) mutations in each 
newly synthesized viral genome are shown. Approximately 30% of all single point mutations are 
lethal and lead to non-infectious virions. As mutation rates increase, a larger proportion of the 
viral population (area under the curve) is non-infectious (purple).  
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Resistance to increased mutation rates 
Lethal mutagenesis was initially proposed to be a resistance-proof antiviral 
strategy because it was thought that any putative resistance mutations would likely arise 
within highly mutagenized genomes or have too low of fitness to be maintained (85). 
This idea was quickly found to be untrue, as resistant variants have been isolated in 
several RNA virus systems (58, 60, 62, 65, 86, 87). RNA virus mutants with a variety of 
mutagen resistance phenotypes have been characterized. These mutants were all 
identified after passaging viral populations in low concentrations of mutagenic drugs.  
The earliest and most broadly recognized mutagen resistance mechanism was a 
decrease in the baseline mutation rate of an RNA virus. Poliovirus passaged in ribavirin 
quickly acquired decreased sensitivity to the effects of the drug. The mutation that 
mediated this resistance was identified to be G64S within the viruses 3D RdRp (58, 59, 
86). It was shown that this mutant virus has a lower mutation rate than the wild type. 
Therefore, it needs to be treated with higher concentrations of ribavirin to achieve the 
same mutation rate as a ribavirin treated wild type poliovirus. Similar phenotypes have 
been identified for FMDV, chikungunya virus, and influenza virus polymerase mutants 
(62, 65, 72). These mutants have been instrumental for understanding the role that 
mutation rates play in RNA virus biology and evolution. As noted above, many viruses 
possessing high fidelity polymerases experience a fitness cost.  
Fidelity variants are not the only mutants that make viruses resistant to 
mutagens. Even within the same virus, multiple resistance mechanisms have been 
found. FMDV has been the subject of much research studying mutagen resistant 
variants. An FMDV polymerase mutant has been identified that increases the viruses 
baseline mutation rate, but selects against the mutagenic effects of ribavirin allowing for 
the maintenance of normal biases in the mutation spectrum (60, 87, 88). Proteins other 
than the RdRp can also affect a virus’ susceptibility to mutagenic drugs. In FMDV, a 
mutation in the 2C gene that associates with the RdRp has been shown to decrease the 
effect mutagens have on genome infectivity, though this does not cause high level 
resistance (89). In the DNA bacteriophage ΦX174, mutations in protein E, which 
regulates lysis and virion release, was shown to give it a fitness advantage in the 
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presence of the mutagen 5-fluorouracil (90). By delaying lysis and increasing the 
number of new virions released by each infected cell (the burst size), the virus 
increases the number of infectious particles created during each infection event. This 
increase occurs because, for two viruses with the same mutation rate, the one that 
generates more complete viral particles will generate more infectious virions.  
The primary genome sequence of an RNA virus has also been hypothesized to 
affect a virus’ tolerance to mutation rates. Not all codons mutate equally. Some are 
biased towards synonymous changes, while others have the potential for large amino 
acid changes or the introduction of stop codons. Therefore, the genotype of a virus may 
have a large impact on how well a virus is able to tolerate mutations. Vesicular 
stomatitis virus and poliovirus were used to experimentally show that the sensitivity of a 
virus to mutagen was dependent on its mutational robustness, or the average fitness 
effect of mutations across its genome (36, 91, 92).  
 Through the characterization of ways that viruses can adapt to limit the 
detrimental effects of elevated mutation rates, the complexity of this seemingly simple 
phenotype has become apparent. How mutations are generated and how they affect the 
dynamics of viral populations are now known to be under several layers of control. The 
RdRp, auxiliary proteins, the replication environment, and the codons that make up a 
viruses genotype all play a role in determining how viruses mutate and, ultimately, how 
they can evolve. Through studying the roles these viral properties play in governing viral 
mutation rates, we will be better prepared to understand and predict RNA virus 
evolution.  
 
Open questions on influenza’s mutation rate     
  Influenza’s short- and long-term evolutionary dynamics are important properties 
that aid the virus in maintaining its status as a perennial human health burden. An 
improved understanding of how influenza generates mutations, which selection acts 
upon, is imperative for a complete understanding of how it evolves. To date, no 
complete characterization of influenza’s mutation spectrum has been undertaken. 
Attempts to study the effects of replication environment on influenza’s mutation rate 
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have been limited in their reliability due to the use of low throughput mutation rate 
assays or artificial biochemical systems. Here, I describe the development of a novel, 
high-throughout mutation rate assay that allows for the individual measurement of all 12 
mutation classes. We developed this assay with viruses encoding non-fluorescent GFP 
constructs and used their reversion to being fluorescent as a scorable phenotype in a 
fluctuation test. We used this assay to directly compare mutation rates and mutational 
spectrums among different virus genotypes, virus strains, and replication environments. 
We also present data documenting the difficulties associated with using next-generation 
sequencing technologies to accurately measure the mutation rates of RNA viruses. 
 Until recently, the effects of high mutation rates on influenza populations had not 
been well explored.  With the Lauring lab’s publication of a large-scale, genome-wide 
analysis of the effects of single nucleotide substitutions and both ribavirin and favipiravir 
(T-705) being shown to be mutagenic as part of their anti-influenza mechanisms of 
action, new questions appeared (65, 69, 93). These included determining how sensitive 
influenza is to increases in its mutation rate, how influenza’s natural mutational bias 
affects mutagenesis, and how easily influenza can evolve resistance to mutagens. 
Here, we undertake the first complete characterization of lethal mutagenesis in 
influenza virus. Using three nucleoside analogs, ribavirin, 5-azacytidine, and 5-
fluorouracil, we investigate how efficiently lethal mutagenesis may function as an anti-
influenza strategy. We focus on the mechanism through which these drugs induce 
mutations, influenza’s tolerance to different classes of mutations, and how easily 
resistance to mutagens is evolved by influenza.    
One of the best ways to study how RNA viruses can tolerate such high mutation 
rates is to look for mutants that are resistant to mutagenic drugs. Two mutations, PB1 
D27N and PB1 V43I, have been reported to provide resistance to ribavirin’s polymerase 
inhibitory and mutagenic activities, respectively (65, 94). Their mechanisms of 
resistance have not been well characterized. Additionally, resistance by PB1 D27N was 
never tested in a replication competent virus and it is uncertain if the ribavirin resistance 
exhibited by PB1 V43I is dependent on the viral strain. Evidence from other RNA 
viruses suggests that multiple mutagen resistance mechanism may be possible. 
Whether this is true for influenza has yet to be studied. From the results of our lethal 
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mutagenesis experiments, we found several mutations within the genes that encode the 
components of influenza’s replicase that mediated 5-fluorouracil resistance. Here, we 
characterize how PB1 T123A, PA T97I, and the previously identified PB1 mutations 
mediate mutagen resistance in the PR8 strain background.  
Mutation rates are a key driver of RNA virus evolution. Understanding the 
mutational dynamics of influenza and other medically important viruses will be integral 
in the development of more effective vaccines and therapeutics. The work I report here 
answers longstanding questions and describes influenza’s mutation rate in 
unprecedented detail. We show some of the factors that can change influenza’s 
mutation rate, how changes affect the virus, and how the virus can combat these 
changes. The cumulative impact of these results may lead to better evolutionary 
models, more effective lethal mutagenesis drugs, and a renewed interest in the role 







The mutation rate and mutational bias of influenza virus 
 
Note: A modified version of this chapter is expected to be submitted for publication in 
January, 2017.  
Abstract 
Influenza virus is a significant world-wide health problem. The virus’ high 
mutation rate is a key driver of the rapid evolution that allows it to evade the effects of 
humoral immunity and antiviral drugs. Here, we investigate two new methods for the 
high throughput and unbiased measurement of influenza’s mutation rate spectrum. We 
demonstrate that next generation sequencing-based methods are not reliable for 
determining the mutation rates of RNA viruses due to the requirement of a reverse 
transcription step during sample preparation. We show that a fluctuation test based on 
virally encoded green fluorescent protein mutants reverting to fluorescence allows for 
accurate mutation rate estimates for all 12 mutation classes. Using this method, we 
measure neutral mutations in the context of a relatively unstructured RNA sequence. 
We measured the mutation rates of two evolutionarily divergent strains, A/Puerto 
Rico/8/1934 H1N1 and A/Hong Kong/4801/2014 H3N2. We found that influenza’s 
overall mutation rate, 1.8 x 10-4 to 2.5 x 10-4 substitutions per nucleotide per strand 
replicated, is higher than previously estimated using other methods and indicates that 
influenza makes an average of 2 to 3 new mutations each time it replicates its genome. 
The mutations that influenza makes are strongly biased towards A to G and U to C 
transitions, resulting in a transition to transversions bias of 2.7 to 3.6, depending on the 
strain. The mutation rates of the two strains are generally similar, but they demonstrate 
the ability of influenza to alter the rates of individual mutation classes independently. We 
also determined that influenza mutation rates are temperature independent over a 
range of physiological temperatures in a mammalian cell culture system. Our work 
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provides the first high-resolution characterization of influenza’s mutation rate spectrum. 
These results will lead to a better informed study of influenza’s evolutionary processes 
that may spur the design of improved vaccines and antivirals with higher barriers to 
resistance.     
 
Introduction 
Influenza virus causes significant morbidity and mortality worldwide. Influenza 
control is especially difficult, because the rapid evolution of influenza virus has led to 
reduced vaccine efficacy, widespread drug resistance, and the annual emergence of 
novel strains (2–5). Like most RNA viruses, influenza has a high mutation rate because 
the RNA-dependent RNA polymerase (RdRp) that it uses to replicate its genome lacks 
the ability to proof-read or correct errors that are introduced during RNA synthesis (20, 
21). This high mutation rate is a key driver of influenza’s rapid evolution. 
 Mutations are the raw material on which selection acts, so a precise description 
of influenza’s mutation rate and mutational bias is essential for our understanding of the 
virus’ evolution. Mutations are typically measured as either frequencies or rates (18). A 
virus’ mutation frequency is the number of mutations identified in a sample per 
nucleotide sequenced. Frequency measurements can be skewed by pre-existing 
mutations within a population and by selection acting upon mutants. In contrast, 
mutation rates measure how many mutations are made in a discrete unit of time, such 
as per infection cycle or per strand copied. Mutation rates are therefore a better 
representation of polymerase error.  
Viral mutation rates are often measured by Sanger sequencing randomly 
selected clones obtained through plaque purification or limiting dilutions (28–32). 
Mutation frequencies obtained in this manner can be converted to mutation rates by 
adjusting for the number of replication cycles between fixing a single genotype and 
sampling single clones for sequencing (18). While sequencing approaches can 
potentially measure the rate of all substitution classes, they lack precision and have 
poor power for detecting differences across strains or conditions. Indeed, sequencing 
based estimates of influenza virus mutation rates range from 7.1x10-6 to 4.5x10-5 
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substitutions per nucleotide per cell infection cycle (18, 28–30). Additionally, these 
approaches have the drawback of being biased towards sampling higher fitness 
genomes due to the methods used for clone selection. While methods exist for 
increasing the throughput and power of clonal sequencing, they require the use of 
reverse transcriptase (RT), which itself has a mutation rate in the mid 10-5 substitutions 
per nucleotide range (95–97). The contribution of RT errors to the sequencing of RNA 
virus samples has not been thoroughly investigated.     
 A more direct way to measure mutation rates is to use a Luria-Delbrück 
fluctuation test (37–40, 44). In this method, a large number of parallel cell cultures are 
infected with a small population of a virus. After a period of exponential growth, each 
culture is assessed for the presence of specific newly generated mutants by assaying 
for a scorable phenotype that differentiates them from wild type virus. The mutations 
that cause the scorable phenotype are rare and random, following a Poisson distribution 
within a culture. Utilizing the null class (P0, proportion of cultures with no scorable 
mutants) allows for the calculation of mutation rates independently of knowing if a virus’ 
mode of replication is linear or binary (18, 27). Influenza’s mutation rate has been 
measured to be 2.7 x 10-6 to 3.0 x 10-5 substitutions per nucleotide per strand copied, 
using resistance to monoclonal antibodies as a scorable phenotype (41, 42). While 
fluctuation tests are more precise than sequencing assays, most scorable phenotypes 
sample just a few sites or mutational classes.  
 Here, we apply two new approaches for measuring the influenza virus mutation 
rate that overcome the drawbacks of low statistical power and bias inherent in the 
currently available methods. The first relies on measurements of nonsense mutation 
frequencies within a short segment of the influenza genome using PrimerID, an error-
controlled next-generation sequencing approach (33, 98).  Nonsense mutations are 
lethal and generally not propagated. Therefore, their frequencies approximate the 
mutation rate in the prior replication cycle (99). The second is a Luria-Delbrück 
fluctuation test that scores reversion to fluorescence in virally encoded green 
fluorescent protein (GFP) mutants. The GFP method allows us to interrogate all 12 
mutation classes independently and estimate the mutation rate and mutational biases of 
different strains under different conditions (100).  
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Materials and Methods 
Viruses, plasmids, and cells 
 Madin Darby Canine Kidney (MDCK) cells and 293T cells were maintained in 
Dulbecco’s modified Eagle medium (Gibco 11965) supplemented with 10% fetal bovine 
serum and 25 mM HEPES in a humidified incubator at 37°C and 5% CO2.  
 Influenza A/Puerto Rico/8/1934 H1N1 was obtained from ATCC (VR-1469). 
A/Hong Kong/4801/2014 H3N2 was obtained from the Centers for Disease Control and 
Prevention International Reagent Resource (FR-1483).  A/Wisconsin/03/2007 H3N2 
was provided by Dr. Arnold S. Monto (University of Michigan School of Public Health). 
Each of the 8 genomic segments for these virus strains were amplified by reverse 
transcription polymerase chain reaction (RT-PCR) and cloned into the pHW2000 
plasmid (101, 102). 
 Cells expressing the hemagglutinin (HA) protein of influenza A/Puerto 
Rico/8/1934 H1N1 (MDCK-HA cells) were generated by co-transfecting Madin Darby 
canine kidney (MDCK) cells with a pCABSD plasmid that expresses a Blasticidin S 
resistance gene and a pCAGGS plasmid encoding the influenza A/Puerto Rico/8/1934 
H1N1 HA gene (103). Pools of cells stably expressing HA were selected in growth 
media containing 5 μg/mL Blasticidin S. These pools were enriched for cells with high 
HA expression by staining with an anti-HA antibody (1:1000 dilution, Takara c179) and 
an Alexa 488-conjugated anti-mouse IgG (1:200 dilution, Life Technologies A11001) 
followed by fluorescence-activated cell sorting on a FACSAria II (BD Biosciences). Cells 
were sorted three times over the course of 5 passages and > 99% of cells in the final 
population were positive for high HA expression.  
 A pPOLI vector encoding eGFP with influenza HA packaging sequences was 
kindly provided by Luis Martinez-Sobrido (University of Rochester). This construct, 
which we call ΔHA-GFP, had eGFP flanked by the 78 3’-terminal bases (33 noncoding, 
45 coding) and 125 5’-terminal bases (80 coding, 45 noncoding) of the HA gene 
segment from influenza A/WSN/33 H1N1 and lacks the HA translation initiation codon 
(104). Twelve mutant ΔHA-GFP constructs (Table 2.2) were generated using a 
QuikChange II site-directed mutagenesis kit (Agilent Technologies 200523) with primers 
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5’- CTCGTGACCACCCTG<mutant sequence>GTGCAGTGCTTCAGC-3’ and 5’- 
GCTGAAGCACTGCAC<mutant sequence’>CAGGGTGGTCACGAG-3’, where mutant 
sequence corresponds to a sequence in Table 2.2 and mutant sequence’ is its reverse 
complement. 
A neutral genetic barcode was incorporated into the PB1 segment of A/Puerto 
Rico/8/1934 H1N1 in the pHW2000 vector by overlap extension PCR using the inner 
primers 5’-GATCACAACTCATTTCCAACGGAAACGGAGGGTGAGAGACAAT-3’ and 
5’-ATTGTCTCTCACCCTCCGTTTCCGTTGGAAATGAGTTGTGATC-3’, and outer 
primers containing BsmB1 sites for cloning into the pHW2000 plasmid (105).    
 Viruses were rescued in 12-well plates after transfection of co-cultures of 2x105 
293T cells and 1x105 MDCK cells with mixtures of pHW2000 plasmids encoding all 8 
influenza genome segments (500 ng each) using 2 μL of TransIT-LT1 (Mirus 2300) per 
ng of DNA (101). Viruses expressing GFP were rescued in the same manner except 
that the pPOLI vector encoding ΔHA-GFP or its mutants and the HA encoding pCAGGS 
vector were used in place of a pHW2000 plasmid encoding influenza HA, and MDCK-
HA cells were used in place of MDCK cells.     
 
PrimerID Sequencing Assay 
 A custom R script (https://github.com/lauringlab/NGS_mutation_rate_assay) was 
used to identify the 402 base region in the A/Wisconsin/03/2007 H3N2 genome 
(positions 865 to 1266 of the PA gene) with the highest concentration of pre-nonsense 
codons. Trizol (Life Technologies 15596) was used to isolate RNA from 293T cells 48 
hours after transfection with a plasmid expressing the A/Wisconsin/03/2007 H3N2 PA 
segment and from cell free supernatants of MDCK cells infected with 
A/Wisconsin/03/2007 H3N2 virus at an MOI of 0.5 for 24 hours. The RNA was treated 
with DNase I (Roche 04716728001) to remove residual plasmid DNA. The 
concentration of PA RNA in each sample was quantified by reverse transcription with 
SuperScript III (Invitrogen 18080051) and primer 5’-AGCAAAAGCAGG-3’ followed by 
quantitative PCR on a 7500 Fast Real-Time PCR system (Applied Biosystems) with 
Power SYBR Green PCR Master Mix (Applied Biosystems 4367659)  and primers 5’-
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TCTCCCATTTGTGTGGTTCA-3’ and 5’-TGTGCAGCAATGGACGATTT-3’. A plasmid 
encoding PA was used to generate a standard curve to relate cycle threshold to copy 
number. The absence of plasmid DNA containing the PA sequence was confirmed by 
the absence of qPCR amplification from RNA samples that were not reverse 
transcribed. Accuscript high fidelity reverse transcription (Agilent Technologies 200820) 
was performed on 2 x 105 copies of PA RNA using primer (5’-
CCTACGGGAGGCAGCAGNNNNNNNNNNAATTCCTCCTGATGGATGCT-3’) which 
binds to bases 842 to 861 of the PA gene (positive strand numbering) and contains a 
degenerate N10 barcode sequence (1,048,576 unique sequences). By using only 2 x 105 
copies of PA RNA, which is one-fifth the total number of barcode sequences, we 
minimized the likelihood that the same barcode would prime multiple complementary 
DNA (cDNA) molecules (33). Three separate reverse transcription reactions were 
performed for RNA harvested from both transfected and infected cells to increase the 
total number of RNA templates in the experiment. The resulting Primer ID barcoded 
cDNA was purified using Agencourt AMPure XP beads (Beckman Coulter A63881) to 
remove residual primers. The purified cDNA was PCR amplified using Phusion high 
fidelity DNA polymerase (New England Biosciences M0530) for 26 cycles (10 seconds 




CAGCAG-3’ where i5 and i7 are 8 base Illumina indexing sequences. These primers 
contain the Illumina flow cell adapters at their 5’-ends. Unique index primers were used 
in the PCR for each of the three RT replicates. Products were gel purified using a 
GeneJET Gel extraction kit (Thermo Scientific K0691) and replicates were pooled with 
each product at 1.5 ng/μL. The two pooled sets (one for plasmid transfected cells and 
one for infected cells) were each sequenced on an Illumina MiSeq with 2 x 250 paired 
end reads, V2 chemistry, and the sequencing primers 5’-
TATGGTAATTGGCCTACGGGAGGCAGCAG-3’, 5’-
AGTCAGTCAGTATGGGGCTACGTCCTCTCCAA-3’ and 5’-
TTGGAGAGGACGTAGCCCCATACTGACTGACT-3’. Each pooled set made up half of 
 
21 
the DNA input on a separate sequencing run with the remaining DNA being composed 
of bacterial genome libraries. This allowed for sufficient sequencing diversity at each 
base. We obtained over 15 million combined reads from the two samples.  
 Consensus sequences were created for each PrimerID that met empirically 
determined count cutoffs using Ruby scripts kindly provided by Ronald Swanstrom and 
colleagues (University of North Carolina). We obtained greater than 449,000 consensus 
sequences for each of the two samples, suggesting greater than 75% of RNA templates 
were sampled. Consensus sequences were aligned to the A/Wisconsin/03/2007 H3N2 
PA sequence using Bowtie2 and alignments were analyzed using Samtools. A custom 
Python script was used to determine the base composition at each position 
(https://github.com/lauringlab/NGS_mutation_rate_assay) and the number of stop 
codons within Primer ID consensus sequence. The mutation frequency for eight 
mutation classes were determined by dividing the number of stop codons resulting from 
that substitution class by the number of sites sequenced that could possibly mutate to a 
stop codon through that same class.   
 Raw sequencing fastq files from this experiment are available at the Sequence 
Read Archive under BioProject accession number PRJNA347826. 
 
GFP mutation rate assay 
 Passage 1 (P1) stocks of ΔHA-GFP viruses were made by passing transfection 
rescued virus once on MDCK-HA cells at a multiplicity of infection (MOI) of 0.01 for 48 
hours.  For each fluctuation test, 24 or more parallel cultures of MDCK-HA cells were 
infected with P1 influenza viruses encoding one of the twelve ΔHA-GFP mutants in viral 
media (Dulbecco’s modified Eagle medium (Gibco 11965) supplemented with 0.187% 
BSA, 25 mM HEPES, and 2 μg/mL TPCK treated trypsin (Worthington Biochemical 
3740)). Depending on the mutation class, these infections were carried out in 96-well 
plates (1.2 x 104 cells infected with 400 TCID50 of virus in 100μL), 48-well plates (3.6 x 
104 cells infected with 1200 TCID50 in 300μL), or 24-well plates (7.2 x 10
4 cells infected 
with 2400 TCID50 in 600μL). At 17-30 hours post infection (depending on the mutation 
class, drug treatment, and temperature being assessed) supernatants were transferred 
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to black 96-well plates (Perkin Elmer 6005182) containing 1.5 x 104 MDCK cells and 
50μL of viral media. Supernatants from each well of 48-well and 24-well plates were 
transferred in 150μL aliquots to 2 or 4 wells of the black 96-well plate, respectively. Two 
to four wells were infected with virus equivalent to the amount used to initially infect the 
parallel cultures. These wells are used to determine Ni in the mutation rate calculation. 
At 14 hours post transfer, when GFP expression reached its maximum, cells were fixed 
using 2% formaldehyde for 20 minutes. Cells were then rinsed with phosphate buffered 
saline (PBS) and permeabilized using 0.1% triton-X-100 for 8 minutes. After rinsing with 
PBS, 2% BSA in PBS containing 0.1% tween-20 (PBS-T) was added for 1 hour to block 
nonspecific antibody binding. Cells were stained using 1:5000 Hoechst (Life 
Technologies 33342) and 1:400 anti-GFP Alexa 647 conjugate (Life Technologies 
A31852) diluted in 2% BSA in PBS-T for 1 hour. Cells were washed three times with 
PBS-T and the plates were sealed with black tape prior to removing the final wash. 
Plates were imaged using an ImageXpress Micro (Molecular Dynamics) using DAPI, 
Cy5, and FITC specific filter cubes with a 4x magnification lens. Four non-overlapping 
quadrants were imaged from each well to ensure that their entire surface area was 
captured, Cellular nuclei and antibody stained cells were counted using MetaXpress 
version 6 software (Molecular Dynamics). Cells expressing fluorescent GFP were 
manually counted from the collected images.  
 Mutation rates were calculated by a Luria-Delbrück fluctuation test using the null-
class model and the equation μ(s/n/r) = -ln(P0)/(Nf-Ni), where μ(s/n/r) is the mutation rate per 
strand replicated, P0 is the proportion of cultures that do not contain a cell infected by a 
virus encoding fluorescent eGFP, and Nf and Ni are the final and initial viral population 
sizes, as determined by staining with the anti-GFP antibody (recognizes both 
fluorescent and non-fluorescent eGFP) (40, 44). Cultures that contained a number of 
green cells greater than or equal to 0.8(Nf/Ni) were removed from the calculation 
because they likely contained a pre-existing fluorescent revertant in the inoculum. 
These occurrences were extremely rare due to the use of a small inoculum.  This 
measurement is most precise when P0 is between 0.1 and 0.7 (39, 40). Due to the rarity 
of certain mutation classes and the constraints of the maximum viral population size per 
culture and per well on the imaging plate, not all of our measurements fell within this 
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range. Measurements where the P0 was above 0.7 are indicated in the graphical 
representations of our data. 
 Ribavirin (1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-
1,2,4-triazole-3-carboxamide) (Sigma-Aldrich R9644) was dissolved in PBS at 100mM. 
5-azacytidine (4-Amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one) (Sigma-Aldrich A2385) 
and 5-Fluorouracil (2,4-Dihydroxy-5-fluoropyrimidine)  (Sigma-Aldrich F6627) were 
dissolved in dimethyl sulfoxide (DMSO) at 100mM and 384mM, respectively. For 
mutation rate measurements in the presence of drug, MDCK-HA cells were pretreated 
with viral media containing 2.5μM ribavirin, 0.625 μM 5-azacytidine, or 15 μM 5-
fluorouracil for three hours. Mutation rate assays were carried out according to the 
above protocol except that the viral media for the initial infections contained drugs at the 
indicated concentrations.  
 Mutation rate measurements at different temperatures were carried out as above, 
except that the initial replication was performed in incubators maintained at 32°C or 
39°C. The imaging plates were kept at 37°C for the 14 hours after the supernatant 
transfer.    
 
Competition assay 
 Equal quantities (TCID50) of selected mutant ΔHA-GFP viruses were mixed with 
wild type ΔHA-GFP viruses containing a neutral sequence barcode in the PB1 gene, 
and used to infect 4 x 105 MDCK-HA cells in a 6-well plate at a multiplicity of infection 
(MOI) of 0.01 in viral media. At 24 hours post infection, supernatants were harvested 
and infectious particles were titered by TCID50 assay. The resulting virus was passaged 
three more times, maintaining an MOI of 0.01. Each viral competition was performed in 
triplicate. RNA was harvested from the initial mixture and passaged supernatants using 
a Purelink Pro 96 viral DNA/RNA kit (Invitrogen 12280). Complementary DNA was 
synthesized using Superscript III and random hexamers. Quantitative PCR was used to 
determine the relative amount of total PB1 (primers 5’-CAGAAAGGGGAAGATGGACA-
3’ and 5’-GTCCACTCGTGTTTGCTGAA-3’), barcoded PB1 (primers 5’-
ATTTCCAACGGAAACGGAGGG-3’ and 5’-AAACCCCCTTATTTGCATCC-3’), and non-
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barcoded PB1 (primers 5’-ATTTCCAACGGAAACGGAGGG-3’ and 5’-
AAACCCCCTTATTTGCATCC-3’)in each sample. The relative amounts of barcoded 
and non-barcoded PB1 at each passage were normalized by subtracting the Ct 
threshold for the total PB1 primer set from their Ct thresholds (ΔCt = Ctcompetitior – Cttotal 
PB1). The normalized values at each passage were compared to the initial viral mixture 
to get a relative Ct (ΔΔCt = ΔCtP1 – ΔCtP0). The relative Ct was converted to reflect the 
fold change in genome copies (Δratio = 2–ΔΔCt). The slope of the differences between 
the log10 Δratios of the two viruses as a function of the passage number is equal to the 
log10 relative fitness of the non-barcoded virus ([log10Δrationon-barcoded- log10 
Δratiobarcoded]/passage) (69).   
 
Growth curves 
 100 TCID50 of mutant ΔHA-GFP viruses (in 100μL of viral media) were used to 
infect 1.2 x 104 MDCK-HA in a 96-well plate. At two hour intervals between 14 and 26 
hours post infection, supernatants from 4 wells were transferred to a black 96-well plate 
containing 1.5 x 104 MDCK cells and 50μL of viral media. Virus equivalent to the initial 
inoculum was added to 4 wells so that the virus present at 0 hours post infection could 
be determined. At 14 hours after supernatant transfer, the cells were fixed, stained and 
imaged as described above.       
 
RNA minimum free energy  
 The minimum free energy of the ΔHA-GFP RNA was determined using the RNA 







Sequencing influenza virus using the Primer ID method 
 We employed Illumina sequencing with the PrimerID method to increase the 
power and decrease the sampling bias associated with measuring viral mutation rates 
through the sequencing of individual viral clones (33, 98). We measured the frequencies 
of nonsense mutations within the population to mitigate the effect of selection upon viral 
mutants (99). Eighteen of the 61 codons can mutate to a stop codon through 23 unique 
single nucleotide changes, representing 8 of the 12 substitution classes. We identified a 
region within the PA gene of A/Wisconsin/03/2007 H3N2 (bases 865 to 1266, positive-
sense numbering) that has the highest and most balanced distribution of pre-nonsense 
codons within the virus’ genome. There are 80 unique substitutions that create a stop 
codon within these 402 bases. We used the PrimerID method on the Illumina 
sequencing platform to sequence individual PA clones from an influenza population. 
This method has the added advantage of controlling for errors introduced during the 
sequencing library preparation PCR steps and during the sequencing itself, through the 
use of a reverse transcription primer containing a string of 10 random nucleotides 
(1,048,576 unique Primer IDs) (33, 98). This method does not, however, control for 
errors that are introduced during the reverse transcription step of sample preparation.  
 In an attempt to distinguish RT errors from mutations introduced by the influenza 
RdRp, we applied PrimerID to the sequencing analysis of two samples (Figure 2.1A). 
The control sample originates from RNA expressed off of a pol I driven plasmid in 
transfected cells. Mutations identified in this sample arise from either RT or cellular RNA 
polymerase I. While error rates for RNA polymerase I have not been reported, 
eukaryotic RNA polymerase mutation rates range from to 4 x 10-6 to 1.8 x 10-4 
substitutions per nucleotide (34, 107, 108). The second sample is derived from genomic 
influenza RNA, and measures mutations made by both RT and the influenza RdRp.  
 We obtained over 449,000 consensus sequences that aligned to bases 865 to 
1266 of the influenza PA gene from each sample, suggesting we obtained consensus 
sequences for greater than 75% of starting RNA templates. The number of nonsense 
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mutations that were identified in each sample is shown in Table 2.1. The frequency of 
nonsense mutations were similar for 5 of the 8 substitution mutation classes analyzed 
(Figure 2.1B). The other three mutation classes (A to U, C to A, and U to G) are only 
slightly higher in the samples derived from RNA replicated by the influenza RdRp than 
those that were not. In support of RT errors causing much of the mutation signal we 
observe, G to A mutations were found at the highest frequency. Guanine to adenine 
mutations have been shown to predominate the in vitro RT mutation spectrum with rates 
around 1 x 10-4 substitutions per nucleotide (34). These results suggest that the 
background error rate of reverse transcriptase during sample preparation is equal to or 
higher than the rate of mutations introduced by the influenza RdRp.  
We also compared the frequency of nonsense mutations to the frequency of all 
observed mutations. Mutations introduced after the RNA is harvested are expected to 
occur at an equal frequency across the gene being analyzed. This is indeed what we 
see for the cell derived RNA sample (Figure 2.1C). On the other hand, we see higher 
frequencies of total mutations than we do nonsense mutations for the viral derived RNA 
sample. This is because nonsense mutations arose strictly within the previous viral 
replication cycle, while mutations at other sites have the possibility of being passed 
generation to generation.  
Together, our data show that standard next generation sequencing-based assays 
are not reliable for the measurement of RNA virus mutation rates. These methods can 
not be used when the viral mutation rate is similar to that of reverse transcriptase. Even 
when viral mutation rates are higher than that of RT, the mutational bias of RT may 




Figure 2.1. Influenza mutation rates by Illumina sequencing 
(A.) Work flow for sequencing mutation rate assay. RNA samples were isolated from cells 
transfected with PA expressing plasmids or the supernatants of cells infected with influenza 
virus. These samples were processed, sequenced, and analyzed using the Primer ID method as 
described in methods. We obtained 449,655 consensus sequences for the cell derived RNA 
sample and 481,286 consensus sequences for the viral derived RNA sample. (B.) The 
frequency of nonsense mutations in each sample were determined by dividing the number of 
nonsense mutations by the total possible sites sequences that could have a nonsense mutation. 
(See table 2.1) (C.) The frequency of all mutations was determined as the number of observed 
mutations from a particular mutation class divided by the number of sequences sites that could 
mutate by a mutation class. The ratio of nonsense mutation frequency to the frequency of all 
mutations within the sample is shown.      
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Table 2.1. Nonsense mutation counts from Illumina sequencing of the influenza 





Development of a GFP-based mutation rate assay 
 Since we were unable to measure influenza’s mutation rate using Primer ID 
sequencing methods, we investigated another method for measuring viral mutation 
rates in a high throughput manner. We used a Luria-Delbrück fluctuation test with the 
scorable phenotype of reversion to GFP fluorescence to measure influenza mutation 
rates. Enhanced GFP (eGFP) contains three amino acids; T65, Y66, and G67, that 
create the protein’s fluorescent chromophore (109). Mutations at any of these three 
amino acid positions cause the protein to be either non-fluorescent or to have altered 
fluorescent properties (110–112). We created twelve unique eGFP constructs with 
mutations within these three amino acids in the context of a virus with eGFP replacing 
HA (ΔHA-GFP). Each has a single nucleotide mutation that will cause reversion of the 
protein to eGFP or to wild type GFP (S65) (Table 2.2) (100). These twelve mutant ΔHA-
GFP constructs allow us to probe all twelve substitution mutation classes.  
 We first verified that viruses encoding each of the mutant ΔHA-GFP constructs 
expressed the eGFP protein. Since these proteins were not fluorescent at the 
wavelengths of eGFP, we stained infected cells with an anti-GFP antibody conjugated 
to AlexaFluor 647. All 12 viral construct expressed a protein that was both non-
fluorescent and recognized by the antibody. We also identified rare cells that expressed 
eGFP by antibody staining and were fluorescent at the excitation and emission 
wavelengths of eGFP, consistent with reversion to fluorescence (Figure 2.2A). 
 We measured the fitness of viruses carrying mutant ΔHA-GFP and wild type 
ΔHA-GFP constructs to ensure that the mutations were selectively neutral. We 
competed a subset of the mutant ΔHA-GFP viruses against a version of the wild type 
ΔHA-GFP virus containing a neutral sequence barcode in the PB1 gene. We used RT-
quantitative PCR to measure the frequency of the competitors over serial passage on 
MDCK-HA cells (69). We found that the each of 6 mutant viruses were as fit as the wild 
type ΔHA-GFP virus, maintaining stable frequencies over 4 passages (Figure 2.2B). We 
found no statistically significant differences for any of the 6 viruses, which represent 
mutations affecting each of the 3 amino acid positions (One way ANOVA). These data 
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demonstrate that the scorable phenotype and the mutations interrogated are selectively 
neutral. 
 Secondary structure of nucleic acids is known to influence mutation rates in a site 
specific manner (51, 113, 114). We calculated the minimum free energy of RNA folding 
using sliding window analysis and ViennaRNA to determine if the ΔHA-GFP RNA was 
likely to form secondary structures (106). The mutations we created within ΔHA-GFP 
are located within a region of high minimum free energy (Figure 2.2D). This result 
predicts that our region of interest is less likely to form a secondary structure than are 
other locations within the ΔHA-GFP RNA. The lack of strongly predicted secondary 
structures, along with the fact that nucleoprotein limits the formation of secondary 
structure in replicating influenza RNA, suggest that the mutation rates we measure at 
these sites will not be biased by RNA structure. 
 We measured the growth kinetics of mutant ΔHA-GFP A/Puerto Rico/8/1934 
H1N1 viruses by antibody staining for eGFP expression (Figure 2.2C). We found that 1 
x 104 viruses (1 x 105/mL), which is the maximum that can be accurately measured by 
fluorescence in a single well of a 96-well plate, was reached by 22 hours at 37°C.  
 We used a Luria-Delbrück fluctuation test to measure mutation rates for all 12 
substitution mutation classes with the mutant ΔHA-GFP viruses (Figure 2.3A). We 
infected parallel cultures of MDCK-HA cells with mutant ΔHA-GFP viruses, allowed the 
virus to replicate, and then transferred supernatants to a 96-well imaging plate. The 
replication time and transfer volume were empirically determined for each mutation 
class, drug, temperature, and virus background being assessed. We used a null class 
model to estimate mutation rates with green fluorescence measuring the proportion of 
parallel cultures without any reversion events (P0), and antibody staining to measure the 
initial and final numbers of viruses. The mutation rates we report using this method are 
in the coding (+) sense of the RNA. We present the mutation rates in this way, rather 
than the genomic (-) sense, because influenza sequences are typically reported in the 
coding sense.       
 We used mutagenic nucleoside analogs to validate the specificity of our assay to 
specific mutation classes. Ribavirin, 5-azacytidine, and 5-fluorouracil each increase the 
mutation rates of different mutation classes. Ribavirin induces C to U and G to A, 5-
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azacytidine increases C to G and G to C, and 5-fluorouracil is known to increase the 
frequency of all transitions (A to G, C to U, G to A, and U to C) (115). Figures 2.3B, 
2.3C, and 2.3D show that each of these mutagens specifically increases the measured 
rates of only the expected mutation classes. Some of the mutation classes or treatment 
conditions we tested did not allow measurements within the ideal P0 range of 0.1-0.7 
due to low frequency of reversion or low virus titers (39, 40). In all of the mutation rates 
we report here, open symbols denote these measurements that did not fall within the 
ideal P0 range.  
 
Table 2.2. Non-fluorescent mutant ΔHA-GFP constructs  
 
a Mutations are in the mRNA coding sense. 
 
b Nucleotides 193-201 of the eGFP reading frame are shown. Changes from wild type are in 
bold and italics. Site that allows reversion to fluorescence is capitalized.  
 
c Amino acids 65-67 of eGFP are shown. Changes from wild type are in bold and italics  
 




Figure 2.2. Characterization of ΔHA-GFP and mutant ΔHA-GFP influenza viruses  
(A.) Fluorescent images of cells infected with mutant ΔHA-GFP (A to C) and stained using 
Hoechst and anti-GFP Alexa 647 conjugate. Images were taken at 4x magnification. (B.) The 
fitness of 6 of the mutant ΔHA-GFP viruses were compared to wild type ΔHA-GFP through 
direct competition with a genetically barcoded competitor over 4 serial passages. Quantitative 
PCR was used to determine the relative changes in the population frequency of the two 
competitors from which fitness values were calculated. Viruses are divided by which amino acid 
within the eGFP protein is mutated. Wild type is shown in black, mutations at T65 are shown as 
gray bars, at Y66 are shown as striped bars, and at G67 are shown as white bars. Data shown 
represents the mean and standard deviation for three competitions and fitness measurements 
for each virus. A one-way ANOVA test was used and determined no significant differences 
among the fitness values of the viruses. (C.) Growth kinetics of mutant ΔHA-GFP virus at 32°
C, 37°C, and 39°C. MDCK-HA cells were infected at an MOI of 0.01 in 96-well plates and 
incubated at the indicated temperature. At each time point, the supernatants from 4 wells were 
transferred to a new 96-well plate containing MDCK cells. After 14 hours the cells were fixed 
and stained using an anti-GFP antibody. The number of cells stained were determined by 
fluorescence microscopy and used to calculate the number of GFP expressing virus per 
milliliter. Data shown is the cumulative mean and standard deviations for two mutant ΔHA-GFP 
viruses (C to U and U to A) each measured 4 times at each time point. (D.) The minimum free 
energy of RNA folding for 100 base sliding windows (80 base overlaps) were determined for the 
ΔHA-GFP construct. The location of the sites where mutations can cause regain of eGFP 




Figure 2.3. GFP mutation rate assay workflow and validation  
(A.) General workflow for measuring the mutation rate using mutant ΔHA-GFP viruses. Mutation 
rates determined by fluctuation tests using the null class model are most precise when the 
proportion of cultures containing no viruses expressing fluorescent GFP (P0) is between 0.1 and 
0.7. The time for initial viral replication varied in an attempt to obtain measurements within this 
range and depended upon the virus, temperature, and mutation substitution class being probed. 
Mutation rate measurements were made for viruses infecting cells while being treated with 
mutagenic nucleoside analogs that increase characteristic mutation substitution classes. The A 
to G (B.), G to A (C.), and G to C (D.) mutation rates for A/Puerto Rico/8/1934 H1N1 were 
measured in cells pretreated with 0.625μM 5-azacytidine (AzaC), 15 μM 5-fluorouracil (5FU), or 
2.5 μM ribavirin (Rib). No data is shown for G to C with 2.5 μM ribavirin because large titer 
decreases upon drug treatment prohibited measurements with the experimental conditions 
used. Filled symbols represent measurements in which P0 is between 0.1 and 0.69. Open 
circles represent data with P0 between 0.7 and 0.9. Lines and error bars represent arithmetic 
means and standard deviations. A one-way ANOVA with a Dunnett’s correction for multiple 
comparisons was used for each mutation class to compare each drug treatments to no drug 
treatment. * = p < 0.05, ** = p < 0.01, *** = p < 0.005.   
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The mutation rates of influenza virus 
 We used our GFP fluctuation test to measure the mutation rates of two 
evolutionarily divergent influenza viruses. Influenza A/Puerto Rico/8/1934 H1N1 (PR8) 
was the second strain of influenza isolated and has been extensively passaged in 
various cell, animal, and egg culture systems (116, 117). Influenza A/Hong 
Kong/4801/2014 H3N2 (Hong Kong) was recently circulating in the human population 
and passaged briefly in cell culture prior to cloning.  The PR8 virus we tested contained 
the ΔHA-GFP segment with seven PR8 genome segments. The Hong Kong virus 
contained the ΔHA-GFP segment, the segments coding for the polymerase complex, 
PB2, PB1, PA, and NP from A/Hong Kong/4801/2014 H3N2, and the segments 
encoding NA, M, and NS from PR8.  
Both PR8 and Hong Kong make predominantly A to G and U to C transitions 
(Figure 2.4 and Table 2.3). The other two transitions (C to U and G to A) have similar 
rates to some of the higher rate transversions mutation classes. The rate and spectrum 
of mutations for each virus is very similar, although there are differences between the 
two viruses in specific mutation classes. Performing multiple t-tests using the Holm-
Sidak correction for multiple comparisons shows that Hong Kong has a significantly 
higher rate than PR8 for G to A mutations (7.2 x 10-5 vs. 3.1 x 10-5, p = 0.0018) and a 
slightly higher rate for G to U mutations (6.0 x 10-5 vs. 3.5 x 10-5, p = 0.083). The overall 
mutation rates for each virus suggest that there are 2 to 3 new mutations incorporated 
into the virus’ 13.5 kilobase genome every time it is replicated. These new mutations 
are 2.7 to 3.6 times more likely to be a transition than a transversions for PR8 and Hong 
Kong, respectively. For both viruses the rates of mutations away from A are symmetrical 
to mutations away from U. This is expected because these mutations are the inverse of 
each other. Interestingly, we do not observe this symmetry for mutations away from C 
and away from G. In PR8 G nucleotides are 3.8 times more likely to mutate than C 
nucleotides. In Hong Kong this difference is 2.7 fold. This difference may be the result of 
influenza virus’ mode of replication.   
To assess if influenza virus’ mode of replication is linear or binary, we determined 
mutation rates per cell infection cycle by measuring the bulk number of fluorescent 
revertants per experiment and dividing by the total amount of replicated virus. Unlike the 
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P0 fluctuation test method, this method takes into account that a single infected cell can 
produce multiple fluorescent revertants if the correct mutation occurs early within the 
replication cycle. The ratio of per cell cycle and per strand replicated mutation rates 
informs how many strand replications occur before a given viral genome is released 
from the cell as a new virus (18). Theoretically, the minimum value of this ratio for a 
single stranded RNA virus is 2.  Assuming a single replication cycle occurred during 
each experiment and using all 12 mutation classes, we determined the average ratio to 
be 1.2 and 1.1 for the PR8 and Hong Kong strains, respectively. This suggests that 




Figure 2.4. The mutation rate spectrum of influenza virus  
The GFP mutation rate assay was used to measure the mutation rates of all 12 substitution 
mutation classes. (A.) Measurements were made on A/Puerto Rico/8/1934 H1N1 viruses 
encoding the 12 different mutant ΔHA-GFP constructs. (B.) Measurements were also obtained 
using and a virus containing the PB2, PB1, PA, and NP genes from A/Hong Kong/4801/2014 
H3N2 with the remaining genes coming from A/Puerto Rico/8/1934 H1N1 and the mutant ΔHA-
GFP constructs. Filled symbols represent measurements in which P0 is between 0.1 and 0.69. 
Open circles represent data with P0 between 0.7 and 0.95. The arithmetic means and standard 





Table 2.3. Influenza virus mutation rates 
 
 
a Mutation rates shown are the arithmetic mean plus or minus the standard deviation calculated 
from at least three replicates.  
 
b Overall mutation rates were determined as a weighted average of mutation rates, taking into 





The temperature independence of influenza’s mutation rate 
 Biochemical assays using purified influenza RdRp, suggest that replication 
temperature can affect influenza fidelity (57). Influenza replicates throughout the 
respiratory tract in mammals. In humans this site exhibits a temperature gradient from 
32°C in the nose to 37°C in the lung alveoli (52, 53). In febrile influenza, the core body 
temperature can rise to 39°C or higher (54).  Additionally, birds, which are the natural 
host for ancestral influenza strains, have a core body temperature of 41°C (55, 56). We 
used the PR8 virus encoding mutant ΔHA-GFP segments to measure mutation rates at 
different temperatures. This virus is able to replicate in MDCK-HA cells at 32°C and 
39°C, but slower and to lower maximum titers than at 37°C (Figure 2.2C). We measured 
5 of the mutation classes at these temperature extremes (Figure 2.5). We determined 
that mutation rates for a virus that is well-adapted to its host are constant over a 7 
degree range of physiological temperatures in MDCK cell culture. We were unable to 
make mutation rate measurements at higher temperatures using this system due to its 




Figure 2.5. The effect of temperature on the mutation rate of influenza virus  
The mutation rates were determined for A/Puerto Rico/8/1934 H1N1 viruses encoding 5 of the 
mutant ΔHA-GFP constructs at different temperature. The initial viral replication step in the 
assay was performed at 32°C (▼), 37°C (●), and 39°C (▲) for each virus. Filled symbols 
represent measurements in which P0 is between 0.1 and 0.69. Open symbols represent data 
with P0 between 0.7 and 0.90. The arithmetic means and standard deviations are indicated. A 









 We have investigated two novel methods for measuring influenza’s mutation rate. 
We determined that next-generation sequencing methods are not able to reliably 
measure influenza’s mutation rate due to the high level of background errors introduced 
by reverse transcription. We developed a high throughput GFP based assay for 
accurately and individually probing all 12 mutation classes. This assay could be easily 
adapted to any virus that tolerates the addition of the GFP gene into its genome. We 
used it to identify that there are strain dependent differences in individual mutation 
classes, but that influenza’s mutation rate is generally stable between evolutionarily 
divergent strains. We also determined that influenza has a higher mutation rate than 
what has been previously estimated using low throughput Sanger sequencing-based 
methods. Finally, we found that temperature changes have little effect on the mutation 
rate of influenza virus in a mammalian cell culture system. 
We investigated the use of Illumina sequencing to measure the mutation rate of 
influenza virus. We used the PrimerID method to increase the power and reliability of 
our sequencing, but found that the high background introduced by reverse transcriptase 
during sample preparation prevented reliable mutation rates measurements (33, 98). 
This result demonstrates the need for caution when interpreting very rare events 
measured using sequencing methods that have the goal of determining the sequences 
of individual RNA molecules. Reverse transcriptase may have mutational biases that 
are distinct from those of the RNA virus being studied. In Influenza, this is most evident 
in G to A mutations, which RT makes much more frequently than the influenza RdRp.  
Alternative methods that allow reverse transcription errors to be controlled for include 
Circular Sequencing (CirSeq) and Replicated Sequencing (Rep-Seq) (34, 48). The 
amount of required RNA template and/or the number of required sequencing reads 
make these methods less feasible for mutation rate measurements with some RNA 
viruses or for studies across multiple conditions.  
 We sought an alternative method to measure influenza’s complete spectrum of 
mutation rates in a high throughput manner. We settled on a method developed by 
Zhang et. al. that is based on measuring the rate of non-fluorescent virally encoded 
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GFP regaining fluorescence (100). We adapted their method from measles virus to 
influenza virus and improved on it by (i) extending it to all 12 mutation classes, (ii) using 
anti-GFP antibodies to directly measure the number of GFP expressing viruses in a 
culture, and (iii) and making it high throughput with the use of a high content automated 
microscope and image analysis software (100). Using this method we measured the 
rates of all 12 substitution mutation classes in a neutral and unbiased way. The 
mutations we measured had a neutral fitness effect on the ability of the virus to replicate 
and the mutation sites were in the context of an RNA sequence that is not predicted to 
form a strong secondary structure. Although these characteristics of the mutations 
suggest that their rates are representative of the influenza RdRp in a neutral context, it 
does not preclude biases in rates that depend on localized sequence contexts. We 
attempted to assess if mutation rate sequence context dependencies were a factor in 
influenza virus using the PrimerID method, but that method did not allow for reliable 
measurements.  
 Using the GFP-based mutation rate assay, we found that the mutation rates of 
the lab adapted PR8 H1N1 strain were similar to those of an H3N2 strain that had been 
recently circulating in the human population. While the two strains we tested had 
generally similar mutation rates, this method allowed us to identify differences in the 
spectrum of the mutations that each made. This result has several implications for our 
understanding of the evolution of influenza’s mutation rate. It informs us that influenza’s 
mutation rate is not a simple phenotype that can be represented by a single number. 
The rates of specific mutation classes can evolve independently of one another, while 
the overall mutation frequency remains relatively constant. It also suggests that overall 
mutation rates do not change much between evolutionary divergent strains of influenza. 
Within the replicase complex, the PR8 and Hong Kong strains share only 95%, 96%, 
95%, and 91% amino acid identity in PB2, PB1, PA, and NP, respectively.  
 The mutation rates that we measured for influenza virus using the GFP method 
are higher than those estimated using sequencing based methods. Our overall mutation 
rate estimates range from 1.8 x 10-4 to 2.5 x 10-4 mutations per nucleotide per strand 
replicated, while previous estimates range between 7.1x10-6 to 4.5x10-5 mutations per 
nucleotide per cell infection (18, 28–30). These discrepancies may be explained by the 
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low power of clonal sequencing methods to identify the rates of rare mutations and that 
these methods are biased towards sampling more fit clones. The mutation rates that we 
measured for influenza virus using the GFP method are similar to those determined by 
other using fluctuation tests. Suarez et al. measured mutation rates using monoclonal 
antibody resistance to be 1 x 10-5 (41, 42). The mutations that caused antibody 
resistance were primarily G to A mutations. Our measured G to A mutation rates for the 
two influenza strains, 3.1 x 10-5 and 7.2 x 10-5, are similar to the previously measured 
value, although, it should be noted that use of a different monoclonal antibody led to a 
much lower rate estimation of 9x10-7 (41, 42), Comparing the mutation rate spectrum we 
measured for influenza virus to those estimated for poliovirus, we notice a similar range 
of mutation rate values (low 10-6 to low 10-4 mutations per nucleotide per cell infection) 
and a similar overall mutation rate (low 10-4 mutations per nucleotide per cell infection) 
suggesting similarities among mutation rates for different RNA viruses (48).  
 The mutation rates that we measured for influenza virus suggest that on average 
2 to 3 new mutations are made within the virus’ 13.5 kilobase genome every time it is 
copied. This high rate of mutation has dramatic consequences for the virus. Our group 
and others have reported that most mutations are detrimental to viruses, with around 
30% preventing viral replication (66, 67, 69, 118). Using a 70% probability that a given 
mutation results in a viable virus, the likelihood of any given genome being able to 
replicate is only 34 to 49%. It is known that only 1% to 10% of influenza particles are 
infectious. Therefore, the effect of mutations accounts for a sizable portion of the non-
infectious genomes found within influenza populations. This high mutation rate is near 
the limit that influenza can tolerate. We have shown increasing influenza’s mutation rate 
through the use of mutagenic nucleoside analogs leads to rapid losses in genome 
infectivity (chapter 3) (115). Thus, influenza exists as swarms of genetically distinct 
genomes that are near to an error threshold, above which the population’s infectivity 
rapidly collapses (23).   
We determined that influenza’s mode of replication is near linear. The ratio of 
mutation rates per cell infection to per strand replicated are 1.2 and 1.1 for the PR8 and 
Hong Kong strains, respectively. This finding suggests that (-) sense genomic RNA 
introduced during an infection is copied to (+) sense replication intermediates 
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approximately once before new (-) sense genomes are synthesized. The reason that 
our observed ratios are lower than 2, which is the theoretical minimum for a single 
stranded RNA virus, may be due to our method of measurement (18). We assessed 
only a single mutation site in the viral genome for each mutation class. The mutation 
that causes fluorescence reversion and its inverse mutation are unlikely to occur at the 
exact same rate, invalidating a key assumption of using ratios of mutation rates to infer 
replication mode. Additionally, since we allowed approximately one replication cycle and 
started with very low numbers of infecting virus genomes, our measurements would by 
strongly biased towards observing mutations generated during synthesis of the (-) 
sense genomic RNA rather than during synthesis of the (+) sense replication 
intermediates in a system with a linear replication mode. This linear or “stamping 
machine” replication mode, may actually assist the virus in tolerating its high mutation 
rate because it allows fewer opportunities for mutations during each viral replication 
cycle (25, 26).         
 When we look at the mutation spectrum of influenza virus we notice several 
interesting characteristics. Adenine to guanine and uracil to cytosine overwhelmingly 
predominate the mutations made by influenza virus. This finding supports previous 
reports suggesting that influenza RNA is modified by the host enzyme adenosine 
deaminase acting on RNA (ADAR-1) (49, 119). Through the deamination of adenosine 
bases, this enzyme induces the mutation classes observed to have the highest rates in 
influenza. We found that the other two transitions, C to U and G to A, occurred at similar 
rates to some of the transversion mutation classes. Despite this, there is still a strong 
transition to transversions bias of 2.7 to 3.6, due to the predominance of A to G and U to 
C mutations. 
We also found that influenza is approximately 3 times more likely to mutate away 
from G than it is to mutate away from C. This pronounced asymmetry is unexpected 
because these mutation classes are the inverse of one another. This finding may be 
related to influenza’s mode of replication that we identified as being very near to linear. 
In this replication mode, mutations would have many more opportunities to be made in 
the genomic (-) sense RNA than they would in the replication intermediate (+) sense 
RNA. This replication mode would cause the rate of a particular mutation class to be 
 
43 
only slightly dependent on the rate of its inverse mutation class. Both viruses that we 
measured the mutation rates of have genomes composed of 33% adenine, 19% 
cytosine, 24% guanine, and 24% uracil. These genomic compositions neither predict, 
nor are expected consequences, of the observed mutational asymmetry. One factor that 
may help to explain the bias for mutations away from guanine is the low CTP 
concentrations relative to the other ribonucleoside triphosphates in both influenza 
infected and non-infected MDCK cells (120). Therefore, it is possible that other cell 
types with differences in the relative concentrations of nucleotide pools may cause 
different biases in influenza’s mutation rate.    
 We were also interested in the effects that temperature has on influenza’s 
mutation rate. Influenza replicates within a variety of temperature environments as it 
infects its human host (52, 53). Biochemical assays suggest that temperature affects 
the misincorporation rate of influenza’s RdRp, with temperatures at the bird core body 
temperature of 41°C showing elevated misincorporation rates (57). We measured 
influenza’s mutation rate in cell culture over the physiological human respiratory tract 
temperature range of 32°C to 39 °C using our GFP assay. We identified no effect of 
replication temperature on viral mutation rate in the context of MDCK cells. This result 
suggests that the mutation rates of mammalian influenza viruses are robust to 
temperature effects. It is important to note that these measurements were made in a cell 
culture model. They do not rule out the effects of temperature in vivo, or the effects that 
different cell or host types may have on the virus’ mutation rate (45, 121).   
 Our work has important implications for how we think about influenza evolution. 
These accurate measurements for the rate of each mutation class, coupled with recent 
reports characterizing mutation fitness effects in influenza, greatly improve our ability to 
construct phylogenies that recreate evolutionary histories. This information may also be 
integral for the design of antiviral drugs and vaccines that are less likely to result in the 
evolved resistance. By greatly improving our understanding of influenza’s mutation rate, 
our work has provided a valuable tool for influenza researchers studying influenza 
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Abstract 
Lethal mutagenesis is a broad-spectrum antiviral strategy that exploits the high 
mutation rate and low mutational tolerance of many RNA viruses. This approach uses 
mutagenic drugs to increase viral mutation rates and burden viral populations with 
mutations that reduce the number of infectious progeny. We investigated the 
effectiveness of lethal mutagenesis as a strategy against influenza virus using three 
nucleoside analogs, ribavirin, 5-azacytidine, and 5-fluorouracil. All three drugs were 
active against a panel of seasonal H3N2 and laboratory-adapted H1N1 strains. We 
found that each drug increased the frequency of mutations in influenza virus populations 
and decreased the virus’ specific infectivity, indicating a mutagenic mode of action. We 
were able to drive viral populations to extinction by passaging influenza virus in the 
presence of each drug, indicating that complete lethal mutagenesis of influenza 
populations can be achieved when a sufficient mutational burden is applied. Population-
wide resistance to these mutagenic agents did not arise after serial passage of 
influenza populations in sub-lethal concentrations of drug. Sequencing of these drug-
passaged viral populations revealed genome-wide accumulation of mutations at low 
frequency. The replicative capacity of drug-passaged populations was reduced at higher 
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multiplicities of infection, suggesting the presence of defective interfering particles and a 
possible barrier to the evolution of resistance. Together, our data suggest that lethal 
mutagenesis may be a particularly effective therapeutic approach with a high genetic 
barrier to resistance for influenza virus.  
 
Introduction 
Influenza virus is a single stranded, negative-sense RNA virus with a genome 
consisting of 8 segments (7). Like other RNA viruses, influenza virus replicates with 
extremely low fidelity. Its RNA-dependent RNA polymerase (RdRp) complex, which 
includes the viral proteins PB1, PB2, PA, and NP (57, 122), has a mutation rate of 
approximately 2.3x10-5 substitutions per nucleotide per cell infection (18). This high 
mutation rate limits the effectiveness of seasonal vaccines and antivirals as it allows the 
virus to generate mutations that mediate escape from neutralizing antibodies and 
resistance to antiviral drugs (4, 5, 123–125)(5, 125). While a high mutation rate allows 
RNA viruses to rapidly adapt to new selective pressures, most newly generated 
mutations are deleterious (66, 67, 118). RNA viruses, therefore, exist at a threshold of 
viability, where even small increases in mutational load can cause population extinction 
(23, 74). 
Lethal mutagenesis is a broad-spectrum antiviral strategy that exploits the high 
mutation rate and low mutational tolerance of many RNA viruses. This approach utilizes 
mutagenic drugs to increase the virus’ mutation rate, thereby burdening the population 
with a large number of mutations that are either lethal or highly detrimental to ongoing 
replication. Extinction of the population will occur when the number of infectious 
progeny generated by each infectious particle drops to less than one (74). Lethal 
mutagenesis has been applied to a number of RNA viruses, most commonly with 
nucleoside (e.g. ribavirin and 5-azacytidine) and base (e.g. 5-fluorouracil) analogs. 
Ribavirin is a broad spectrum antiviral that has been demonstrated to cause lethal 
mutagenesis of poliovirus, hantaan virus, lymphocytic choriomeningitis virus (LCMV), GB 
virus, and West Nile virus in vitro (77–79, 83, 126). While ribavirin is used clinically for 
hepatitis C virus and respiratory syncytial virus, its mode of action against these viruses 
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in vivo is less clear (127–129). Lethal mutagenesis with 5-azacytidine has been 
demonstrated in HIV-1 and foot-and-mouth disease virus (FMDV) in vitro (81, 82). The base 
analog 5-fluorouracil is processed intracellularly into a nucleoside analog and has demonstrated 
activity as a lethal mutagen against LCMV, exonuclease-deficient coronaviruses, and FMDV in 
vitro (80, 81, 130). For simplicity, we will refer to all three drugs as nucleoside analogs. 
In most cases, the mutagenic activity of nucleoside analogs is attributable to the 
misincorporation of their triphosphate forms into replicating genomes by the viral RdRp. The 
structure of the nucleoside analog, its base-pairing properties, and the sense of the RNA strand 
determine the classes of mutations observed (73). Ribavirin, a guanosine analog, causes an 
increase in both C to U and G to A transitions (77), and 5-fluorouracil, which mimics uridine, 
leads to the accumulation of A to G and U to C transitions (80). Interestingly, 5-azacytidine, a 
cytidine analog, is able to induce both C to G and G to C transversions by virtue of a pyrimidine 
ring-opening mechanism that allows it to base pair with cytosine (82, 131). Ribavirin also has 
additional mechanisms that may play a role in its anti-viral activity. Within host cells it alters GTP 
pool concentrations by inhibiting inosine monophosphate dehydrogenase (IMPDH) (132, 133). 
Other modes of action may include direct inhibition of the influenza virus RdRp (94, 134) and 
interference with capping of viral RNA (135). Some data suggest that ribavirin affects 
inflammatory and T-cell responses in vivo (136–138).  
Initially, lethal mutagenesis was believed to be a “resistance proof” strategy, 
since a newly arising resistance mutation would, in many cases, be linked to a lethal 
one on the same genome (85). However, in poliovirus, FMDV, and Chikungunya virus, 
mutagen resistant variants have been recovered after fewer than 14 passages in sub-
lethal concentrations of drug (62, 72, 86). The RdRp of these resistant viruses have 
replication fidelity phenotypes that make them less sensitive to mutagenesis by 
nucleoside analogs. Population genetic theory suggests that high mutation rates will 
also select for viruses that are more tolerant of mutation, or mutationally robust (23, 
139). This mechanism of mutagenic drug tolerance has recently been identified in 
vesicular stomatitis virus populations passaged in 5-fluorouracil and in coxsackievirus 
populations passaged in ribavirin (91, 92). 
The viability of lethal mutagenesis as a therapeutic approach to influenza virus infection 
has yet to be systematically explored. While the anti-influenza activity of ribavirin has long been 
recognized, its mechanism of action is unclear (134, 140). Recent data suggest that it may 
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function as a lethal mutagen for influenza A virus, and that a high fidelity polymerase variant is 
less sensitive to its antiviral activity (65). Similarly, a new broad-spectrum antiviral, favipiravir, 
has been shown to be mutagenic to influenza virus in vitro and norovirus in vivo (93, 141). 
We performed a systematic investigation of lethal mutagenesis as a therapeutic 
strategy to target influenza virus. We utilized ribavirin, 5-azacytidine and 5-fluorouracil, 
which are three structurally distinct nucleoside analogs that are known to increase the 
frequency of specific mutations in a range of RNA viruses. We set four criteria for 
demonstrating lethal mutagenesis: (i) a concentration-dependent decrease in infectious 
viral titer, (ii) an increase in viral mutation frequency, (iii) a concentration-dependent 
decrease in the specific infectivity of the viral population, and (iv) the ability to extinguish 
the viral population upon multiple rounds of replication in the presence of drug. In 
addition to demonstrating their mutagenic action, we investigated the ability of influenza 
virus populations passaged in sub-lethal concentrations to acquire resistance to each of 
these nucleoside analogs.  
 
Materials and Methods 
Cells, viruses, and drugs 
Madin Darby Canine Kidney (MDCK) cells were provided by Dr. Arnold S. Monto 
(University of Michigan School of Public Health) and were maintained in Dulbecco’s 
modified Eagle medium (Gibco 11965) supplemented with 10% fetal bovine serum 
(Gibco 10437) and 25 mM HEPES (Gibco 15630). Cells were maintained at 37˚C and 
5% CO2 in a humidified incubator.  
A biological clone of influenza A/Puerto Rico/8/1934(H1N1) was obtained from 
ATCC (VR-1469). Influenza A/WSN/33(H1N1) was rescued following transfection of 8 
plasmids that express the viral RNA and proteins from each genome segment (101). 
The plasmids were provided by Dr. Robert G. Webster (St. Jude Children’s Research 
Hospital). Biological clones of influenza A/Panama/2007/1999(H3N2) and 
A/Wyoming/03/2003(H3N2) were provided by Dr. Arnold S. Monto (University of 
Michigan School of Public Health). Unless otherwise indicated, infections were 
performed in viral infection media consisting of Dulbecco’s modified Eagle Medium 
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supplemented with 25 mM HEPES, 0.18% bovine serum albumin (Gibco 15260), and 2 
μg/mL TPCK treated trypsin (Worthington Biochemical 3740).  
Ribavirin (1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-
1,2,4-triazole-3-carboxamide) (Sigma-Aldrich R9644) was dissolved in phosphate 
buffered saline (PBS) to make a 100 mM stock. 5-azacytidine (4-Amino-1-(β-D-
ribofuranosyl)-1,3,5-triazin-2(1H)-one) (Sigma-Aldrich A2385), guanosine (Sigma-Aldrich 
G6752), and mycophenolic acid (Sigma-Aldrich M5255) were dissolved in dimethyl 
sulfoxide (DMSO) at 100 mM. 5-Fluorouracil (2,4-Dihydroxy-5-fluoropyrimidine) (Sigma-
Aldrich F6627) was dissolved in DMSO at 384 mM. Aliquots of all stocks were stored at 
minus 20°C.  
 
Cellular toxicity assays 
The viability of MDCK cells after drug treatment was measured using an 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) assay (142). Briefly, 24 well 
plates were seeded with 20,000 MDCK cells in 500 μL of media. The following day, the 
culture media was replaced with viral infection media containing drug. After 24 hours of 
incubation in drug, 50 μL of 5 mg/mL MTT (Sigma-Aldrich M5655) were added and the 
cells were incubated at 37°C. After 2 hours, 550 μL of 10% triton-X-100 (Acros Organics 
327372500) and 0.1 N HCl(aq) in isopropanol (Fisher BP2610) were added. One hour 
later, the resulting precipitates were dissolved by repeated pipetting. One additional 
hour later, the absorbance at 595 nm was measured using a Synergy HT microplate 
reader (Bio-Tek). 
  Cytotoxicity was measured using the CytoTox-Glo Cytotoxicity Assay (Promega 
G9290), according the manufacturer’s protocol. Briefly, 3,200 MDCK cells per well were 
seeded in a white, flat bottom, 96 well plate (Fisher 353296). Drugs were diluted in viral 
infection media and added to the cells as above. Luminescence was measured after 24 
hours using a Synergy HT microplate reader both before and after digitonin 




Drug treatment of viruses  
MDCK cells were seeded in 24-well cell culture plates at a density of 6.5x104 
cells per well in 500 μL media. The next day, cells were washed with PBS and treated 
for 3 hours with drug diluted in viral infection media. Cells were infected with influenza 
virus at a multiplicity of infection (MOI) of 0.1 TCID50 / cell in 200 μL of drug media. The 
inoculum was removed after 1 hour and the cells were washed with PBS. Infected cells 
were incubated in 500 μL of fresh drug media for an additional 24 hours. Viral 
supernatants were clarified by centrifugation for 4 minutes at 1400 x g, and stored at -
80°C with glycerol at a final concentration of 0.5%. Viral titers were determined using 
either plaque assay (143) or median tissue culture infectious dose (TCID50). For TCID50 
assays, 4x103 MDCK cells per well were seeded into a 96-well tissue culture plate in 
100 μL of viral infection media lacking TPCK trypsin. The next day, serial 10-fold 
dilutions of viral supernatants were added to each row on the plate in 100 μL of viral 
infection media with 4 μg/mL of TPCK treated trypsin. After four days, the wells were 
scored for cytopathic effect (CPE), and the titers calculated using the method of Reed 
and Muench (144). 
 
RNA extraction, RT-PCR, and qPCR 
RNA was extracted from clarified supernatants using either TRIzol Reagent 
(Ambion 15596026), Purelink Pro 96 Viral RNA/DNA Kits (Invitrogen 12280), or QIAamp 
Viral RNA Mini Kits (Qiagen 52904) according to the manufacturers’ instructions. 
Complementary DNA was generated using random hexamer priming and the 
SuperScript III First-Strand Synthesis System (Invitrogen 18080). Quantitative PCR was 
performed on a 7500 Fast Real Time PCR system (Applied Biosystems) using FastStart 
Universal SYBR Green Master mix (Roche 04913850001) with primers PB2for (5’ 
GTTGGGAGAAGAGCAACAGC 3’) and PB2rev (5’ GATTCGCCCTATTGACGAAA 3’). 
Serial ten-fold dilutions of plasmid containing the PB2 gene of A/WSN/33(H1N1) were 
used to generate a standard curve for quantification of cDNA copy number based on 




Measurement of viral mutation frequency 
Complementary DNA corresponding to the eight viral RNAs were generated with 
primer uni12 (5’ AGCAAAAGCAGG 3’) using Superscript III as above. A 957 base 
fragment of the HA gene was amplified using Taq DNA polymerase (Invitrogen 18038) 
with primers HAfor (5’ GAAGGCAAACCTACTGGTCC 3’) and HArev (5’ 
GCACTCTCCTATTGTGACTGG 3’). Polymerase chain reaction products were purified 
using the GeneJET PCR Purification Kit (Thermo K0701) and terminally adenylated by 
incubation with 500 μM dATP and Taq DNA polymerase for 10 minutes at 72°C. PCR 
products were then cloned into the pCR4-TOPO-TA vector using the TOPO-TA Cloning 
Kit for Sequencing (Invitrogen 45-0071). Individual clones were sequenced at the 
University of Michigan DNA sequencing core using both T3 and T7 primers. Sequences 
were aligned over an 859 bp region that had adequate quality sequencing reads for all 
clones and mutations were identified using SeqMan Pro version 10.1.1 (DNASTAR). 
Only mutations present in both the forward and reverse reads of a clone were counted, 
and mutations found in multiple clones were counted once.     
  
Drug passages 
To evolve influenza virus mutants that are resistant to the detrimental effects of 
mutagens, virus was passaged in low concentrations of drug. Three passage lineages 
for the mock-treated control and each drug were generated in the following way. Three 
million MDCK cells were seeded into 75 cm2 flasks. The next day, cells were washed 
with PBS and treated with 10 mL of viral infection media containing either 7.5 μM 
ribavirin, 7.5 μM 5-azacytidine, 30 μM 5-fluorouracil, or an equivalent volume of DMSO 
for 3 hours. The media was then removed and replaced with 7.5 mL of drug containing 
media with 5x104 plaque forming units (PFU) of influenza A/Puerto Rico/8/1934(H1N1) 
(MOI 0.01). After 1 hour, the virus was removed, the cells were washed with PBS, and 
18.5 mL of drug containing media were added. Culture supernatants were harvested at 
24 hours post infection and titered by plaque assay. This procedure was performed 
iteratively with 5x104 PFU from the previous passage being used to infect the next. If 
titers dropped below the level that allowed for this MOI,1 mL of undiluted culture 
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supernatant was used. Passaged viral populations were tested for their sensitivity to 
drugs at an MOI of 0.01 and 0.1 using the above drug treatment protocol.  
To demonstrate lethal mutagenesis and population extinction through serial drug 
passage, virus was passaged in high concentrations of drug. Three lineages in 40 μM 
ribavirin, 25 μM 5-azacytidine, 100 μM 5-fluorouracil, or an equivalent volume of DMSO 
were passaged as described above, except at an MOI of 0.1 and scaled to 25 cm2 
flasks. If titers dropped below 1.6x105 PFU, 500 μL of undiluted culture supernatant 
from the previous passage were used. If titers dropped below detectable levels, we 
attempted to recover any remaining virus by adding 800 μL of undiluted culture 
supernatant to MDCK cells in the absence of drug. Supernatants of recovery passages 
were harvested at 4 days and titered by plaque assay. If titers were still undetectable 
the viral population was considered extinct.   
 
Next Generation Sequencing 
Multiplex-Reverse Transcription-PCR amplification of all 8 influenza genome 
segments was performed on RNA samples using Superscript III with HiFi platinum Taq 
(Invitrogen 12574) with the primers Uni12/Inf1 (5’ GGGGGGAGCAAAAGCAGG 3’), 
Uni12/Inf3 (5’ GGGGGAGCGAAAGCAGG 3’), and Uni13/Inf1 (5’ 
CGGGTTATTAGTAGAAACAAGG 3’) (145). Seven hundred fifty nanograms of the each 
amplified cDNA were sheared to an average size of 300-400 bp using a Covaris S220 
focused ultrasonicator. Sequencing libraries were prepared using the NEBNext Ultra 
DNA Library prep kit (NEB E7370L), Agencourt AMPure XP beads (Beckman Coulter 
A63881), and NEBNext multiplex oligos for Illumina (NEB E7600S). Indexed samples 
were pooled in equal volumes and sequenced on an Illumina MiSeq instrument with 2 x 
250 base, paired end reads.  
Sequencing reads that passed standard Illumina quality control filters were 
binned by index, culled of low quality bases (phred < 25), and aligned to the reference 
genome using bowtie (146). Single nucleotide variants were identified and analyzed 
using DeepSNV (147). The DeepSNV algorithm relies on a clonal control to estimate 
the local error rate within a given sequence context and to identify strand bias in base 
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calling. It then applies a hierarchical binomial model based on mutation calls for test and 
control at each base and position to identify true positive single nucleotide variants 
(SNV). The clonal control was a library prepared in an identical fashion from 8 plasmids 
containing the A/PR/8/1934 genome and sequenced in the same flow cell. The optimal 
p-value and frequency cutoffs for variant base calls were determined empirically from 
MiSeq data in which a mutant virus was spiked in at known frequencies. We calculated 
our sensitivity and specificity for variant detection using DeepSNV based on a p-value of 
0.01. For a mutation at 5% frequency, sensitivity = 0.9916 and specificity = 0.9926. For 
a mutation at 2.5% frequency, sensitivity = 0.9875 and specificity = 0.9933. For a 
mutation at 1.25% frequency, sensitivity = 0.9562 and specificity = 0.9934. For a 
mutation at 0.63% frequency, sensitivity = 0.9102 and specificity = 0.9928. Based on 
these data, only SNV with a Benjamini-Hochberg corrected p-value of < 0.01 and 
present at a frequency of ≥ 1% were used in downstream analyses. 
 
Statistical analysis 
Mutation frequencies were compared to the mock-treated control using the chi-
squared test. The one-tailed Mann-Whitney U test was used to analyze the number of 
mutations per clone compared to the mock-treated control. Viral titers and specific 
infectivities were compared to the no drug control using the Kruskal-Wallis test with 
Dunn’s multiple comparisons test. All statistical tests were performed using either R or 




Anti-influenza virus effects of nucleoside analogs 
In our study of lethal mutagenesis, we used ribavirin, 5-azacytidine, and 5-
fluorouracil, each of which are known mutagens of other RNA viruses (75, 77, 80, 82). 
These three drugs were selected, in part, due to their activity against a range of RNA 
viruses as well as differences in the types of mutations that they are known to induce. 
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We tested the activity of each drug against two laboratory-adapted H1N1 strains 
(A/PR8/34 and A/WSN/33) and two seasonal H3N2 strains (A/Panama/2007/1999 and 
A/Wyoming/03/2003). All three drugs were active against this panel of influenza viruses, 
reducing viral titer in a concentration-dependent manner (Figure 3.1). Ribavirin and 5-
azacytidine exhibited comparable activity in this assay, with 2 to 3 log10 reductions in 
influenza virus titer at 10 µM. 5-Fluorouracil was less potent, with similar reductions at 
80 µM. The A/Panama/2007/1999 (H3N2) strain appeared to be less sensitive to both 
ribavirin and 5-fluorouracil than the other three strains. This strain is not known to be 
inherently resistant to these drugs and does not contain either PB1 D27N or PB1 V43I, 
two mutations that are known to confer ribavirin resistance (65, 94). The reduced 
sensitivity could be due to the reduced replicative capacity of A/Panama/2007/1999 in 
MDCK cells, where its average titer of 3.2 x 105 TCID50 / mL in the absence of drug was 
at least 1.5 log10 lower than the other strains. This reduced replicative capacity may 
decrease the number of replication cycles over which an antiviral can act. Given the 
general similarity in drug effect on the other three influenza strains, we used A/PR8/34 
for all subsequent experiments.  
 
 
Figure 3.1. Sensitivity of influenza virus to nucleoside analogs   
MDCK cells were infected with influenza A/PR8/34 (●), A/WSN33 (■), A/Panama/2007/1999 (♦), 
or A/Wyoming/03/2003 (▼) at an MOI of 0.1 in the presence of nucleoside analogs at the 
indicated concentrations (x-axis). Cells were treated with (A) ribavirin, (B) 5-azacytidine, or (C) 
5-fluorouracil. Supernatants were titered at 24 hours and are shown relative to the 0µM drug 
control. Solid lines are H1N1 strains, and dashed lines are H3N2 strains. Points are plotted as 




Effects of nucleoside analogs on cultured cells 
Nucleoside analogs have structural similarity to cellular nucleosides and may 
reduce viral titer through pleiotropic effects on cellular polymerases and metabolic 
pathways. We investigated this possibility by quantifying both direct cytotoxicity and the 
effect of each drug on cellular viability. Cellular viability is distinct from direct 
cytotoxicity, as it reflects both cell proliferation and cell death over the assay period. We 
assayed relative cell viability using the MTT assay, which measures mitochondrial 
succinate dehydrogenase activity. The CytoTox-Glo assay, which quantifies the release 
of cellular proteases, was used to assay drug-induced cytotoxicity. 
Using the MTT assay, we found a modest decrease in cellular viability in both 
120 μM ribavirin and 480 μM 5-fluorouracil, and a 50% decrease in cellular viability in 
20 μM 5-azacytidine (Figure 3.2A). Using the protease release assay, we determined 
that direct cytotoxicity was minimal for both ribavirin and 5-fluorouracil up to the maximal 
concentrations tested (60 μM and 200 μM, respectively). We found approximately 50% 
cytotoxicity with 5-azacytidine at 25 μM (Figure 3.2B). We also assessed the health of 
our cell cultures by light microscopy after incubation in drug for 24 hours. At the highest 
drug concentrations used in any of our assays involving influenza virus, the drug treated 
cells were less overgrown than the mock-treated control and did not display signs of cell 
death, such as rounding or detachment. (Figure 3.2C). Taken together, these data 
suggest that the observed decreases in cellular viability are due to reduced proliferation 
rather than direct cytotoxicity, as is expected based upon the effects of these drugs on 
cellular physiology (148, 149). Given the relatively small reductions in cellular viability at 
the doses used, the large decreases in viral titer observed with each of the three 




Figure 3.2. Effect of nucleoside analogs on MDCK cells 
(A) Number of viable cells relative to mock-treated controls after 24 hours of drug treatment at 
the indicated concentrations (x-axis) as analyzed by MTT assay.  Each point represents the 
mean ± standard deviation for 3 replicates. (B) Cytotoxicity was measured using the CytoTox-
Glo protease release assay on cells plated at low density and treated for 24 hours with 
nucleoside analogs. Percent cytotoxicity (y-axis) is expressed relative to untreated cells. (C) 
Images of cells after treatment with the indicated nucleoside analogs for 24 hours. The drug 
concentrations shown are the highest used in any of the experiments involving influenza virus 





Mutagenic effects of nucleoside analogs on influenza virus 
We used clonal sequencing to determine whether the three drugs are mutagenic 
to influenza virus over a single passage in MDCK cells (150). In this mutation frequency 
assay, we passaged influenza virus on cells in the presence of drug for 24 hours at 
concentrations that caused a 2 log10 decrease in viral titers. We then amplified a 957 
base HA gene fragment from RNA in the culture supernatant. These cDNAs, which 
include sequences from both viable and nonviable progeny, were cloned and 
sequenced. Using this assay, we observed a statistically significant increase in overall 
mutation frequency for viruses passaged in 10 μM 5-azacytidine (p=0.013, chi squared 
test) and 50 μM 5-fluorouracil (p=0.027) (Figure 3.3A). Viruses treated with 5-
azacytidine also exhibited an increase in C to G transversions (p=0.00023) and a strong 
statistical trend of increased A to G mutations (p=0.13). Viruses recovered from cells 
treated with 50 μM 5-fluorouracil exhibited a trend of increased A to G (p=0.15) and U to 
C (p=0.063) mutations. In this analysis, we noted that some mutations were present in 
multiple clones. Since we could not exclude their presence as stable polymorphisms in 
the population prior to drug-treatment, we re-analyzed the data set excluding these 
mutations. In all but one case, the significance level of the p-values remained 
unchanged. In this more conservative analysis, the change in A to G transitions in 
viruses exposed to 10 μM 5-azacytidine achieved statistical significance (p=0.043).  
In our initial mutation frequency assay, virus exposed to 10 μM ribavirin exhibited 
an increase in C to U transitions (p=0.0025) compared to the mock-treated control, but 
the change in the overall mutation frequency did not achieve statistical significance 
(Figure 3.3A). In an independent experiment, we measured mutation frequency over a 
range of ribavirin concentrations. Here, we used ribavirin at 5 and 40 μM, as these 
concentrations caused moderate and large reductions in specific infectivity, respectively 
(see next section). In this experiment, we identified a significant increase in overall 
mutation frequency at both drug concentrations (5 μM p=0.014, 40 μM p=0.0091) 
relative to the control population (Figure 3.3B). The frequency of C to U transitions in 
the 40 μM ribavirin sample was also significantly higher than in the 5 μM ribavirin 
sample (p=0.038) and the no drug control (p=0.00074), suggesting a concentration 
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dependence. We noted a relationship between drug concentration and the frequency of 
G to A mutations, which has been reported in other viruses treated with ribavirin (77). 
Importantly, the statistical significance of these results was not affected by exclusion of 
mutations present in multiple clones. The fact that the overall mutation frequency of 5 
μM ribavirin treated viral populations was significantly higher than mock-treated 
populations, but the overall frequency of 10 μM ribavirin treated viral populations was 
not, may be due to differences in the background mutation frequency in the untreated 
control, experiment to experiment variability, and issues of statistical power. 
We also assessed the mutagenic activity of each drug by comparing the number 
of mutations present per clone. We found that the 5 μM ribavirin (1.74 mutations per 
clone, p=0.018, 1-tailed Mann-Whitney U test), 40 μM ribavirin (1.66 mutations per 
clone, p=0.031), and 10 μM 5-azacytidine (1.35 mutations per clone, p=0.025) samples 
had significantly more mutations per clone than the mock-treated controls (1.13 for 
ribavirin control and 0.93 for the 5-azacytidine and 5-fluorouracil control). There was a 
strong statistical trend in the 50 μM 5-fluorouracil treated sample (1.27 mutations per 
clone, p=0.057). Together, these results demonstrate the mutagenic activity of ribavirin, 





Figure 3.3. Mutation frequency in influenza virus populations treated with nucleoside 
analogs 
MDCK cells were infected with influenza A/PR8/34 (H1N1) at an MOI of 0.1 in drug containing 
media. Supernatants were harvested at 24 hours post infection. A 957 base fragment of the HA 
gene was amplified and cloned. Between 51 and 110 clones from each sample were 
sequenced, and mutations were identified. Overall mutation frequencies are expressed per 104 
bases sequenced. Wild type bases are on the left of the tables. Specific mutation types are 
expressed per 104 wild type bases sequenced. Mutations identified in multiple clones were 
counted once. A chi-squared test was used to determine the statistical significance of the 
differences in total mutation frequency for each mutation type relative to the no drug control. * = 
p < 0.05, ** = p < 0.005. Statistically significant increases are highlighted by shading. (A) Each 
nucleoside analog compared to a no drug control. (B) Treatment with multiple concentrations of 
ribavirin.  
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Effect of nucleoside drugs on specific infectivity 
A hallmark of lethal mutagenesis is a reduction in the specific infectivity of a viral 
population. As mutations induced by the drugs accumulate in progeny genomes, fewer 
of the corresponding virions maintain infectivity. We calculated the specific infectivity of 
drug-treated viral populations relative to mock-treated control samples based on the titer 
and genome copy number in cell-free supernatants. All three drugs caused a 
concentration dependent decrease in specific infectivity (Kruskal-Wallis test; ribavirin 
p=0.0036, 5-azacytidine p=0.0029, and 5-fluorouracil p=0.0071) (Figure 3.4). When 
virus was treated with 20 μM ribavirin there was a greater than 5-fold reduction in 
specific infectivity, which persisted at higher concentrations (Figure 3.4A). We found 
that treatment with 12.5 μM 5-azacytidine was sufficient to cause a greater than 10-fold 
decrease in specific infectivity, with larger reductions at higher drug concentrations 
(Figure 3.4B). Similar reductions in specific infectivity were achieved at 100 μM 5-
fluorouracil (Figure 3.4C). These reductions in specific infectivity are consistent with a 
mutagenic mode of action for each of the nucleoside analogs.  
 
 
Figure 3.4. Specific Infectivity of influenza virus populations treated with nucleoside 
analogs 
MDCK cells infected with influenza A/PR8/34 (H1N1) at an MOI of 0.1 and treated with (A) 
ribavirin, (B) 5-azacytidine, or (C) 5-fluorouracil. Supernatants were harvested at 24 hours post 
infection and titered for infectious virus by TCID50 assay. Quantitative-reverse transcription-PCR 
was used to determine the genome copy number in the samples. This was used to calculate the 
specific infectivity (TCID50 / genome copy), which is shown relative to the 0 μM drug sample. 
Statistical significance was determined using the Kruskal-Wallis test with a Dunn correction. * = 





Alternative mechanisms of ribavirin activity 
Ribavirin is known to have both mutagenic and non-mutagenic effects on viral 
replication. A well characterized antiviral mechanism is its inhibition of IMPDH, a cellular 
enzyme that catalyzes the rate limiting step in de novo guanine nucleotide synthesis 
(140, 151). This inhibition typically causes a reduction in intracellular GTP pools (152), 
which can be reversed with guanosine supplementation (132). To determine the 
potential contribution of IMPDH inhibition to the antiviral action of ribavirin, we measured 
the effect of mycophenolic acid, a potent and specific IMPDH inhibitor, on influenza 
virus titer and specific infectivity. Mycophenolic acid has been reported to have 100-fold 
greater inhibitory activity against IMPDH in MDCK cells than ribavirin (151). Using the 
MTT cell viability assay, we determined that in 10 μM mycophenolic acid there was a 
50% reduction in the number of viable MDCK cells (data not shown). We found that 
treatment with mycophenolic acid caused a decrease in viral titer (Figure 3.5A), but not 
in specific infectivity (Figure 3.5B), suggesting a non-mutagenic effect of IMPDH 
inhibition on viral replication. We determined that there was no additional decrease in 
viral titer at concentrations above 10 μM mycophenolic acid (data not shown). This 
effect was completely reversed by guanosine supplementation, demonstrating the 
importance of adequate GTP pools to influenza virus replication.  
In contrast, we found that ribavirin significantly reduced the specific infectivity of 
the viral population (Figure 4A and Figure 3.5B), and was able to cause titer reductions 
100-fold greater than those maximally achieved by mycophenolic acid (Figure 3.5A). 
While the effect of ribavirin on infectious titer was greater at an MOI of 0.01 than at an 
MOI of 5, its effect on specific infectivity was not (data not shown). Guanosine 
supplementation completely reversed the antiviral effect and reduced the decrease in 
specific infectivity caused by ribavirin. Together, these results suggest that ribavirin’s 
inhibition of IMPDH is important for its activity against influenza, and that the resulting 
changes in GTP pools may augment the drug’s mutagenic activity. 
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Figure 3.5. Effect of IMPDH inhibition on influenza virus 
MDCK cells were treated with ribavirin or mycophenolic acid either with or without 40 μM 
guanosine and infected with influenza A/PR8/34 (H1N1) at an MOI of 0.1. At 24 hours post 
infection culture supernatants were harvested and used for both titering of infectious virus by 
TCID50 assay and quantitative-reverse transcription-PCR. (A) Infectious titer and (B) Specific 
infectivity (TCID50 / genome copy) data are shown normalized to 0 μM drug. Specific infectivities 
were compared to the 0 μM drug samples using the Kruskal-Wallis test with a Dunn Correction. 
* = p < 0.05. Solid lines are samples treated with drug only and dashed lines are samples with 




Lethal mutagenesis of influenza virus 
We next determined whether the mutagenic action of each nucleoside analog 
was sufficient to drive influenza virus populations to extinction. Influenza populations 
were passaged in nucleoside analog concentrations that were sufficient to cause 
significant decreases in specific infectivity and 3 to 4 log10 reductions in viral titer (Figure 
3.6). At 40 μM ribavirin, virus was undetectable by passage 3, and we were unable to 
recover any infectious virus after blind passage in the absence of drug. Using an 
identical approach, we observed extinction at passages 4 and 5 with 100 μM 5-
fluorouracil and 25 μM 5-azacytidine, respectively. Together with the results above, 
these data suggest that lethal mutagenesis of influenza virus can be achieved provided 
the viral population accumulates a significant mutational load.  
 
 
Figure 3.6. Lethal mutagenesis of influenza virus   
Influenza A/PR8/34 (H1N1) was passaged on MDCK cells in (A) ribavirin, (B) 5-azacytidine, or 
(C) 5-fluorouracil. Cells were infected at each passage with an MOI of ≤ 0.1 as described in the 
methods, and progeny were harvested at 24 hours post infection. Three viral lineages were 
passaged for each condition. Solid lines are the 3 mock-treated control lineages, and dashed 
lines indicate the 3 drug-treated lineages. The horizontal dotted line indicates the limit of 
detection for the last passage of each experiment. When titers dropped below the limit of 
detection, 0.8 mL of supernatant were added to fresh MDCK cells in the absence of drug and 
titered at 4 days post infection. Daggers indicate that no virus was recovered from any of the 





Antiviral susceptibility after serial passage in drug 
While lethal mutagenesis was initially believed to have a high genetic barrier to 
resistance, serial passage in sub-lethal concentrations of drug may select for drug-
resistant viruses that express variant, high fidelity polymerases (62, 65, 86). To evaluate 
the potential for evolved resistance in influenza, we passaged virus in each nucleoside 
analog at concentrations that cause 1 to 2 log10 reductions in viral titer. These sub-lethal 
concentrations were chosen as they impose a significant selective pressure for evolved 
resistance without driving the viral population into extinction. As in our single passage 
experiments, we initially passaged viral populations at an MOI of 0.1. We found that 
titers of both drug-treated and mock-treated populations initially declined and were 
followed by a rapid rebound. As this cyclical effect was independent of drug treatment, 
we hypothesized that it was related to the generation and purging of defective 
interfering (DI) particles (153, 154). To control for this effect, we repeated the 
experiment at an MOI of 0.01, which should limit the accumulation of DI particles. Under 
these conditions, titers for the control lineages (D1-D3) remained stable over 16 
passages (Figure 3.7A). For the three lineages passaged in the presence of 7.5 μM 
ribavirin (R1-R3), infectious titers initially dropped for the first several passages and 
then reached a new equilibrium by passage 12. By passage 16, the titers of the ribavirin 
treated populations were higher than those observed after a single drug passage, but 
lower than mock-treated samples. Lineages A1-A3, which were passaged in 7.5 μM 5-
azacytidine, exhibited significant fluctuations in their titers across the 16 passages, but 
remained lower than those of mock-treated samples. Viruses passaged in 30 μM 5-
fluorouracil (F1-F3) maintained their titer after the initial 10-fold drop at passage 1.  
Given the stabilization in titer across all 9 drug-treated lineages by passage 16, 
we assessed the drug sensitivity of these populations using the same drug 
concentrations as in Figure 3.1. We tested the sensitivity of each passage 16 population 
to the drug in which it had been passaged at the MOI used in single passage (0.1) and 
serial passage (0.01) drug treatments. In both cases, we found no significant 
differences in the sensitivity of drug-passaged populations relative to either the 
unpassaged stock or the control lineages at the tested concentrations (Figure 3.7C). 
The only exception was the F1 population, which exhibited a statistically significant 
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decrease in drug sensitivity at 80 μM 5-fluorouracil relative to the unpassaged stock (p < 
0.05). The biological significance of this finding is unclear, as the lineage was just as 
sensitive to drug as the mock-treated passage control (see D2 passage 16). 
We also noticed that, in the absence of drug, the titers of drug passaged viral 
lineages were at least 10-fold lower when infections were carried out at an MOI of 0.1 
as opposed to 0.01 (Figure 3.7B). The mock-treated control passages replicated to 
equivalent titers at both multiplicities of infection. The sensitivity of the drug-treated 
populations to the multiplicity of infection suggests that drug treatment accelerates the 
accumulation of highly mutated, defective particles that interfere with the replication of 
other less mutated progeny through lethal defection. Together, these data indicate the 
importance of lethal defection in drug-passaged populations, which may limit the 




Figure 3.7. Serial passage of influenza in sub-lethal concentrations of nucleoside analogs 
Influenza A/PR8/34 (H1N1) was passaged on MDCK cells in the presence of nucleoside 
analogs. Passages were performed at an MOI of 0.01 using supernatant from the previous 
passage, and harvested at 24 hours post infection. (A) Infectious titers are shown for 16 
passages at the indicated drug concentrations. (B) Infectious titers of passage 16, drug-treated 
and mock-treated (D2) populations after a single passage at an MOI of 0.1 (black bars) or 0.01 
(gray bars) over a 24 hour period in the absence of nucleoside analogs. (C) Sensitivity of 
passage 16 populations to the drugs in which they had been passaged. Infectious titers of 
viruses after a single passage at an MOI of 0.01 in drug for 24 hours are shown. Titers are 
relative to those from virus passaged in the absence of drug. Solid lines with solid points 
represent unpassaged and DMSO passaged controls. Dashed lines with empty points represent 
viruses that had been passaged in drug. The horizontal dotted line indicates the limit of 
detection. Points are plotted as mean ± standard deviation for 3 replicates. 
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Drug induced shifts in the viral mutant spectrum 
The stabilization of viral titers in each drug-passaged population suggested that a 
new equilibrium had been reached by passage 16. We performed deep sequencing of 
the passage 16 populations to determine the consensus sequences, predominant 
mutation types, and minority variants found within each viral population. Using a 
conservative, empirically determined cut-off for variant detection (see Methods), we 
identified relatively few non-synonymous mutations at a frequency of >50% in passaged 
populations (Table 3.1). Many of the consensus mutations (>50% frequency) within the 
drug-passaged lineages were also identified at lower levels in the mock-treated lineages 
or in the unpassaged population. Since the drug-passaged and the control populations 
were equally sensitive to drug (Figure 3.7B), it is unlikely that any of these high-level 
mutations confer resistance to the antiviral effects of the nucleoside analogs.  
We determined the type, location, and frequency of all mutations present at a 
frequency greater than 1%. In each case, the drug-passaged populations exhibited a 
large number of mutations across the genome (Figure 3.8). In the ribavirin lineages, we 
observed an increase in both C to U and G to A transitions. Viruses passaged in 5-
azacytidine had an excess of C to G and G to C tranversions, and the 5-fluorouracil 
lineages had an accumulation of A to G and U to C transitions. All of these mutations 
are characteristic of the drug used. While the drug-treated populations had a higher 
mutational load than the control lineages, nearly all of the mutations were present at a 
frequency of less than 5%. In one of the ribavirin passaged populations (R2), we 
identified PB1 D27N, a mutation that has been reported to confer ribavirin resistance, at 
a frequency of 2.5% (94). A second, previously described ribavirin resistance mutation, 
PB1 V43I, was not observed in any of the lineages (65). Our comprehensive analysis of 
drug-passaged populations confirms the mutagenic activity of each drug and suggests 






Figure 3.8. Mutation accumulation within viral populations after serial passage in 
nucleoside analogs  
Influenza A/PR8/34 (H1N1) was serially passaged in 7.5 μM ribavirin (R1-R3), 7.5 μM 5-
azacytidine (A1-A3), 30 μM 5-fluorouracil (F1-F3), or without drug (D1-D3). At passage 16, viral 
populations were sequenced to a high depth of coverage using the Illumina platform. The 
location, frequency, and type of all mutations above 1% frequency and with a p-value below 
0.01 are shown. The influenza genome segments are concatenated with positions 1-2341 
representing PB2, 2342-4682 representing PB1, 4683-6915 representing PA, 6916-8693 
representing HA, 8694-10258 representing NP, 10259-11671 representing NA, 11672-12698 
representing M, and 12699-13588 representing NS. Mutations above the dashed line (frequency 
0.5) are consensus mutations within the population. Red dots indicate C to U and G to A 
transition mutations, blue dots indicate C to G and G to C transversion mutations, black dots 















Frequency is given as percentage of population. 




We used three structurally distinct nucleoside analogs to systematically explore 
the potential of lethal mutagenesis as a therapeutic strategy for influenza virus infection. 
Our studies of viruses exposed to ribavirin have established mutagenic and non-
mutagenic modes of action for this drug against influenza virus. We also found that two 
other broad-spectrum antivirals, 5-azacytidine and 5-fluorouracil, are effective lethal 
mutagens for influenza virus in vitro. Additionally, we found that populations subjected 
to extended passage in sub-lethal concentrations of these mutagens did not readily 
acquire resistance. These results support the utility of lethal mutagenesis as an 
approach for the treatment of influenza virus.   
Ribavirin has broad-spectrum antiviral activity with documented mutagenic and 
non-mutagenic modes of action (134, 135, 138, 140) Previous work suggests that 
ribavirin’s mode(s) of action may be specific to certain viruses or taxa. In influenza, we 
found that its mode of action is more complex than previously realized. We determined 
that ribavirin was mutagenic to influenza virus by assessing mutation frequency and 
specific infectivity. While ribavirin is known to inhibit IMPDH in MDCK cells, this 
mechanism is unlikely to directly account for mutagenesis as the more potent IMPDH 
inhibitor, mycophenolic acid, did not affect the virus’ specific infectivity (140, 151). 
Guanosine supplementation reversed ribavirin’s effect on both titer and specific 
infectivity, suggesting that GTP pool concentrations are an important factor in the 
mutagenic activity of ribavirin. The simplest explanation for these data is that ribavirin’s 
inhibition of IMDPH creates a cellular environment that allows for mutagenesis. Since 
ribavirin is a guanosine analog, reduced levels of GTP within the cell may increase the 
probability of ribavirin triphosphate incorporation into replicating viral RNA. The 
concentrations of ribavirin that are effective against influenza virus are lower than those 
reported for several other RNA viruses (15, 18), which may reflect increased sensitivity 
to this drug. Alternatively, differences in host cell transport and metabolism of a given 
nucleoside analog may affect its antiviral activity. 
The results from our mutation frequency assay and deep sequencing of serially 
passaged populations support a mutagenic mode of action for ribavirin, 5-azacytidine, 
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and 5-fluorouracil. After 16 passages in drug, we observed an increase in two mutation 
types for each drug that are consistent with their chemical structures and previous work 
in other viral systems (77, 80, 82, 131). In contrast, only one of the two expected 
mutation types was observed in the mutation frequency assay after a single passage in 
ribavirin or 5-azacytidine. The mutation frequency assay may have insufficient power to 
detect increases in transition mutations, which are already present at high frequencies 
in the control populations due to the inherent transition bias of the influenza RdRp. This 
issue of statistical power could explain the lack of significant increases in G to A 
mutations in ribavirin treated populations and both A to G and U to C in 5-fluorouracil 
treated populations using this assay. It is also possible that the sense of the RNA strand 
into which the nucleotide analog is incorporated may bias the observed mutation types 
in the single passage experiment. During influenza replication, negative-sense viral 
RNA is known to be transcribed at levels 10-fold to 100-fold higher than positive-sense 
complementary RNA (156). This suggests that for a given nucleotide position, there 
would be a greater likelihood of nucleoside analog incorporation into the negative-sense 
strand. Indeed, our data support this model, as we observed an increase in mutations 
predicted from 5-azacytidne incorporation into the negative-sense strand (C to G), but 
not the positive-sense strand (G to C) in our mutation frequency assay.  
The mutational space explored by a virus may be an important aspect of its 
genetics that influences the effectiveness of a lethal mutagen. We determined that the 
influenza virus RdRp has a strong bias towards transition mutations, especially A to G 
and U to C. This mutational bias suggests that influenza virus populations may more 
thoroughly explore the sequence space accessible through these mutation types. This 
natural exploration could confer a certain level of genetic robustness to the detrimental 
effects of A to G and U to C transitions (36, 157). Therefore, mutagens that induce the 
same types of mutations as influenza’s normal bias may be less effective at inducing 
lethal mutagenesis. In support of this model, we observed that the least potent 
mutagen, 5-fluorouracil, templates the two mutation types that are most commonly 
made by the influenza virus RdRp. We also found that 5-azacytidine, which induces 
transversion mutations rarely made by the influenza virus RdRp, was able to cause the 
largest reductions in specific infectivity. These results suggest that for maximal 
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effectiveness, a lethal mutagen should force a viral population to explore regions of 
sequence space that are not normally accessed under normal replication conditions.  
As opposed to other viral systems where resistant variants quickly rose to 
prominence within the viral population, we did not observe emergence of high-level 
resistance after serial passage in sub-lethal concentrations of nucleoside analog (62, 
72, 86). This lack of resistance is despite the fact that viral populations persisted 
through 16 passages and achieved a new equilibrium with titers higher than those 
observed at passage 1. These observations suggest that population-wide resistance, 
either through the evolution of resistance mutations or genetic robustness, is not readily 
acquired by influenza virus. Since the lack of a resistance phenotype suggests that a 
more mutationally robust population has not evolved, the mechanism by which the viral 
population persists may be through the maintenance of lightly mutated genomes. At 
sub-lethal concentrations of mutagen, a small percentage of genomes may remain 
unmutated. Together with genomes containing neutral mutations, these viruses will 
have a selective advantage over their highly, or lethally, mutated brethren and will be 
maintained within the population. We also found that concentrations of drug 3- to 5-fold 
higher than those used for the serial passage experiment were able to completely 
extinguish influenza populations. Together, these results suggest that for these three 
nucleoside analogs, there is a narrow window between the concentrations that allow for 
persistence and those that quickly cause extinction. The utility of lethal mutagenesis as 
an anti-influenza strategy is further supported by these results, because they suggest 
that even if the drug dose is insufficient to cause extinction of the viral population, it may 
be unlikely to lead to the evolution of a population resistant to the drug.  
Our data suggest that DI particles, by interfering with the replication of less 
mutated progeny through lethal defection, contribute to the antiviral effect of lethal 
mutagens on influenza virus populations. Consistent with this model, we found that virus 
passaged in mutagenic nucleoside analogs replicated to lower titers when infected at a 
high MOI. The dependency on MOI suggests that this effect is the result of DI particles 
within the viral population (153, 155). Our deep sequencing data show that hundreds of 
mutations accumulate at frequencies greater than 1% when influenza is passaged in 
drug. There are likely hundreds or even thousands more mutations that accumulate at 
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lower frequencies. Thus, under conditions in which co-infection of cells is more likely, 
mutagenized genomes can effectively interfere with the replication of their less mutated 
brethren. The effect of lethal defection may be more pronounced in a segmented, 
negative-stranded RNA virus due to its mode of replication. In support of this model, 
treatment of LCMV, another segmented, negative-stranded RNA virus, with 5-
fluorouracil was shown to generate defective particles capable of interfering with the 
replication of the viral population (155). Lethal defection may also explain why we did 
not observe population-level resistance. Even though single mutations are known to 
mediate mutagen resistance, defective interfering particles may keep those mutations 
from increasing in frequency within the population. In addition to causing lethal 
defection, the mutational burden induced by the drugs also would increase the 
likelihood of a beneficial mutation arising within a defective genome.  
We note that other investigators have failed to identify population-wide resistance 
in influenza populations exposed to lethal mutagens. In a recent study, a ribavirin 
resistance variant (PB1 V43I in influenza A/Wuhan/359/95 (H3N2)) was only identified 
in a plaque reduction assay and subsequent screening of 182 plaques (65). 
Additionally, passaging influenza virus in the mutagen favipiravir did not cause the viral 
population to become resistant (93). Ribavirin has also been demonstrated to suppress 
resistance to conventional anti-influenza drugs when used in combination (158). Each of 
these examples, along with our results, suggest that an increased mutational burden 
reduces the potential for high-level resistance within an influenza population.  
Our study reinforces the attractiveness of lethal mutagenesis as an antiviral 
strategy. We have demonstrated that three nucleoside analogs, which each induce 
different types of mutations, can function as lethal mutagens of influenza virus. Our data 
suggest that segmented, negative-stranded RNA viruses may have a higher barrier to 
resistance to this class of antiviral due to the impact of lethal defection. Influenza is now 
one of several viruses that have been shown to be sensitive to drugs that are capable of 
inducing lethal mutagenesis. The fact that favipiravir, which is currently in clinical trials 
as an influenza therapy, also functions as a lethal mutagen suggests the clinical 
relevance of this strategy. Current drawbacks to using nucleoside analogs clinically as 
antivirals are off target effects and their relatively low potency (73, 148, 149). If novel 
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mutagenic nucleoside analogs can be identified that overcome these hurdles, lethal 
mutagenesis may emerge as an effective strategy for treating a broad spectrum of RNA 
viruses, including influenza.  
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Influenza resistance to mutagenic drugs 
 




 Viruses with RNA genomes have mutation rates that are several orders of 
magnitude higher than most organisms with DNA genomes. These high mutation rates 
are key to allowing viruses to evolve rapidly. They also make the viruses highly 
susceptible to mutagenic drugs that push mutation rates beyond the genetically 
tolerable limit. Several RNA viruses, including influenza, evolve resistance to increased 
mutation rates via a variety of mechanism when treated with mutagenic nucleoside 
analogs. Knowledge of these resistance mechanisms is invaluable for our 
understanding of the mutation rate and population dynamics that govern the 
evolutionary processes of RNA viruses. We have previously identified the mutations 
PB1 T123A and PA T97I as putative polymerase fidelity variants in influenza 
populations treated with mutagenic nucleoside analogs. Here, we characterize their 
effects on influenza virus replication, mutation rate, and mutational tolerance. We found 
that PB1 T123A, and PA T97I both mediate 5-fluorouracil resistance through the 
maintenance of robust genome production. These mutants make more genomic RNA 
than wild type during 5-fluorouracil treatment, leading to higher infectious titers, despite 
a similar specific infectivity. We also identified secondary mechanism for both of these 
mutants. PB1 T123A has an increased baseline mutation rate and prevents 5-
fluorouracil from increasing the rate of C to U mutations. PA T97I maintains a more 
equal production of different genomic segments upon 5-fluorouracil treatment. 
Additionally, we determined that mutagen resistance mutations are strain dependant. 
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PB1 V43I, which was previously identified to allow for ribavirin resistance, was not 
resistant to ribavirin in the influenza A/Puerto Rico/8/1934 H1N1 strain. Our results 
show a new mechanism by which populations of RNA viruses can increase the 
tolerance to nucleoside analogs. By producing larger numbers of genomes, viral 
populations can buffer the negative effects that increased mutation rates impose on 
genome infectivity.         
 
Introduction 
 Influenza virus causes significant morbidity and mortality during annual, seasonal 
epidemics. One of the main reasons that influenza is a persistent human health problem 
is its rapid rate of evolution. Influenza rapidly acquires antigenic changes and antiviral 
resistance, which limit effectiveness of vaccinations and antiviral drugs (2–5). This rapid 
rate of evolution is made possible, in part, by a very high mutation rate. Like many RNA 
viruses, influenza has a high mutation rate due to the absence of proofreading and 
repair mechanisms during genome replication (20, 130). We have previously estimated 
influenza’s mutation rate to be greater than 1 x 10-4 mutations per nucleotide per RNA 
strand replicated, which suggests that, on average, 2 new mutations are introduced into 
every newly synthesized genome (see chapter 2). This high mutation rate causes 
populations of influenza viruses to exist as swarms of distinct genetic variants. Through 
the generation of this rich genetic diversity, adaptive mutations can arise quickly.  
 High mutation rates cause a large proportion of the genomes within a viral 
population to be non-infectious. Similarly to other viruses, it is estimated that 30% of all 
single nucleotide changes within influenza’s genome completely prevent the virus from 
replicating (69). This fact led to the idea of targeting viral mutation rates as an antiviral 
strategy called lethal mutagenesis. Lethal mutagenesis utilizes drugs, often nucleoside 
analogs, to increase a virus’ mutation rate in order to promote the generation of non-
infectious viral particles. This antiviral process has been shown to be effective in a 
variety of viral systems, including poliovirus, human immunodeficiency virus, foot-and-
mouth disease virus (FMDV), lymphocytic choriomeningitis virus, and influenza virus 
(76, 80, 81, 115, 159).             
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RNA virus mutants that are resistant to lethal mutagenesis have been identified 
by serial passage of viral populations in low concentrations of mutagenic nucleoside 
analogs. The general mechanistic paradigm for resistance is increased polymerase 
fidelity. High fidelity polymerases, which exhibit a lower baseline mutation rate, have 
been identified for several viruses including poliovirus, FMDV, Chikungunya virus, and 
influenza virus (58, 59, 62, 65, 72, 86). By having a lower mutation rate, these variant 
viruses require higher concentrations of mutagenic drug to increase the viral mutation 
rate to the same level as a wild type virus.   
Mechanisms other than increased polymerase fidelity have also been identified 
for resistance to nucleoside analogs. Other polymerase mutants have been found that 
cause the polymerase to select against incorporation of nucleoside analogs into RNA or 
to prevent the mutagen from causing large biases in the virus’ mutation spectrum (60, 
87). Recently, a mutation in the polymerase associated 2C protein of FMDV was shown 
to mediate mutagen resistance through an unclear mechanism that decreases the effect 
of mutations on viral infectivity (89). Increases in the burst size, or the number of 
progeny produced per infected cell, have been shown to mitigate the effects of 
mutagenesis in the DNA bacteriophage ΦX174 (90). Finally, a virus’ primary sequence 
has also been shown experimentally to affect mutagen sensitivity through its genetic 
robustness or ability to buffer the fitness effects caused by mutations (36, 90, 91). 
Collectively, this work studying how RNA viruses resist the effects of mutagenic agents 
has improved our knowledge of RNA virus mutation rate dynamics and population 
structure, which are important for a thorough understanding of RNA virus evolution.  
Much of the work on lethal mutagenesis and resistance to increased mutation 
rates has been done using RNA viruses with (+) sense genomes. Influenza virus, on the 
other hand, contains a single-stranded, segmented, (-) sense RNA genome. 
Additionally, influenza replicates its genome using a heterotrimeric replicase complex. 
This complex is composed of the PB2 5’-cap binding protein, the 5’-cap stealing PA 
protein, and the RNA-dependent RNA-polymerase (RdRp) PB1 protein (11). Whether 
these differences in viral replication would cause different mechanisms of lethal 
mutagenesis resistance to be available to a virus is unknown.   
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 We have previously performed 16 passages of influenza A/Puerto Rico/8/1934 
H1N1 (PR8) in sub-lethal concentrations of ribavirin, 5-azacytidine, and 5-fluorouracil to 
assess the ability of influenza populations to become resistant to mutagenic drugs 
(115). While no population-wide resistance was observed, PB1 T123A, PB1 M645I, and 
PA T97I were found within the genes encoding the components of the viral replicase 
only upon mutagen treatment (see chapter 3). Interestingly, these mutations did not 
include the PB1 V43I mutation previously identified to be mutagen resistant through 
increased nucleotide selectivity in the A/Wuhan/359/95 H3N2 and A/Vietnam/1203/04 
H5N1 strains (65). Another mutation, PB1 D27N, that has been suggested to provide 
ribavirin resistance was found in only one of our ribavirin passaged populations at very 
low frequency (94, 160). Here, we characterize the effects of PB1 T123A, PB1 M645I, 
and PA T97I on nucleoside analog sensitivity, viral fitness, and mutation rate. 
Additionally, we investigate the effects of PB1 V43I and PB1 D27N in the context of the 
PR8 strain. We found that two of the mutations we identified provide resistance to 5-
fluorouracil by maintaining high genome production during treatment with the drug while 
neither of the previously described mutations mediate resistance in our viral system.   
                    
Materials and Methods 
Cells, viruses, plasmids, and drugs 
 Human embryonic kidney 293T fibroblasts were provided by Dr. Raul Andino 
(University of California San Francisco). Madin Darby canine kidney cells were provided 
by Dr. Arnold Monto (University of Michigan). Both cell lines were maintained in growth 
medium (Dulbecco’s modified Eagle medium (Gibco 11965) supplemented with 10% 
fetal bovine serum and 25 mM HEPES) at 37°C and 5% CO2 in a humidified incubator. 
 MDCK Cells expressing the hemagglutinin (HA) protein of influenza A/Puerto 
Rico/8/1934 H1N1 (MDCK-HA cells) were generated by co-transfection with a pCABSD 
plasmid that expresses a Blasticidin S resistance gene and a pCAGGS plasmid 
encoding the influenza A/Puerto Rico/8/1934 H1N1 HA gene (103). Cells stably 
expressing HA were selected in growth medium containing 5 μg/mL Blasticidin S and 
were enriched for high HA expression by staining with an anti-HA antibody (1:1000 
 
78 
dilution, Takara c179) and an Alexa 488-conjugated anti-mouse IgG (1:200 dilution, Life 
Technologies A11001) followed by fluorescence-activated cell sorting on a FACSAria II 
(BD Biosciences). Over the course of 5 passages, cells were sorted three times to 
achieve a final population where >99% were positive for high HA expression. 
 All eight genomic segments of influenza A/Puerto Rico/8/1934 H1N1 (PR8) 
(ATCC VR-1469) were cloned into the pHW2000 vector. Briefly, genomic RNA was 
harvested from the supernatants of infected cells using TRIzol reagent (Life 
Technologies 15596). Complementary DNA was synthesized by reverse transcription 
PCR using SuperScript III (Invitrogen 18080051) and Phusion high fidelity DNA 
polymerase (New England Biosciences M0530) with the primers described by Hoffmann 
and colleagues (101, 102). PCR products and pHW2000 were digested using BsmB1 
(New England Biosciences R0580), Bsa1 (New England Biosciences R0535) or Aar1 
(Thermo Scientific ER1581). Digested DNA was gel purified (Thermo Scientific K0691) 
and PCR products were ligated into pHW2000 using T4 DNA ligase (New England 
Biosciences M0202). 
 Mutant PB1 and PA segments were generated within the pHW2000 vector using 
overlap extension PCR (105). Two rounds of PCR were performed using Phusion high 
fidelity DNA polymerase with pHW2000 plasmids encoding either PB1 or PA from the 
PR8 virus as a template, the inner mutagenic primers (PB1 D27N, Fwd 5’- 
CCCTTATACTGGAAACCCTCCTTACAGC-3’, Rev 5’- 
GCTGTAAGGAGGGTTTCCAGTATAAGGG-3’; PB1 V43I, Fwd 5’- 
CACCATGGATACTATCAACAGGACAC-3’, Rev 5’- 
GTGTCCTGTTGATAGTATCCATGGTG-3’; PB1 T123A, Fwd 5’- 
GTAGACAAGCTGGCACAAGGCCGAC-3’, Rev 5’- 
GTCGGCCTTGTGCCAGCTTGTCTAC-3’; PB1 M645I, Fwd 5’- 
CAATGCAGTGATAATGCCAGCACATGG-3’, Rev 5’- 
CCATGTGCTGGCATTATCACTGCATTG-3’; PA T97I, Fwd 5’- 
CAGTATTTGCAACATTACAGGGGCTGAG-3’, Rev 5’- 
CTCAGCCCCTGTAATGTTGCAAATACTG-3’) and the outer primers containing AarI or 
BsmBI restriction sites (PB1, Fwd 5’- 
TATTCACCTGCCTCAGGGAGCGAAAGCAGGCA-3’, Rev 5’- 
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ATATCACCTGCCTCGTATTAGTAGAAACAAGGCATTT-3’; PA Fwd 5’- 
TATTCGTCTCAGGGAGCGAAAGCAGGTAC-3’, Rev 5’-
ATATCGTCTCGTATTAGTAGAAACAAGGTACTT-3’). Two first found PCR reactions 
using Fwd inner primers with Rev outer primers and Rev inner primers with Fwd outer 
primers were run. The products of these reactions were purified using a GeneJET PCR 
Purification Kit (Thermo K0701), mixed and used as templates for a second round PCR 
reaction using only the outer primers.  Full-length PB1 and PA genes were gel purified, 
digested, and cloned into pHW2000 plasmid as above. PB1 containing a neutral genetic 
barcode was created in the same way using the inner mutagenic primers; 5’-
GATCACAACTCATTTCCAACGGAAACGGAGGGTGAGAGACAAT-3’ and 5’-
ATTGTCTCTCACCCTCCGTTTCCGTTGGAAATGAGTTGTGATC-3’.   
 A pPOLI vector encoding enhanced green fluorescent protein (eGFP) with 
influenza HA packaging sequences (ΔHA-GFP) was kindly provided by Luis Martinez-
Sobrido (University of Rochester). This construct contains eGFP flanked by the 78 3’-
terminal bases (33 noncoding, 45 coding) and 125 5’-terminal bases (80 coding, 45 
noncoding) of the influenza A/WSN/33 H1N1 HA segment and lacks the HA translation 
initiation codon (104). QuikChange II site-directed mutagenesis (Agilent Technologies 
200523) was used to generate mutant ΔHA-GFP constructs with primers 5’- 
CTCGTGACCACCCTG<mutant sequence>GTGCAGTGCTTCAGC-3’ and 5’- 
GCTGAAGCACTGCAC<mutant sequence’>CAGGGTGGTCACGAG-3’, where mutant 
sequence corresponds to the sequences ACCUACGAC for A to G mutation rate 
assessment, ACCCACGGC for C to U mutation rate assessment, ACCUGCGGC for G 
to A mutation rate assessment, and AUAUACGGC for U to C mutation rate assessment 
and mutant sequence’ is its reverse complement. 
 Viruses were rescued from plasmids by transfecting co-cultures of MDCK and 
293T cells (101). pHW2000 plasmids encoding all eight influenza genome segments 
were mixed (500 ng each) in Opti-MEM (Gibco 31985062) with 8 μL of TransIT-LT1 
(Mirus 2300) and allowed to incubate for 30 minutes. Mixtures were added to 12-well 
plated seeded the previous day with 2x105 293T cells and 1x105 MDCK cells and 
containing viral medium (Dulbecco’s modified Eagle medium (Gibco 11965) 
supplemented with 0.187% BSA, 25 mM HEPES, and 2 μg/mL TPCK treated trypsin 
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(Worthington Biochemical 3740)). After 24 hours the media was changed. Cell free 
supernatants were harvested with the addition of 0.5% glycerol at 48 hours post 
transfection. All rescued viruses were subsequently passaged on MDCK cells at an MOI 
of 0.01. Passage 1 (P1) virus was harvested at 48 hours post infection. All described 
experiments used P1 virus stocks.    
 Ribavirin (1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-
1,2,4-triazole-3-carboxamide) (Sigma-Aldrich R9644) was dissolved in phosphate 
buffered saline (PBS) at 100 mM. 5-Fluorouracil (2,4-Dihydroxy-5-fluoropyrimidine)  
(Sigma-Aldrich F6627) was dissolved in dimethyl sulfoxide (DMSO) at 384 mM. 5-
Azacytidine (4-Amino-1-(β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one) (Sigma-Aldrich 
A2385) was dissolved in DMSO to make a stock at 100 mM. Aliquots of these drug 
stocks were stored at minus 20°C.  
   
Mutagen sensitivity assays      
 Viral medium containing ribavirin, 5-azacytidine, or 5-fluorouracil was added to 
24-well plates that had been seeded with 6.5 x 104 MDCK cells the previous day. After 
three hours, 1.5 x 104 PR8 viruses (MOI 0.1) were used to infect the cells in 300 uL of 
viral media containing drug. After one hour, the viral containing medium was removed 
from the cells and 500 uL of viral medium containing drug was added. Twenty-four 
hours after infection, cell free supernatants were harvested by adding 0.5% glycerol, 
centrifuging for 5 minutes at 3,000 x g, and freezing at -80°C.  
 Infectious viral titers were measured by TCID50 assays. Four-thousand MDCK 
cells were added to each well of a 96-well plate in 100 μL of viral infection medium 
lacking TPCK treated trypsin. On the next day, viral supernatants were serially diluted 
10-fold in viral infection media containing 4 μg/mL of TPCK treated trypsin. One-
hundred microliters of each viral dilution were added to 12 wells of the 96-well plate. 
After four days all wells were scored for cytopathic effect (CPE), and the titers were 




Competition assays  
 Mutant PB1 or PA viruses were mixed with PR8 viruses containing a neutral 
genetic barcode at equivalent TCID50 titers. Viral mixtures were used to infect 4 x 10
5 
MDCK cells in a 12-well plate at an MOI of 0.01. After 24 hours, supernatants were 
harvested and passaged 3 more times on MDCK cells at an MOI of 0.01. All 
competitions were performed with three biological replicates. Viral RNA was harvested 
from the supernatants of all passages using a Purelink Pro 96 viral DNA/RNA kit 
(Invitrogen 12280). Superscript III and random hexamers were used to generate cDNA. 
Quantitative PCR was used to determine the relative amount of total PB1 (primers 5’-
CAGAAAGGGGAAGATGGACA-3’ and 5’-GTCCACTCGTGTTTGCTGAA-3’), barcoded 
PB1 (primers 5’-ATTTCCAACGGAAACGGAGGG-3’ and 5’-
AAACCCCCTTATTTGCATCC-3’), and non-barcoded PB1 (primers 5’-
ATTTCCAACGGAAACGGAGGG-3’ and 5’-AAACCCCCTTATTTGCATCC-3’) in each 
sample. The amounts of barcoded and non-barcoded PB1 genome segments at each 
passage were normalized by subtracting from them the Ct threshold for the total PB1 
primer set (ΔCt = Ctcompetitior – Cttotal PB1). A relative ΔCt was obtained by comparing 
these values at each passage to the initial P0 viral mixture (ΔΔCt = ΔCtP1 – ΔCtP0). The 
relative ΔCt was converted to the fold change in genome copies (Δratio = 2–ΔΔCt). The 
slope of the differences between the log10 Δratios of the two viruses as a function of the 
passage number is equal to the log10 relative fitness of the non-barcoded virus 
([log10Δrationon-barcoded- log10 Δratiobarcoded]/passage) (69).       
 
Specific infectivity assays 
RNA was extracted from the supernatants of virally infected cells using either 
TRIzol Reagent (Life Technologies 15596), or Purelink Pro 96 Viral RNA/DNA Kit 
(Invirogen 12280). SuperScript III (Invitrogen 18080) was used to synthesize cDNA 
using random hexamers. Quantitative PCR was performed on a 7500 Fast Real Time 
PCR system (Applied Biosystems) using FastStart Universal SYBR Green Master mix 
(Roche 04913850001) with primers 5’-GTTGGGAGAAGAGCAACAGC-3’ and 5’-
GATTCGCCCTATTGACGAAA-3’ with an annealing temperature of 57°C for PB2 copy 
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number detection.  For M segment copy number detection, Superscript III RT/Platinum 
Taq (Thermo 2574030) was used with the primers 5’-
GACCRATCCTGTCACCTCTGAC-3’ and 5’-AGGGCATTYTGGACAAAKCGTCTA 
-3’, and the TaqMan probe FAM-TGCAGTCCTCGCTCACTGGGCACG-3’ with 
Blackhole Quencher 1 with an annealing temperature of 55°C. Quantification of cDNA 
copy numbers based on cycle threshold (Ct) values was performed using standard 
curves from ten-fold dilutions of plasmid containing the PB2 or M gene of A/Puerto 
Rico/8/1934 H1N1. The ratio of the infectious titer per mL to the genome copy number 
per mL gives the specific infectivity of the sample.        
Mutation rate assays 
 Twenty-four wells containing 1.2 x 104 MDCK-HA cells were infected with 400 
TCID50 of influenza viruses encoding mutant ΔHA-GFP segments in viral medium. 
Depending on the mutation class and drug treatment supernatants were transferred to 
black 96-well plates (Perkin Elmer 6005182) containing 1.5 x 104 MDCK cells and 50μL 
of viral medium at 17-23 hours post infection. Two wells were infected with virus 
equivalent to the amount used to initially infect the parallel cultures. These wells are 
used to determine Ni in the mutation rate calculation. After 14 hours, cells were fixed 
using 2% formaldehyde for 20 minutes. Cells were rinsed with PBS and permeabilized 
using 0.1% triton-X-100 for 8 minutes. After rinsing again, nonspecific antibody binding 
sites were blocked using 2% BSA in PBS containing 0.1% tween-20 (PBS-T) for 1 hour. 
Cells were stained using 1:5000 Hoechst (Life Technologies 33342) and 1:400 anti-GFP 
Alexa 647 conjugate (Life Technologies A31852) diluted in 2% BSA in PBS-T for 1 hour. 
After three washes with PBS-T, the plates were sealed with black tape prior to removing 
the final wash. Plates were imaged using an ImageXpress Micro (Molecular Dynamics) 
using DAPI, Cy5, and FITC specific filter cubes with a 4x magnification lens. The entire 
surface area of each well was imaged using four non-overlapping quadrants. 
MetaXpress version 6 software (Molecular Dynamics) was used to count cellular nuclei 
and antibody stained cells. Cells expressing fluorescent GFP were manually counted 
from the collected images.  
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 A null class Luria-Delbrück fluctuation test was used to calculate the mutation 
rates with the equation μ(s/n/r) = -ln(P0)/(Nf-Ni), where μ(s/n/r) is the mutation rate per 
strand replicated, P0 is the proportion of cultures that do not contain a cell infected by a 
virus encoding fluorescent eGFP, and Nf and Ni are the final and initial viral population 
sizes, as determined by anti-GFP antibody staining (18, 40). If the number of green cells 
in a culture was greater than 0.8(Nf/Ni) it was removed from the calculation because it 
likely contained a pre-existing fluorescent revertant in the inoculum. Cultures with this 
many green cells were extremely rare due to the use of a small inoculum.  The null 
class fluctuation test measurement is most precise when P0 is between 0.1 and 0.7. As 
a result of lower titers from drug treated viral cultures, not all of our measurements fell 
within this range. Measurements where the P0 was above 0.7 are indicated in the 
mutation rate figures (Figure 4.3) 
 
Results 
 We have previously shown that passaging influenza A PR8 in low concentrations 
of ribavirin, 5-fluorouracil, or 5-azacytidine did not select for a population-wide 
resistance phenotype after 16 passages (115). This result did not preclude the 
possibility that there were resistance mutations present within these populations at low 
levels or masked by the mutational load imposed by mutagen treatment. To identify 
candidate resistance mutations, we deeply sequenced all passage 16 populations and 
the initial influenza population and identified all mutations present at a frequency greater 
than 1%. We limited our search to nonsynonymous mutations that were present in 
mutagen passaged viral populations, but absent in both the initial population and control 
populations passaged in the absence of drug. Since the viral replicase complex is the 
main target of nucleoside analogs, we further focused our search on mutations within 
PB2, PB1, and PA. We identified three mutations that met these criteria. PB1 T123A 
was found only in the three populations passaged in 5-fluorouracil at 34%, 31%, and 8% 
frequency. PA T97I was only found in the three ribavirin passaged populations at 
frequencies of 88%, 55%, and 11%. These same ribavirin passaged populations also 
contained PB1 M645I at 90%, 14%, and 1%. We also investigated two previously 
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identified ribavirin resistance mutations. Of these, PB1 V43I was not found in any of the 
populations and PB1 D27N was only found in one ribavirin passaged population at 3% 
(65, 94).  
We cloned these five mutations into clean PR8 genetic backgrounds. We created 
influenza virus containing each mutation singularly, as well as two double mutants 
containing either PB1 T123A and PA T97I, or PB1 M645I and PA T97I. The PB1 M645I, 
PA T97I double mutant was found in our ribavirin passaged viral populations. The PB1 
T123A, PAT97I double mutant was not found naturally, but we decided to create it 
because it was plausible that they could have epistatic interactions as a result of being 
in different genes.  
While we did create and characterize the PB1 M645I mutant and the PB1 M645I, 
PA T97I double mutant, the data for them is only briefly described here and shown in 
Appendices 1 and 2. We did not identify any phenotypic differences for PB1 M645I 
compared to wild type. The PB1 M645I, PA T97I double mutant phenocopied the PA 
T97I mutation alone in all regards except for replication fitness. The PB1 M645I 
mutation appears to increase the replication fitness of the PA T97I mutant while not 
affecting its ability to resist nucleoside analogs.  
 
Mutagen sensitivity  
 We identified mutations within the replicase complex after serial passage in low 
concentrations of mutagenic nucleoside analogs. Therefore, we expected that they 
would be resistance mutations. We assessed if any of these candidate resistance 
mutations caused reduced sensitivity to ribavirin, 5-fluorouracil, or 5-azacytidine by 
treating cells with or without drug and then infecting them with PR8 or the mutant 
derivatives. We compared the viral titers from drug treated and untreated cultures at 24 
hours post infection (Figure 4.1). We selected drug concentration that would decrease 
infectious viral titers by 3 – 4 orders of magnitude so that we would be able to observe 
both large and small resistance phenotypes, while limiting cytotoxicity. The 
concentrations we used were roughly 3 times higher than the concentrations in which 
our mutants evolved.  
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PB1 T123A, which was identified in 5-fluorouracil passaged populations, showed 
an approximately 10-fold reduction in sensitivity to 100 μM 5-fluorouracil, but no change 
in sensitivity to 20 μM ribavirin or 20 μM 5-azacytidine. Interestingly, PA T97I, which 
was isolated from ribavirin passaged virus, was resistant to 100 μM 5-fluorouracil, but 
not to treatment with 20 μM ribavirin or 20 μM 5-azacytidine. The PB1 T123A, PA T97I 
double mutant has a dramatic 100-fold reduction in sensitivity to 100 μM 5-fluorouracil 
and a slight, but significant reduction in sensitivity to 20 μM ribavirin. Paradoxically, this 
double mutant was slightly more sensitive to treatment with 20 μM 5-azacytidine than 
WT PR8. We found that the two previously identified ribavirin resistant mutants, PB1 
D27N and PB1 V43I, were no less sensitive than wild type PR8 to ribavirin or 5-
fluorouracil treatment. Both of these mutants were hypersensitive to 5-azacytidine.   
We have identified two mutations within influenza’s replicase complex that 
display a 10-fold decrease in 5-fluorouracil sensitivity but are not resistant to other 
nucleoside analogs. When we combine these two mutants, which did not evolve 
together, their sensitivity to 100 μM 5-fluorouracil, decreases multiplicatively to 100-fold. 
In combination, these mutations provide a slight decrease in sensitivity to ribavirin 
treatment. We also identified that the PB1 D27N and PB1 V43I mutations previously 
suggested to be resistant to ribavirin are not resistant in the genetic background of the 






Figure 4.1. Sensitivity of PR8 polymerase mutants to mutagenic nucleoside analogs  
MDCK cells were pretreated with viral media containing 0 μM drug, 100 μM 5-fluorouracil, 20 
μM ribavirin, or 20 μM 5-azacytidine for 3 hours. Cells were then infected with virus mutants at 
an MOI of 0.1. After 24 hours, cell free supernatants were harvested and titered for infectious 
virus by TCID50 assay. The decrease in the log10 of the infectious titer for drug treated samples 
relative to untreated samples for each virus is shown. Three replicate samples were harvested 
for each virus at each drug concentration, with the mean and standard deviation being shown. 
Mean decreases were analyzed by one-way ANOVA with a Dunnett’s multiple comparison test 






 Viral variants that are resistant to mutagens have often been found to have a 
fitness defect compared with wild type virus in the absence of mutagen. We measured 
the replicative fitness of each mutant virus relative to the fitness of wild type PR8. We 
competed mixtures of two viruses over 4 passages and used quantitative RT-PCR to 
determine the changes in the frequency of each competitor to measure relative fitness 
(69). In the absence of mutagenic drugs, we identified a range of fitness effects for the 
mutants we assessed (Figure 4.2A). PB1 T123A had slightly higher fitness and PA T97I 
was neutral. The PB1 T123A, PA T97I double mutant, which was highly resistant to 5-
fluorouracil, showed reciprocal sign epistasis with the two contributing mutations 
increasing fitness individually and decreasing fitness together. This mutant virus 
reaches maximum infectious titers that are approximately 10-fold lower than WT PR8.  
Both PB1 D27N and PB1 V43I had dramatically reduced fitness compared with wild 
type PR8. The decreased fitness of PB1 V43I matches a previous report that it 
significantly slows viral growth kinetics (65). Since neither of these viruses showed 
resistance to any of the tested nucleoside analogs, we did not test them in any 
subsequent experiments.   
 To verify that some of these mutants are resistant to 5-fluorouracil, we used 
fitness measurements in the presence of 25 μM and 50 μM 5-fluorouracil as a more 
quantitative and precise test for resistance (Figure 4.2B). We were unable to use higher 
concentrations of drug because viral replication would be too low after four passages to 
accurately measure genome copy numbers. We found that both PB1 T123A and the 
PB1 T123A, PA T97I double mutant increased their fitness relative to wild type virus 
when treated with 5-fluorouracil. The highly resistant double mutant has such a strong 
fitness disadvantage that high 5-fluorouracil concentrations are required for it to 
compete effectively against wild type virus. These findings support the conclusion that 
these two mutant viruses mediate resistance to 5-fluorouracil. We have not yet tested 
the fitness of PB1 T97I alone in 5-fluorouracil, but plan to do so soon. The range of 
fitness values that we observed for resistant mutants may suggest that each possesses 





Figure 4.2. Fitness of PR8 polymerase mutants  
A. Direct competition assays were performed for WT PR8 and each mutant against a WT PR8 
virus containing a neutral genetic barcode. Equivalent viral mixtures were passaged at an MOI 
of 0.01 on MDCK cells for 24 hours four times. Fitness values were determined using 
quantitative RT-PCR to measure relative changes in the amounts of the two competitor viruses. 
Data shown is the mean and standard deviation from three individual competitions, each were 
analyzed using a one-way ANOVA with a Dunnett’s multiple comparison test comparing each 
mutant to WT PR8. * = p-value < 0.05, ** = p-value < 0.01, **** = p-value < 0.001. B. 
Competition assays were also performed for the PB1 T123A, and PB1 T123A, PA T97I mutants 
in the presence of 5-fluorouracil. Competitions versus barcoded WT PR8 were performed over 




Mutation rate  
 Nucleoside analogs function as antiviral drugs through two main mechanisms. 
They decrease the proportion of infectious genomes that are made by functioning as 
mutagens, and they decrease genome synthesis by inhibiting the viral RdRp. We next 
attempted to characterize how our influenza mutants mediate resistance. The most 
commonly identified mechanisms of viral resistance to nucleoside analogs are through 
an altered mutation rate or an RdRp that selectively excludes the analog from its active 
site (58, 60, 62, 72, 87). We directly assessed the mutation rates of two of our mutants 
in and out of 5-fluorouracil using a GFP-based fluctuation test (Figure 4.3). We only 
used 5-fluorouracil for these experiments because that was the drug for which we saw 
the main resistance phenotypes. We used 15 μM 5-fluorouracil because higher 
concentrations would have decreased infectious viral titers too much to allow for precise 
mutation rate measurements. We measured the rates of only the four transition 
mutation classes, A to G, C to U, G to A, and U to C, because these are the mutation 
types induced by 5-fluorouracil treatment. Therefore, we would expect any fidelity 
phenotypes that mediate 5-fluorouracil resistance to be within these mutation classes. 
Additionally, these mutation classes have some of the highest baseline rates, 
suggesting that we would have the greatest power to detect differences in them (see 
chapter 2, Figure 2.4). 
 We found that in the absence of drug, PB1 T123A has a generally increased 
mutation rate among these mutation classes with C to U mutations being significantly 
higher than the wild type virus. This mutant virus, which was isolated during 5-
fluorouracil passage, selectively buffers against 5-fluorouracil induced increases in C to 
U mutations (Figure 4.3B). This phenotype is very dramatic. Treatment with 15 μM 5-
fluorouracil increases all transition mutations approximately 5-fold in wild type virus. We 
see no increase in C to U mutations by the PB1 T123A mutant upon drug treatment, 
while the other three transition mutation classes increase similarly to wild type.     
 The PB1 T123A, PA T97I double mutant has an identical transition mutation 
spectrum to wild type PR8 in the absence of drug. Our data cannot rule out differences 
in the rates of transversion mutations, but since these classes are lower to begin with, 
changes to their rates would not be expected to change the overall replication fidelity. 
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When this mutant virus is treated with 5-fluorouracil, there may be a slight buffering 
against C to U mutations although not as dramatically as the PB1 T123A single mutant. 
Both mutant viruses we tested have C to U mutation rate phenotypes that may partially 
explain their decreased sensitivity to the effects of 5-fluorouracil. We have not yet 
measured any mutation rates for the PA T97I mutant alone, but have that as a high 




Figure 4.3. Mutation rates of PR8 and polymerase mutants  
Mutation rates were measured using the GFP fluctuation test. The four mutation classes; (A) A 
to G, (B) C to U, (C) G to A, and (D) U to C, which are known to be increased by 5-fluorouracil 
(5FU) treatment, were measured for WT PR8 (●), PB1 T123A (■), and PB1 T123A, PA T97I (▲) 
both in and out of 5FU. Measurements within the ideal P0 range of 0.1 - 0.7 are shown as filled 
symbols. Those outside of that range, with P0 values between 0.7 – 0.9 are shown as open 
symbols. Arithmetic means and standard deviations are shown for the replicate measurements. 
The three viruses within each condition were analyzed by one-way ANOVA with Dunnett’s 






 The increase of viral mutation rates by nucleoside analogs decreases the specific 
infectivity (the proportion of viral particles that are infectious) within a population. A virus 
resistant to the mutagenic effects of a nucleoside analog would be expected to exhibit a 
smaller decrease in specific infectivity upon drug treatment. We tested if the viral 
mutants that are resistant to nucleoside analogs have a specific infectivity phenotype.  
We measured specific infectivity as the number of infectious particles (TCID50) 
per genome copy determined by quantitative RT-PCR. We initially measured the 
baseline specific infectivity of each mutant in the absence of drug using copies of the 
PB2 genome segment as a surrogate of genome copies (Figure 4.4A). We found that 
both PB1 T123A and PA T97I had similar specific infectivities to wild type PR8 (around 
1 infectious particle per 100 PB2 genome segments). The PB1 T123A, PA T97I double 
mutant, however, had a 5-fold decrease in specific infectivity. We initially thought that 
this phenotype was interesting, especially considering the low fitness phenotype of this 
virus. We then realized that the primers we used to determine genome copy number 
recognized a region in the middle of the PB2 genome segment. Therefore, they would 
not recognize classic defective interfering (DI) particles, which are characterized by 
internal deletions from the longer genome segments, including PB2 (153, 161).  
 We, therefore, measured specific infectivity using M segment copies as a 
measure of influenza genomes in cell free supernatants (Figure 4.4B). This assay 
allowed us to investigate if specific infectivity measurements depend on the genome 
segment being assessed and if there may be differences in the production of DI 
particles. Specific infectivities by M segment were similar among wild type and the 
tested mutant viruses, including the PB1 T123A, PA T97I double mutant that had a 
lower PB2 specific infectivity. These M segment specific infectivity values were 
approximately 2-fold lower than the PB2 specific infectivity values. These results show 
that specific infectivity measurements and comparisons between viruses depend on 
which genome segment is used as a surrogate for total genomes. It also suggests that 
there may be differences in DI particle production among these viruses.   
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We attempted to measure DI particle production. We used the ratio of PB2 
genome segments to M genome segments as a rough readout of DI particles containing 
internal deletions within PB2 (Figure 4.4C). Ratios less than one would suggest the 
presence of DI particles, since our M primers should recognize every M segment, while 
our PB2 primers would fail to recognize internally deleted PB2 segments. We found that 
wild type PR8 and PB1 T123A contained more M genome segments than PB2 
segments in cell free supernatants suggesting they produce DI particles. This was not 
the case for PA T97I and the PB1 T123A, PA T97I double mutant, which had PB2 
segment output that was equal to or higher than M segment output. Interestingly, 5-
fluorouracil caused a decrease in PB2 segments relative to M segments, suggesting an 
increase in DI particle production. This drug-induced phenotype was not observed in PA 
T97I, which generated equivalent numbers PB2 and M copies both in and out of drug. 
While our measurements are not true readouts of DI particles, they may indicate that DI 
particles are produced at higher levels upon 5-fluorouracil treatment. The PA T97I 
mutant may affect the baseline output of DI particles and also prevent 5-fluorouracil 
from inducing their production although this does not appreciably affect the decrease in 
specific infectivity associated with drug treatment.  




Figure 4.4. Specific infectivity of WT PR8 and polymerase mutants  
MDCK cells were treated with or without 100 μM 5-fluorouracil and infected with influenza at an 
MOI of 0.1 for 24 hours. Cell-free supernatants were collected and used for infectious titer 
determination by TCID50 and genome copy number determination using primers specific for the 
PB2 or M genome segments. The infectious particles per PB2 genome segment (A) and per M 
genome segment (B) in the absence of drug are shown with means and standard deviations for 
three replicates. One-way ANOVA with Dunnett’s multiple comparison test relative to WT PR8 
were performed for each data set. * = p < 0.05 C. The number of PB2 segments per M segment 
in the supernatants from infected cells not treated with drug (●) or treated with 100 μM 5-
fluorouracil (□) are shown for three replicates with means and standard deviations. Values with 
and without drug were compared for each virus using t-tests with the Holm-Sidak correction for 
multiple comparisons. No significant differences were identified after correcting for multiple 






We next tested the effect of drug treatment on specific infectivity. We measured 
the specific infectivity of viral populations treated with no drug or 100 μM 5-fluorouracil 
and determined the difference (Figures 4.5A and 4.5B). All three mutant viruses that we 
tested had similar specific infectivity decreases when treated with 5-fluorouracil. This 
effect was consistent regardless of whether PB2 or M segment copy numbers were 
used to calculate specific infectivity. These data suggest that limiting the ability of 5-
fluorouracil to decrease viral specific infectivity is not the mechanism of resistance for 
any of these mutants. They also suggest that the observed decrease in 5-fluorouracil 
induced C to U mutations for the PB1 T123A virus is not sufficient to cause a specific 
infectivity difference.  
 We also tested the change in specific infectivity for the PB1 T123A, PA T97I 
double mutant virus treated with ribavirin (Figure 4.5C). Similarly to 5-fluorouracil 
treatment, there was no difference from wild type PR8. Therefore, limiting the effect of 
ribavirin on genome infectivity is not a mechanism for the minor resistance phenotype 




Figure 4.5. The effect of nucleoside analogs on the specific infectivity of influenza  
MDCK cells were treated with or without nucleoside analogs and infected with influenza at an 
MOI of 0.1 for 24 hours. Specific infectivities were determined by TCID50 and quantitative RT-
PCR specific for the PB2 or M genome segments. The decreases in the log10 of the specific 
infectivity following treatment with 100 μM 5-fluorouracil were determined using PB2 (A) or M 
(B) segment and are shown as the average and standard deviation of three replicates. Data 
analysis by one-way ANOVA showed no significant differences among the viruses. C. Wild type 
PR8 and the PB1 T123A, PA T97I double mutant were also treated with 20 μM ribavirin and the 
means plus standard deviations for three replicates are shown. Analysis using a Student’s t-test 
showed no statistical differences between the two tested viruses for specific infectivity changes 




  We found that three 5-fluorouracil resistant mutants did not function through 
limiting the drug’s mutagenic effect on the specific infectivity of viral populations. 
Therefore, we looked at the other known 5-fluoruracil mechanism of action, its ability to 
inhibit viral RdRps. We directly assessed the number of PB2 and M genome segments 
present in the supernatants of virally infected cells at 24 hours post infection at an MOI 
of 0.1 for each mutant virus using quantitative RT-PCR. We measured genome 
segment copy numbers for cells treated with 100 μM 5-fluorouracil (Figure 4.6A and 
4.6B). Wild type PR8 exhibited an approximately 100-fold decrease in genome copies 
upon drug treatment. For the PB1 T123A and PA T97I mutant viruses with intermediate 
resistance phenotypes the genome copy decrease was only about 10-fold. For the PB1 
T123A, PA T97I double mutant, which had the highest resistance phenotype, we see 
that there is almost no decrease in genome output. These data suggest that the primary 
mechanism of 5-fluorouracil resistance is through preventing the ability of the drug to 
decrease genome output. By making more total genomes, these viruses are able to 
better tolerate a high mutation rate than wild type PR8. 
 Since the PB1 T123A, PA T97I mutant had a slight decrease in ribavirin 
sensitivity, we tested if there was a similar mechanism of resistance as to 5-fluorouracil. 
Treating with 20 μM ribavirin, we found an equivalent, 1,000-fold, genome copy 
decrease for both wild type PR8 and the double mutant virus (Figures 4.6C and 4.6D). 
This suggests that the mechanism of increased genome output to tolerate treatment by 
nucleoside analogs is specific to 5-fluorouracil.  
 We also noticed that the PB1 T123A mutant generated significantly more 
genomes than wild type PR8 in the absence of drug (Figures 4.6A and 4.6B, t-test, p = 
0.026, and 0.015, respectively). This may permit the virus to have both a higher 
mutation rate and a higher fitness than wild type PR8. The generation of more genomes 





Figure 4.6. Genome production by mutant PR8 viruses  
Influenza virus mutants were used to infect MDCK cells at an MOI of 0.01 for 24 hours in the 
presence or absence of 100 μM 5-fluorouracil. Supernatants were harvested and the PB2 (A) or 
M (B) genome segment copy number per milliliter was determined by quantitative RT-PCR. 
Additionally, wild type PR8 and the PB1 T123A, PA T97I double mutant were treated with or 
without 20 μM ribavirin. Genome copies were determined by PB2 (C) and M (D). Black bars 
represent samples with no drug treatment and gray bars represent samples treated with 
nucleoside analogs. Values for each virus with and without nucleoside analog treatment were 
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 Determining how viruses counteract the negative effects of an artificially imposed 
mutation rate increase has been a valuable tool for our understanding of RNA virus 
mutation rates and their consequences on viral populations (58, 59, 62, 72, 130). We 
used influenza virus to investigate several questions surrounding mutational tolerance in 
a segmented, negative-sense virus that has a trimeric replicase complex. Specifically, 
we looked at mechanisms of nucleoside analog resistance, if proteins other than PB1, 
which catalyzes RNA synthesis, can mediate resistance, and if resistance mutations are 
dependent on the viral strain. We used three mutants identified by passaging the 
influenza PR8 strain in ribavirin or 5-fluorouracil, two mutations that have been shown to 
mediate ribavirin resistance, and a double mutant to study potential mechanism of 
influenza resistance to mutagens. We identified PB1 T123A, and PA T97I as 5-
fluorouracil resistance mutations that interact epistatically. We determined that PB1 
D27N and PB1 V43I show no signs of being resistant to nucleoside analogs in the 
background of the PR8 strain. We showed that viruses resistant to nucleoside analogs 
do not necessarily possess a lower mutation rate and that they sometimes have a 
higher baseline mutation rate as we see with PB1 T123A. We identified increased 
genome output as the main mechanism of 5-fluroruracil resistance for thee influenza 
replicase variants.   
 The influenza replicase complex is composed of PB2, PB1, and PA (11, 162, 
163). PB1, like the RdRp from other viruses, is shaped like a right hand where the 
fingers and thumb domains enclose the palm domain, which contains the catalytic 
active site. PB2 is involved in binding 5’-caps found on cellular RNA molecules and PA 
contains the endonuclease that cleaves the 5’caps from the RNAs for influenza to use in 
mRNA synthesis. The mutation PB1 T123 is found within the fingers domain near where 
the RNA template enters the RdRp active site (Figure 4.7). PB1 M645 is located on the 
priming loop that is in the catalytic active site and is important for initiating the synthesis 
of (+) sense RNA that is used as a replication intermediate. PB1 D27 and PB1 V43 are 
located near the catalytic active site and nucleoside triphosphate entry site, 






Figure 4.7. Location of influenza replicase mutants  
The locations of all polymerase mutants that we investigated were modeled on the structure of 
the replicase from a bat strain of influenza (Protein Data Bank # 4wsb) (163). PB1 is shown in 
green, PA is shown in orange, and PB2 is shown in pink. Sites where we generated mutations 
are shown in red. The residues of the PB1 catalytic active site are shown in teal. A bound RNA 





 We identified PB1 T123A as an influenza mutation that specifically provides 
resistance to 5-fluorouracil, but not ribavirin or 5-azacytidine. Unlike previously identified 
nucleoside analog resistant viruses, which had lower mutation rates, PB1 T123A has an 
elevated mutation rate. Its higher mutation rate is class specific with the greatest 
increase in C to U mutations. This higher mutation rate is consistent with the slight 
specific infectivity decrease that it exhibits (Figure 4.4A and 4.4B). The higher genome 
output of this mutant virus likely enables it to tolerate the higher mutation rate and also 
allow it to have a greater replicative fitness than wild type PR8 (Figure 4.8). We found 
that while the baseline C to U mutation rate is higher for this mutant, the mutagenic 
effect of 5-fluorouracil on this mutation class is dramatically reduced (Figure 4.3B). This 
phenotype is similar to that of the ribavirin resistant 3D M296I FMDV mutant (60, 88). 
This property of the mutant polymerase may indicate increased selectivity against 
misincorporation of 5-fluorouracil as a possible mechanism of resistance although 
decreased mutagenesis seems inconsistent with the specific infectivity decrease we 
observe upon drug treatment (Figure 4.5). The most likely mechanism of resistance 
seems to be through the maintenance of high genome output in the presence of 5-
fluorouracil, possibly by preventing its inhibition of genome synthesis. Failure to resist 
the detrimental effect of ribavirin and 5-azacytidine suggest that the resistance 
phenotype mediated by PB1 T123A is not broadly applicable to other nucleoside 
analogs.  
 One of the mutants we investigated was located in the PB1 associated protein, 
PA. PA T97I had fitness and genome outputs that were very similar to those of wild type 
PR8. Interestingly this mutant was selected for during ribavirin treatment, but it was 
resistant to 5-fluorouracil and not ribavirin. This mutant closely mirrored PB1 T123A in 
terms of its smaller decreases in both infectious titer and genomic output upon 
treatment with 100 μM 5-fluorouracil. This mutant may differ from both PB1 T123A and 
WT PR8 in its production of defective interfering particles. We found that PA T97I 
releases equivalent amounts of PB2 and M genome segments, suggesting very few DI 
particles containing PB2 segments with internal deletions. Unlike the other viruses, we 
found that this mutant maintains its baseline ratio of PB2 and M segment production 
upon 5-fluorouracil treatment. We have yet to measure the mutation rate of this virus in 
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or out of drug, so it is unknown if this mutant functions similarly to PB1 T123A, which 
has a higher mutation rate and selects against certain types of 5-fluorouracil 
mutagenesis. Since this mutant has a similar specific infectivity change to WT PR8 after 
drug treatment it is unlikely that the primary mechanism of resistance influences the 
mutation rate in 5-fluorouracil. With our current data the most likely explanation for the 
resistance mechanism of PA T97I is that it both maintains high genomic output and 
maintains equal production of genome segments in the presence of 5-fluorouracil.  
 Even though PB1 T123A and PA T97I evolved in different passage cultures, we 
combined them to make a double mutant. Serendipitously, we found the most dramatic 
5-fluorouracil resistance phenotype for any of the mutants we tested. These two 
mutations led to a reduced fitness phenotype characteristic of reciprocal sign epistasis. 
The combination of a mutant with increased fitness with a neutral mutant led to a double 
mutant with very low fitness and significantly reduced genomic RNA output. This may 
be why this virus did not evolve naturally. At the concentrations of 5-fluorouracil used for 
selection of resistant variants, this double mutant has a fitness lower than wild type, 
even though it is highly resistant to the drug. This double mutant virus had a nearly 
identical spectrum of transition mutation rates to WT PR8. It may slightly reduce the 
mutagenic effect of 5-fluorouracil on C to U mutations, but the effect of this on the virus’ 
specific infectivity appears to be negligible. Resistance from this mutation combination 
seems to be driven primarily by maintaining high genomic output during 5-fluorouracil 
treatment. Treatment with nucleoside analog leads to almost no reduction in the number 
of genome segments that are released from infected cells. This mechanism allows for 
more infectious viral particles to be produced than wild type despite similar levels of 
mutagenesis and specific infectivity decreases. We also identified a small but significant 
reduction in ribavirin sensitivity for this double mutant. Resistance to ribavirin does not 
appear to be mediated by increased genomic output. Further characterization of its 






Figure 4.8. Increased genome production to tolerate mutation rate increases 
For a virus that produces one mutation per genome, 70% of the progeny population will be 
viable (assuming 30% of all single nucleotide changes are lethal). If the mutation rate increases 
so that the virus generates 2 mutations per genome, 49% of the progeny population will be 
viable. The virus with the higher mutation rate will produce fewer viable progeny than the virus 
with the original mutation rate. However, if the virus with the higher mutation rate produces more 
total genomes it will be able to produce just as many viable progeny as the virus with the 
original mutation rate.  
 
104 
This double mutant virus also produces a higher ratio of PB2 to M genome 
segments than does the WT virus (t-test, p = 0.006). This may mean that this virus 
produces genome segments at relative levels that are skewed differently than WT virus. 
Alternatively, a potentially more interesting mechanism for this result could be the 
decreased production of DI particles. With this virus’ low replicative fitness, this 
mechanism could lend support for a model that suggests a trade-off between replication 
speed and the production of DI particles. Faster RdRps are thought to be more likely to 
make internal genome deletions through inter- or intra-molecular recombination events 
(164). Therefore, a slower polymerase, like the PB1 T123A, PA T97I double mutant 
may posses, would be expected to make fewer DI particles.    
 We showed that the PB1 D27N mutation previously identified as a mutation that 
limited ribavirin inhibition of RNA synthesis in a replicon system is not resistant to 
ribavirin or other mutagenic nucleoside analogs in a replication competent PR8 virus 
(94, 160). Additionally, PB1 V43I, which was shown to be resistant to ribavirin in the 
A/Wuhan/359/95 H3N2 and A/Vietnam/1203/04 H5N1 strains, is not resistant in the 
PR8 strain background (65). This finding suggests that there may be many epistatic 
interactions governing polymerase activity and fidelity in influenza virus and that the 
ability of one virus to evolve resistance to a mutagen may not be reflective of how 
another virus evolves in the face of the same selective pressure. We have not 
measured the mutation rate of either of these viruses, but it would be interesting to 
compare them with WT PR8 as it was suggested that PB1 V43I is a fidelity variant (65).       
 One of the mechanism by which nucleoside analogs function as antiviral agents 
is through the induction higher mutation rates. Our results suggest that other 
mechanism may be of equal or greater importance. We found that three influenza 
mutants are able to effectively resist infectious titer decreases by preventing 5-
fluorouracil from inhibiting the production of viral genomes. We have previously 
recognized that the specific infectivity decreases associated with nucleoside analog 
treatment (up to 10-fold) are much less than the effect of these compounds on 
infectious titer output (> 1,000-fold). We had always assumed that these differences 
were the result of allowing experiments to proceed through multiple viral replication 
cycles during which a mutagenized population would replicate less efficiently. The 
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identification of resistant variants that do not affect the specific infectivity, but do 
increase genome output may suggest that the RdRp inhibition activity of 5-fluorouracil is 
key to its anti-influenza mechanism of action. Without it, the drug’s effectiveness 
decreases substantially, as we see with the PB1 T123A, PA T97I double mutant. During 
treatment with 100 μM 5-fluoruracill, this mutant has no decrease in the production of 
viral genomes, and only a 10-fold drop in infectious titer, driven entirely by the 10-fold 
decrease in specific infectivity. Additionally, we identified a potentially novel anti-
influenza mechanism of 5-fluorouracil to be through the increased production of DI 
particles.          
 In conclusion, we identified two mutations within the influenza replicase complex 
that can function independently or in concert to mediate resistance to 5-fluorouracil. We 
found that mutagen resistant polymerase mutants are not necessarily fidelity variants 
and can mediate resistance to 5-fluorouracil in other ways. We identified preventing 5-
fluoruracil from inhibiting genome synthesis as a common mechanism of resistance to 
this drug. This mechanism does not provide broad protection against other nucleoside 
analogs. One mutation, PB1 T123A had an elevated mutation rate while maintaining 
fitness higher than wild type virus. This was likely made possible by its increased 
genome synthesis. The other mutation, PA T97I, showed that mutations in proteins 
other that the RdRp can mediate resistance to nucleoside analogs. These findings have 
important implications for our understanding of viral mutation rates. They suggest that 
an RNA virus’ ability to tolerate mutations is not strictly governed by its RdRp. It can be 
controlled by the total genomic output of a virus, which is a phenotype that can be 
modulated by proteins associated with the RdRp. If two viruses have the same mutation 
rate, the one that can generate more viral particles will have the advantage. This is an 
important idea to keep in mind during the study of RNA virus mutation rates and their 
effects on viral populations. A virus’ maximum mutation rate may not be defined only by 
the fitness effects of generated mutations, but also on the total amount of genomic RNA 




Implications, future directions, and discussion 
 
 
 Studying viral mutation rates, factors that can alter viral mutation rates, and the 
effects of an altered mutation rate, can inform our understanding of the dynamics of viral 
evolution and population structures. It is well documented that high mutation rates are a 
key component of the rapid evolution of RNA viruses. In particular, influenza virus’ rapid 
evolution allows it to be a major annual health burden, in part, by allowing it to quickly 
evade humoral immunity or acquire resistance to antiviral drugs. While mutation rates 
have been well studied in other RNA virus systems, surprisingly little has been done to 
thoroughly understand the mutation rate of influenza virus. In this work, we have 
characterized the entire mutation rate spectrum (all 12 mutation classes) of influenza for 
the first time. We have identified features of the virus and the replication environment 
that do and do not affect influenza’s mutation rate in mammalian cell culture. We have 
demonstrated that nucleoside analogs can be used to increase the mutation rate of 
influenza virus, and that increased mutation rates decrease the infectivity of viral 
populations. We identified increased genome production as a novel mechanism by 
which an RNA virus can become resistant to a nucleoside analog and tolerate an 
increased mutation rate. This work contributes to the growing body of research on RNA 
virus evolution, antiviral strategies, and the measurement of viral mutation rates. Here, I 
discuss in detail the implications of these findings for our understanding of how 





Figure 5.1. The causes and effects of an altered mutation rate 
The mutation rates of RNA viruses exist as a continuum. Changes that cause higher or lower 
mutation rates are thought to decrease viral fitness. In this thesis I precisely characterized the 
mutation rate of influenza virus and showed that the virus’ RdRp sequence can affect the 
mutation rate of specific mutation classes. I demonstrated that temperature does not 
significantly affect influenza virus’ mutation rate in an MDCK cell culture model. Whether 
temperature has an effect on the mutation rate of influenza virus in other cell culture systems or 
in vivo is still an open question. Nucleoside analogs of diverse chemical structures can cause 
higher mutation rates and mutant viruses with altered polymerase fidelity can limit the 
mutagenic effect of these compounds. I showed that higher mutation rates decrease the 
proportion of the viral population that is infectious, leading to lower infectious virus titers. A novel 
mechanism that allows for the tolerance of higher mutation rates is the increased production of 
genomes. The effects of a lower mutation rate on influenza virus have not yet been investigated 
thoroughly. Check marks that include references indicate results that were known prior to this 
study.      
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The role of mutation rate in population dynamics and evolution 
 
 We developed a novel assay to measure the mutation rates of all 12 mutational 
classes for influenza virus. This assay uses a fluctuation test in which the scorable 
phenotype is GFP fluorescence. All 12 mutation classes are able to be assessed using 
individual viral constructs containing unique mutations that render GFP non-fluorescent. 
We used this assay to measure the mutation rates of the laboratory culture adapted 
A/Puerto Rico/8/1934 H1N1 strain and the A/Hong Kong/4801/2014 H3N2 strain that 
was recently isolated from a human infection. These measurements were made for viral 
replication in MDCK cells at 37°C, which are the standard conditions for influenza cell 
culture. We found overall mutation rates of 1.8 x 10-4 and 2.5 x 10-4 mutations per 
nucleotide per RNA strand replicated for these two viruses, respectively. These values 
are approximately an order of magnitude higher than those previously reported for 
influenza under similar replication conditions (18, 28, 29, 41, 42). These discrepancies 
can be explained in two ways. First, the methods used are different. Sequencing based 
approaches may not have sufficient power to detect rare events like mutations. These 
sequencing based approaches are also biased, sampling the more fit genomes present 
within the viral population through plaque purification. They would have failed to sample 
low fitness clones or those that form small plaques (or no plaques). Lower fitness clones 
likely would have more mutations present while those that they sampled may have had 
a lower mutational burden. Second, our data show large biases in the mutation 
spectrum, with A to G and U to C mutations driving the high mutation rate. Sequencing 
based methods may fail to fully capture these biases due to power and sampling issues. 
Fluctuation tests assaying monoclonal antibody neutralization resistance miss 
mutational biases. Only a few mutation types can lead to the scorable resistance 
phenotype. When we compare the G to A mutation class from our results to those 
reported for fluctuation tests that score primarily G to A mutations we see similar values 
(3.1 x 10-5 vs. 1.0 x 10-5 mutations per nucleotide per strand replicated) (42). 
 This higher mutation rate, along with the biases we report, has a significant 
impact on our understanding of influenza virus dynamics. Using our mutation rate 
values, influenza is expected to make an average of 2 to 3 mutations every time it 
replicates its entire 13.5 kilobase genome. Knowing that 30% of all mutations are lethal 
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to the virus, a large portion of the non-infectious genomes within a population can be 
explained by point mutations (69). The benefit of having a high mutation rate must, 
therefore, outweigh this cost of generating large numbers of non-infectious genomes. 
This high mutational rate means that within a short amount of time, a viral 
population will be able to sample large numbers of mutations and combinations of 
mutations. This would greatly aid in the adaptation and eventual evolution of an 
influenza population. The bias towards A to G and U to C mutations indicates that these 
mutations will be sampled more within the mutant swarm. Therefore, adaptive mutations 
permitted by these mutation classes will be easier for the virus to obtain.  
Our data suggests that influenza uses a replication mode that is near linear. This 
means that very few replication intermediate RNA molecules exist during replication. 
Maintaining linear genome replication may be a mechanism through which influenza is 
able to have such a high mutation rate (25–27). If there were many replication 
intermediates as is characteristic of the binary mode of viral replication, the mutations 
generated would propagate with each subsequent RNA polymerization event. It is likely 
that viruses with very high mutation rates use linear replication to minimize mutational 
burden on their population. It is possible that viruses with lower mutation rates could 
select for binary replication as a way of increasing genetic diversity.  
Linear replication by influenza may enhance mutational biases. Mutations made 
within the genomic strand will be made more often than mutations made within the 
complementary strand. This may help to explain the biases we see in the mutation 
spectrum for higher rates of mutations away from G than mutations away from C. This 
would mean that mutations on the two RNA strands are not generated equally and that 
adaptive mutations would have more chances to be generated during (-) sense RNA 
synthesis.  
The distributions of the fitness effects of single nucleotide substitutions are 
similar for influenza and RNA viruses with unsegmented genomes (68, 69). Despite this 
finding, the segmented genome of influenza may be another mechanism of tolerating 
high mutation rates. Each of influenza’s 8 genome segments are replicated 
independently of one another and later packaged together in a virion to create a whole 
genome (10). This replication mechanism means that mutations made in individual 
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segments are not linked at their time of creation. This is in contrast to a virus with an 
unsegmented genome in which two mutations made within an early RNA replication 
intermediate would likely be linked in subsequent progeny. This linkage could be 
reversed through recombination, but the compartmentalization of individual replication 
complexes during (+) sense RNA virus replication might make recombination inefficient 
at segregating newly generated mutations into individual genomes (165, 166). By 
breaking up the genome into individual segments, influenza may be able to maximize 
the diversity of the genotypes released in virions and, as a result, limit the effect of 
combinations of detrimental mutations within these released virions.  
We found that the evolutionarily divergent PR8 and Hong Kong influenza strains 
had very similar mutation rates and spectra. This suggests that influenza’s mutation rate 
is a highly conserved phenotype at least among human influenza viruses. Therefore, 
our estimates should be reasonably accurate and applicable to a wide diversity of virus 
strains. A key value for studying evolution is the ratio of nonsynonymous mutations to 
synonymous mutations (dN/dS ratio) between two strains or species. The null model, 
which infers neutral selection, is dependent upon the baseline ratio of generating 
transition and transversion mutations (167, 168). The mutational spectra we report, 
combined with the genome-wide mutational fitness effects recently published for 
influenza by the Lauring lab, will allow for the construction of more accurate evolutionary 
models using empirically determined mutation and selection parameters (30).  
While the mutation rates of PR8 and Hong Kong were generally similar, we did 
recognize some key differences between the two. We found that individual mutation 
classes were increased or decreased as much as two-fold. This was most pronounced 
in the significantly different rates of G to A mutations. This finding, along with our study 
of the PB1 T123A mutant, which had significantly elevated C to U mutation rates 
(approximately 2-fold), suggests that influenza’s RdRp can easily accommodate small 
changes to individual mutation classes, but large, mutation spectrum-wide changes are 
rare. The driving forces behind these small changes and their evolutionary 
consequences are unknown. We do know that 5-fluorouracil treatment selected for PB1 
T123A, but this mutation rate increase was likely the byproduct of more robust genome 
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replication or changing the polymerase to prevent 5-fluorouracil induced inhibition of 
RNA synthesis.  
In nature, a selective force driving these changes may be the mutational 
robustness of the genome’s primary structure. A virus’ codon usage changes as its 
genome evolves. Some codons can mutate to cause dramatic amino acid changes 
while others mutate more conservatively. The evolution of different codon usage could 
impact the genome-wide fitness effects of the 12 different mutational classes (36). Small 
changes in the mutation rate of specific mutation classes could evolve in response to 
the changing fitness effects of these mutations. Another possibility is that the optimal 
mutation rate spectrum in cell culture (PR8 virus) is different than the optimal rate in 
humans (Hong Kong virus). It is also possible that these mutation rate changes are just 
the result of drift or genetic hitchhiking with beneficial mutations (71). 
With the high mutation rate of influenza virus, I would not expect these small 
changes to specific mutation classes to have much effect on the long-term evolution of 
the virus. Even though mutations that are beneficial to influenza make up a small 
minority of all possible mutations, influenza maintains large populations, which support 
their generation. Therefore, two-fold changes in certain mutation classes would be 
unlikely to dramatically improve or reduce the likelihood of a beneficial or adaptive 
mutation occurring within the population.  
We found that influenza’s mutation rate is temperature independent. Our results 
in cell culture suggest that influenza does not experience different mutation rates as it 
infects cells at different sites within the human respiratory tract. This may mean that the 
same level of genetic diversity is generated throughout the respiratory tract and that 
there are no replication sites of mutational preference. This idea is dependent on the 
epithelial cells of the human respiratory tract behaving as MDCK cells do, in terms of 
allowing influenza to generate diversity. This idea also does not rule out the possibility 
of adaptive or evolutionary hot spots within the respiratory tract. There may be certain 
sites that are stronger drivers of evolution, either through bottleneck effects or the 




The future of studying mutation rates 
 We have only begun to answer important questions related to influenza’s 
mutation rate and RNA virus mutation rates in general. This study investigated only two 
influenza strains (both isolated from humans) in a host cell type (canine kidney) that it 
would rarely, if ever, encounter in nature. I see the GFP mutation rate assay being 
easily adaptable to new cell types, influenza strains, and other RNA viruses. With the 
current GFP system, mutation rates can be measured in any cell line that influenza 
replicates efficiently in that is tolerant to the constitutive expression of the influenza HA. 
It may be worthwhile to measure mutation rates in a more physiologically relevant cell 
line, such as human lung epithelial A549 cells. Additionally, it would be highly 
informative to measure rates for several more viruses from different points in 
evolutionary time. This experiment would be able to confirm or refute that influenza 
mutation rates are generally similar and determine if the small changes within the 
mutation rate spectrum follow a directed evolutionary path or if they change following a 
less defined pattern. 
 There is evidence for faster evolution by influenza virus after host switching 
events from birds to mammals (171, 172). Whether this is solely due to the virus 
adapting to overcome temperature and cell type mismatches or if mutation rates play a 
role is not known. Avian adapted polymerases have also been suggested to have higher 
RNA replication efficiency than mammalian adapted polymerases, which could suggest 
fidelity differences (173). Additionally, the nucleotide composition of avian and 
mammalian adapted influenza genomes differ (174). It will be important to test if avian 
and mammalian adapted influenza strains have similar mutation rates. If their mutation 
rates are different, we could then use evolutionary intermediates to determine the 
molecular mediators of these differences to track how the mutation rate may decrease 
as the virus becomes better adapted to its host.    
 Influenza’s strong mutational bias towards A to G and U to C mutations are 
suggestive of RNA modification by adenosine deaminases (ADAR-1) (49, 119). By 
using the GFP mutation rate assay with cells that have had ADAR-1 knocked out we 
would be able to determine the mutagenic contribution of RNA modification. This 
experiment may allow us to determine the inherent error rate of influenza’s RdRp.  
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 There are two important aspects of the GFP mutation rate assay that may 
prohibit some of the above-described experiments. First, replacement of the HA gene 
with GFP imposes a fitness cost on influenza virus. For virus strains that replicate to 
high titers in tissue culture, this is not an issue because sufficient titers can still be easily 
reached using the ΔHA-GFP construct. On the other hand, viruses that are not well 
adapted to tissue culture replication may not be able to reach the necessary titers for 
accurate mutation rate measurement once the GFP gene is introduced. The second 
aspect is the requirement for the cell line to be constitutively expressing HA. This may 
make it cumbersome to measure mutation rates for influenza replication in large 
numbers of cell lines.  
 Prior to developing the ΔHA-GFP system, we investigated using GFP inserted 
into segment 8. The initial construct we tested expressed a polyprotein containing an 
NS1-GFP fusion protein and NEP separated by an autoproteolytic cleavage site (175). 
While this construct would have allowed for mutation rate measurements in any cell line, 
it had very low fitness and the functional GFP gene was rapidly lost from the viral 
genome. Since our initial attempt, more tolerable GFP insertions into segment 8 have 
been developed. One that looks particularly promising permits the virus to replicate to 
near wild type titers and maintains high GFP expression over several tissue culture 
passages (176). If we could adapt our GFP mutation rate assay to this system, it would 
permit far easier mutation rate measurements using a broad diversity of influenza 
strains, cell types, and potentially even animal models.    
 The advent of next generation sequencing has raised the possibility of making 
sequencing based mutation rate measurements high throughput. The main problem 
with using this approach for RNA viruses is that a reverse transcription step is required. 
Reverse transcriptase has a mutation rate on the same order as those estimated for 
many RNA viruses (34, 95, 97). Our data clearly show that unless RT errors can be 
controlled for, they will mask and skew the biases within the measured viral mutation 
spectrum. There are methods available that allow for next generation sequencing with 
the ability to remove RT errors including CirSeq and Rep-Seq (34, 48). While these 
methods could potentially allow for mutation rate measurements, they have the 
drawbacks of requiring prohibitive amounts of raw genomic RNA, and very high 
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numbers of sequencing reads, which would limit the power and throughput. I 
recommend that any reported mutation rates or frequencies measured using next 
generation sequencing be interpreted extremely cautiously unless the background 
signal of their assay is carefully investigated. There has been much interest in 
developing a reverse transcriptase that possess higher replication fidelity. Recently 
reported work engineering an enzyme with proofreading capability lends hope to the 
idea of better sequencing methods for accurately identifying mutations in RNA virus 
populations (177).  
 
Lethal mutagenesis as an antiviral strategy 
 We investigated the strengths and weaknesses of lethal mutagenesis as an anti-
influenza strategy. We found that three nucleoside analogs, ribavirin, 5-azacytidine, and 
5-fluorouracil all function as anti-influenza drugs and that each induced higher levels of 
mutations as part of their antiviral mechanisms. We found that higher mutational loads 
were detrimental to the infectivity of individual viral genomes. Each nucleoside analog 
induced different types of mutations in influenza’s genome. We found that the most 
effective mutagen, in terms of genome infectivity loss, was 5-azacytidine, which induces 
transversions mutations as opposed to the transitions induced by the other two drugs. 
Resistance to these compounds may be difficult for influenza to acquire. After serial 
passage in drug, we identified no ribavirin or 5-azacytidine resistant mutants and two 
mutants (PB1 T123A and PA T97I) that were modestly resistant to 5-fluorouracil 
(interestingly, PA T97I was identified in ribavirin passage). Even after 16 passages, no 
population-wide resistance phenotype was present in any of the drug passaged 
populations, despite PB1 T123A having a significant fitness advantage both in and out 
of 5-fluorouracil.     
 These results suggest that lethal mutagenesis may be a usable alternative to 
traditional antiviral drugs that block completion of the viral replication cycle. We showed 
that three drugs that each cause increased mutation rates work against influenza, 
demonstrating that influenza’s mutation rate can be an antiviral target. Influenza does 
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not appear able to quickly evolve high-level resistance and the resistant mutations that 
we did identify are not broadly applicable to multiple mutagens.   
 The idea of drugs that cause lethal mutagenesis as influenza therapeutics is 
supported by the newest anti-influenza drug in late phase clinical testing (178). 
Favipiravir (T-705) is a nucleoside analog that has been shown to be mutagenic to 
influenza virus as one of its antiviral mechanisms (93). This compound increases both 
transitions (C to U) and transversions (G to U) and has more potent in vitro anti-
influenza activity than ribavirin. In addition to influenza, T-705 is broadly active against a 
range of RNA viruses, including norovirus, ebola virus, and lassa virus (141, 179, 180). 
The fact that T-705 has garnered so much attention as a broad spectrum antiviral 
shows the importance of studying lethal mutagenesis so that better mutagens may be 
developed in the future. One aspect of nucleoside analogs that needs to be improved 
upon is the broad off target effects on cellular metabolism. While these off target effects 
likely increase the antiviral properties of the compounds, they greatly limit the 
concentrations that can be administered.      
 My research on lethal mutagenesis of influenza points to the virus’ mutation 
spectrum as a key feature to focus on in mutagen development. My results show that 5-
azacytidine, which induces both G to C and C to G transversions mutations was able to 
have the greatest effect on influenza’s specific infectivity. Transition mutations are 
generally produced at higher rates than transversion mutations by influenza. It would 
seem that mutagenic drugs that are able to increase the rates of mutation classes that 
are rarely made, or that lead to a more dramatic changes within the normal biases of 
the virus’ mutational spectrum are more effective antivirals. Based on this evidence, in 
order for lethal mutagenesis to achieve its full potential as an antiviral strategy, focus 
should be placed on identifying compounds that specifically induce transversion 
mutations. Additionally, a focus should be placed on creating nucleoside analogs with 
greater affinity and specificity for the RdRps of viruses because many of the current 
generation compounds require high concentrations that can cause severe off target 
effects within cells.  
 I foresee the possibility of screening for better influenza mutagens by adapting 
the GFP mutation rate assay that I developed. We showed that the reversion of GFP 
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mutants to being fluorescent was sensitive to mutagen treatment in terms of both the 
number of fluorescent viruses per culture and the proportion of cultures containing at 
least one fluorescent virus. Compound libraries exist that contain nucleoside analogs. 
We could screen these compounds looking for their ability to increase fluorescent 
reversion. This approach could be used to find potential structures that target specific 
mutation classes or that are more potent mutagens than the current generation of 
characterized nucleoside analogs. Even if identified structures would not be suitable for 
drug development, they may provide useful tools for future studies related to mutation 
and evolution in influenza and other RNA viruses. 
 One aspect of increased mutation rates by influenza virus that has surprised me 
is the inhibition it appears to have on the evolution of beneficial or resistant mutations. 
We found that even though the 5-fluorouracil resistant mutant PB1 T123A has a large 
fitness advantage over wild type virus in drug, it was still a minority variant within 5-
fluorouracil treated populations after 16 passages. Similarly, the ribavirin resistant 
mutant PB1 V43I, which was identified by a different group, was only found in a small 
minority of clones after 17 passages in drug (65). Additionally, combinatorial treatment 
of ribavirin and amantadine was shown to limit the emergence of amantadine resistance 
in vitro (158). These findings are in sharp contrast to what is seen in RNA viruses with 
non-segmented (+) sense genomes such as poliovirus, FMDV, and Chikungunya virus, 
where mutations that mediate resistance to mutagenic nucleoside analogs rapidly rise 
to high frequencies within the population and present population wide resistance (59, 
62, 72, 86). I hypothesize that it may be a factor of the differences in replication strategy 
between viruses with (+) sense and (-) sense genomes and the fact that influenza has a 
segmented genome. Mutagenesis increases the proportion of the genomes in a viral 
population that are non-infectious. In laboratory culture this leads to an increase in the 
amount of co-infection of cells with more than one viral particle. At an equivalent MOI, 
more viral particles will be added to cells infected with a mutagenized viral population 
than an unmutagenized population. This increase in co-infection could inhibit the spread 
of beneficial mutations by linking them to detrimental or lethal mutations through genetic 
reassortment or recombination. Reassortment is only possible in segmented viruses 
and is very common in cell culture among genetically compatible viruses (15). While 
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recombination is fairly common for co-infection between two replication competent (+) 
sense viruses and also occurs with noninfectious viruses, it may be less efficient than 
reassortment for generating novel genomes. This may be due to the cis coupling of 
translation, replication complex formation, and genome replication for (+) sense RNA 
viruses (165, 166).          
      
Resistance to mutagenic nucleoside analogs 
 We identified two novel mutagen resistant variants in Influenza virus. PB1 T123A 
was isolated in 5-fluorouracil treated influenza populations and is resistant to 5-
fluorouracil treatment. PA T97I was identified in ribavirin-passaged populations and 
unexpectedly was resistant to 5-fluorouracil but not ribavirin. Combining these two 
mutations resulted in an increased resistance phenotype. We found that the primary 
mechanism of resistance was through the maintenance of high genome sysnthesis. By 
making more viral genomes than wild type, the virus is able to lessen the impact of a 
decrease in specific infectivity caused by an increased mutation rate. We also found 
that PB1 T123A has an increased C to U mutation rate, but it prohibits 5-fluorouracil 
from inducing C to U mutations. These mutants represent previously unrecognized 
mechanisms viruses use to tolerate high mutation rates. Our results also show that not 
all mutants that present decreased sensitivity to nucleoside analogs are necessarily 
high fidelity polymerases. 
 PB1 T123A has a higher mutation rate than wild type PR8 virus. As a result it 
also has a slightly lower specific infectivity. Counter-intuitively, we found that it had a 
higher replicative fitness than wild type PR8. We identified the mechanism that permits 
this is a higher genomic output, similar to the mechanism we determined for 5-
fluorouracil resistance. By making more genomes PB1 T123A is able to overcome 
having a smaller proportion of its genomes be infectious. This finding suggests that 
genomic output is a factor that determines the tolerable level of mutation. It also 
supports the theory that increased mutation rates may be able to evolve for an RNA 
virus as long as genome replication increases to compensate (181, 182). 
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 If PB1 T123A is more fit than wild type in the absence of mutagen, then it is 
obvious to ask why that genotype has not replaced wild type. Our competition assays to 
determine fitness were performed over only four passages starting with an equimolar 
mixture of mutant and wild type viruses. The benefit of generating higher levels of more 
mutagenized genomes may be beneficial in the short term, but over the course of 
numerous generations genomes may become too mutagenized to effectively compete 
with the wild type. This hypothesis would need to be experimentally tested but could 
explain why this mutation has not been identified outside of 5-fluorouracil passaging. 
Additionally, this mutation may not be easily accessible in the genetic backgrounds of 
other influenza viruses.    
 PA T97I was also found to be resistant to 5-fluorouracil. PA is the replicase 
component that is involved in cleaving the 5’ caps from cellular RNA molecules (11, 
162). It is intimately associated with PB1, but is not known have any direct effect on 
RNA polymerization. Our results suggest that PA, through its interaction with PB1, can 
regulate events related to influenza genome synthesis. This may mean that protein 
interactions between PB1 and PB2 could also play important roles in regulating aspects 
of genome synthesis.   
  When we combined PB1 T123A and PA T97I, we observed an increase in 5-
fluorouracil resistance relative to either mutation by itself. This resistance was again 
mediated by permitting higher genome production in the presence of 5-fluorouracil. This 
double mutant virus has a much lower fitness than wild type. Even at relatively high 
concentrations of 5-fluorouracil, its fitness was barely above that of wild type. PB1 
T123A alone has a much higher fitness than the double mutant at the drug 
concentrations used for our passaging experiment, which would explain why we never 
saw this mutation combination generated naturally. The double mutant has such a low 
fitness that even its high level of mutagen resistance is not enough to allow it to arise 
within an influenza population. The double replicase mutant loses the mutation rate 
phenotypes of the PB1 T123A single mutant. This result raises the question of whether 
other synergistic combinations of mutations are possible in the influenza replicase that 
could have an effect on polymerase fidelity or replication efficiency.  
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 The possibility that synergistic interactions influence polymerase functions is 
supported by the lack of a ribavirin resistance phenotype for the PB1 V43I mutation in 
the PR8 background. There must be difference within the genes that encode the 
replicase components that negate the ability of this mutation to resist the effects of 
ribavirin in this genetic background. This finding may mean that certain mechanisms of 
mutagen resistance or polymerase adaptation are inaccessible to certain influenza 
genotypes. This would suggest that different influenza strains may differ in their 
tolerance to mutagens or their potential for evolving effective resistance. Therefore, 
future studies of lethal mutagenesis may be more relevant if recent human strains of the 
virus are used.  
 We have identified increased genome production as a mechanism by which an 
RNA virus can increase its tolerance to higher mutation rates. Increased genome 
production adds to a growing literature describing methods by which RNA viruses can 
resist the negative effects of mutagenesis induced by nucleoside analogs (58, 59, 60, 
62, 65, 72, 86, 87, 89, 90, 91). This mechanism should be broadly applicable to a wide 
range of RNA viruses. Whether the increased genome production in influenza is the 
result of faster replication or a larger burst size from an infected cell is unknown, and 
needs to be investigated further. Both possibilities would lead to the same mutation rate 
tolerance phenotype and could function in other RNA virus systems. Viral genome 
production should be able to increase for RNA viruses provided that replication 
processes can become more biochemically efficient and/or that sufficient cellular 
resources are available.  
 
Concluding thoughts 
 Influenza virus’ mutation rate is a key factor that determines both short- and long-
term evolutionary outcomes. It does this by generating the raw material that selection 
acts upon and influencing the genetic organization of the virus population. We found 
that influenza’s mutation rate is much higher than previously estimated and that it is 
fairly constant among different virus strains. This paints a picture of influenza 
populations that are constantly synthesizing swarms of highly diverse genotypes; many 
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of which are purged due to the presence of detrimental mutations. This population 
structure poises the virus to rapidly adapt to selective pressures that it encounters. It 
also positions the viral population close to a maximum tolerable mutational burden. 
Influenza’s large population size is partially responsible for its ability to permit high 
mutation rates. We have shown that genome output is a viral phenotype that can be 
modulated to increase the mutational burden that a viral population can tolerate. This is 
true both under normal replication conditions and in the presence of a mutagenic agent.  
While we have clarified some important aspects of influenza’s mutation rate, there are 
still several areas that will need attention in the future. These include characterizing the 
strain and cell type dependencies of mutation rates, and further defining of the 
mechanisms that influenza uses to tolerate the accumulation of mutations to better 
understand the functional dynamics of influenza replication. Lethal mutagenesis 
deserves further study as both an anti-influenza and general antiviral strategy because 
of the promise that it continues to show. Our research has begun to lay the intellectual 
ground work and provided several tools that will aid in the development of a more 
complete understanding of how influenza mutates and how this process influences 




Appendix 1. Sensitivity of PR8 polymerase mutants to mutagenic nucleoside analogs  
 
 
MDCK cells were pretreated with viral media containing 0 μM drug, 100 μM 5-fluorouracil, 20 
μM ribavirin, or 20 μM 5-azacytidine for 3 hours. Cells were infected with virus mutants at an 
MOI of 0.1. After 24 hours, cell free supernatants were harvested and titered for infectious virus 
by TCID50 assay. The decrease in the log of the infectious titer for drug treated samples relative 
to untreated samples for each virus is shown. Three replicate samples were harvested for each 
virus at each drug concentration, with the mean and standard deviation being shown. Mean 
decreases were analyzed by one-way ANOVA with a Dunnett’s multiple comparison test 





Appendix 2. Fitness of PR8 polymerase mutants  
 
 
A. Direct competition assays were performed for WT PR8 and each mutant against a WT PR8 
virus containing a neutral genetic barcode. Equivalent viral mixtures were passaged four times 
at an MOI of 0.01 on MDCK cells for 24 hours. Fitness values were determined using 
quantitative RT-PCR to measure relative changes in the amounts of the two competitor viruses. 
Data shown is the mean and standard deviation from three individual competitions, each were 
analyzed using a one-way ANOVA with a Dunnett’s multiple comparison test comparing each 
mutant to WT PR8. * = p-value < 0.05, ** = p-value < 0.01, **** = p-value < 0.001. B. Influenza 
virus mutants were used to infect MDCK cells at an MOI of 0.01 for 24 hours. Supernatants 
were harvested and the M genome segment copy number per mL was determined by 
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